

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

A guide to the use of bioassays in exploration of natural resources

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1953751> since 2024-03-17T22:26:08Z

Published version:

DOI:10.1016/j.biotechadv.2024.108307

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Biotechnology Advances

A guide to the use of bioassays in exploration of natural resources

--Manuscript Draft--

Manuscript Number:	JBA-D-23-00480
Article Type:	Review Article
Keywords:	bioassay selection; Bioactivity; Natural Products; Drug Discovery; Blue biotechnology; screening; bioactivity-guided purification; validation; preclinical trials; biodiscovery
Corresponding Author:	Jerica Sabotič Jozef Stefan Institute SLOVENIA
First Author:	Jerica Sabotič
Order of Authors:	Jerica Sabotič Engin Bayram David Ezra Susana P. Gaudêncio Berat Z. Haznedaroğlu Nika Janež Leila Ktari Anna Luginini Manolis Mandalakis Ivo Safarik Dina Simes Evita Strode Anna Toruńska-Sitarz Despoina Varamogianni – Mamatsi Giovanna Cristina Varese Marlen I Vasquez
Abstract:	<p>Bioassay are the main tool to decipher bioactivities from natural resources thus their selection and quality are critical for optimal bioprospecting. They are used both in the early stages of compound isolation/purification/identification, and in later stages to evaluate their safety and efficacy. In this review, we provide a comprehensive overview of the most common bioassays used in the discovery and development of new bioactive compounds with a focus on marine bioresources. We provide a comprehensive list of practical considerations for selecting appropriate bioassays and discuss in detail the bioassays typically used to explore antimicrobial, antibiofilm, cytotoxic, antiviral, antioxidant, and anti-ageing potential. The concept of quality control and bioassay validation are introduced, followed by safety considerations, which are critical to advancing bioactive compounds to a higher stage of development. We conclude by providing an application-oriented view focused on the development of pharmaceuticals, food supplements, and cosmetics, the industrial pipelines where currently known marine natural products hold most potential. We highlight the importance of gaining reliable bioassay results, as these serve as a starting point for application-based development and further testing, as well as for consideration by regulatory authorities.</p>
Suggested Reviewers:	John R White, PhD director, GSK john.r.white@gsk.com

<p>expert on bioassay development GlaxoSmithKline R&D, 1250 S Collegeville Rd, Collegeville, PA 19426, USA</p>
<p>Cristian Rogel-Castillo, PhD assistant professor, University of Concepción crogel@udec.cl expert in food technology and in development and validation of analytical methods</p>
<p>Maria João Romeu, MSc PhD student, University of Porto Laboratory for Process Engineering Environment Biotechnology and Energy mariaromeu@fe.up.pt expertise in development of antifouling strategies</p>
<p>Agenor Valadares Santos, PhD professor, Federal University of Para avsantos@ufpa.br expertise in biotechnology of microorganisms</p>
<p>Alberto Falco, PhD researcher, Miguel Hernandez University of Elche alber.falco@umh.es expert in fish mucus extracts an their functional compounds and polymer nanostructures for the encapsulation and controlled release of natural compounds</p>
<p>Yasuhiro Igarashi, PhD professor, University of Toyama yas@pu-toyama.ac.jp expert in natural product chemistry</p>
<p>Sabrina Carrella, PhD researcher, Zoological Station Anton Dohrn sabrina.carrella@szn.it expert in developing biomedical applications</p>
<p>Jong Seong Khim, PhD professor, Seoul National University jskocean@snu.ac.kr expert in marine biotechnology and bioassays</p>

Jožef Stefan Institute, Ljubljana, Slovenija
B3 Department of Biotechnology



SI-1000 Ljubljana, Jamova cesta 39 / Tel.: 01 477 3683 / Fax: 01 477 3594

Date: 7 July 2023

Dear Editor,

I am writing on behalf of 16 members of the COST action CA18238 Ocean4Biotech, who combine expertise in various areas of marine biotechnology. During our technical exchanges and discussions, we have found that understanding and conducting high quality bioassays is important for efficient use of natural resources such as the marine environment. Information on bioassays is abundant in the literature, but scattered, and reviews tend to focus on narrow fields or specific applications. Therefore, we decided to create an overview that covers all aspects of bioassays that are important in bringing a natural product from nature to the customer. We focused on marine natural products as they are an increasingly popular source, but the process is similar and applicable to all natural products. We believe that our proposed review entitled "**A guide to the use of bioassays in exploration of natural resources**" will be of interest and use to readers of Biotechnology Advances.

The aim of this review is to highlight the importance of selecting good bioassays and their properties, and to address aspects of the entire process from detection of bioactivity in natural extracts to bioactivity-guided purification and application. We raise important questions that the scientific community using bioassays should consider. We provide a comprehensive and critical overview of the bioassays most commonly used by the marine biodiscovery community, focusing on antimicrobial, cytotoxic, antiviral, antioxidant, and anti-ageing bioassays. We then introduce the concept of validation and quality control that ensures confidence in bioassay results. We then describe the importance of appropriate extraction methods and the steps involved in bioactivity-guided identification and purification. The review concludes with an application-oriented overview focusing on drug discovery, dietary supplements, and cosmetics, the industries most commonly supplied with marine-derived natural products. Safety and regulatory issues that are critical to the transition of substances to a higher stage of development are presented. In the conclusions, an outlook on trends and future developments is provided.

The review is extensive as it cites 273 references and includes 15,420 words, 9 figures, and 2 tables. In addition, a Supplementary table provides comprehensive information on commonly used bioassays with their advantages and limitations.

We believe that this topic will be of interest to a wide audience of researchers working with natural products, as bioassays are routinely used to characterise them. Such a guide would benefit novices in the field as well as those seeking to expand the potential of biodiscovery. The review focuses on marine natural products, but bioassays can be used universally for all natural products, so we believe the review will appeal to all communities that use bioassays in their research.

Yours sincerely,
Dr Jerica Sabotič, corresponding author

Author declaration

[Instructions: Please check all applicable boxes and provide additional information as requested.]

1. Conflict of Interest

Potential conflict of interest exists:

We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below:

No conflict of interest exists.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

2. Funding

Funding was received for this work.

All of the sources of funding for the work described in this publication are acknowledged below:

[List funding sources and their role in study design, data analysis, and result interpretation]

Funding sources had no role in study design, data analysis or result interpretation.

This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) program.

Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4- 2543, J4-4555, P4-0127, P4-0432).

Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001 (application No 1.1.1.2/VIAA/3/19/465).

Susana Gaudêncio: This work is financed by national funds from FCT - Fundação para a

Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB.

Research of Anna Lugini and Giovanna Cristina Varese was financed by the University of Torino (Ricerca Locale) and the European Commission – NextGenerationEU, Project "Strengthening the MIRRI Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.

Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture and Rural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel

Research of Dina Simes was funded by the Portuguese National Funds from FCT— Foundation for Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020 and AAC n° 41/ALG/2020 - Project n° 072583 – NUTRISAFE.

No funding was received for this work.

3. Intellectual Property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

4. Research Ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases)

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

5. Authorship

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two>.

All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

One or more listed authors do(es) not meet the ICMJE criteria.

We believe these individuals should be listed as authors because:

[Please elaborate below]

We confirm that the manuscript has been read and approved by all named authors.

We confirm that the order of authors listed in the manuscript has been approved by all named authors.

6. Contact with the Editorial Office

The Corresponding Author declared on the title page of the manuscript is:

[Insert name below]

Jerica Sabotič

This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

[Insert email address you wish to use for communication with the journal here]

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

[Insert name below]

We understand that this author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.

We the undersigned agree with all of the above.

Author's name (Fist, Last)

Signature

Date

1. Jerica Sabotič

8 July 2023 _____

A guide to the use of bioassays in exploration of natural resources

Jerica Sabotič^{a,*}, Engin Bayram^b, David Ezra^c, Susana P. Gaudêncio^{d,e}, Berat Z. Haznedaroğlu^b, Nika Janež^a, Leila Ktarif^f, Anna Luganini^g, Manolis Mandalakis^h, Ivo Safarik^{i,j}, Dina Simes^{k,l}, Evita Strode^m, Anna Toruńska-Sitarzⁿ, Despoina Varamogianni – Mamatsi^h, Giovanna Cristina Varese^g, Marlen I. Vasquez^o

*Corresponding author: Jerica Sabotič, e-mail: Jerica.Sabotic@ijs.si

Highlights

Bioassay selection and quality is critical for optimal natural resource exploration.

Many variables should be considered when selecting or designing a bioassay.

Different types of bioassays are important for different phases of biodiscovery.

Validation of bioassays is important for more robust and reliable data generation.

Current marine biodiscovery mainly focuses on detection of antimicrobial activities.

A guide to the use of bioassays in exploration of natural resources

Jerica Sabotič^{a,*}, Engin Bayram^b, David Ezra^c, Susana P. Gaudêncio^{d,e}, Berat Z. Haznedaroğlu^b, Nika Janež^a, Leila Ktarif^f, Anna Lukanini^g, Manolis Mandalakis^h, Ivo Safarik^{ij}, Dina Simes^{k,l}, Evita Strode^m, Anna Toruńska-Sitarzⁿ, Despoina Varamogianni – Mamatsi^h, Giovanna Cristina Varese^g, Marlen I. Vasquez^o

^aDepartment of Biotechnology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia

^bInstitute of Environmental Sciences, Bogazici University, Bebek, Istanbul 34342, Turkey

^cDepartment of Plant Pathology and weed research, ARO, The Volcani Institute, P.O.Box 15159, Rishon LeZion, 7528809, Israel

^dAssociate Laboratory i4HB – Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal

^eUCIBIO – Applied Biomolecular Sciences Unit, Department of Chemistry, Blue Biotechnology & Biomedicine Lab, NOVA School of Science and Technology, NOVA University of Lisbon, Caparica, Portugal

^fB3Aqua Laboratory, National Institute of Marine Sciences and Technologies, Carthage University, Tunis, Tunisia

^gDepartment of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy

^hInstitute of Marine Biology, Biotechnology and Aquaculture, Hellenic Centre for Marine Research, 71500 Heraklion, Greece

ⁱDepartment of Nanobiotechnology, Biology Centre, ISBB, CAS, Na Sadkach 7, 370 05 Ceske Budejovice, Czech Republic

^jRegional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic

^kCentre of Marine Sciences (CCMAR), Universidade do Algarve, 8005-139 Faro, Portugal

^l2GenoGla Diagnostics, Centre of Marine Sciences (CCMAR), Universidade do Algarve, Faro, Portugal

^mLatvian Institute of Aquatic Ecology, Agency of Daugavpils University, Riga LV-1007, Latvia

ⁿDepartment of Marine Biology and Biotechnology, Faculty of Oceanography and Geography, University of Gdańsk, 81-378 Gdynia, Poland

^o Department of Chemical Engineering, Cyprus University of Technology, 3036 Limassol, Cyprus

*Corresponding author: Jerica Sabotič, e-mail: Jerica.Sabotic@ijs.si

43 Abstract

44 Bioassay are the main tool to decipher bioactivities from natural resources thus their selection and
45 quality are critical for optimal bioprospecting. They are used both in the early stages of compound
46 isolation/purification/identification, and in later stages to evaluate their safety and efficacy. In this
47 review, we provide a comprehensive overview of the most common bioassays used in the discovery
48 and development of new bioactive compounds with a focus on marine bioresources. We provide a
49 comprehensive list of practical considerations for selecting appropriate bioassays and discuss in detail
50 the bioassays typically used to explore antimicrobial, antibiofilm, cytotoxic, antiviral, antioxidant, and
51 anti-ageing potential. The concept of quality control and bioassay validation are introduced, followed
52 by safety considerations, which are critical to advancing bioactive compounds to a higher stage of
53 development. We conclude by providing an application-oriented view focused on the development of
54 pharmaceuticals, food supplements, and cosmetics, the industrial pipelines where currently known
55 marine natural products hold most potential. We highlight the importance of gaining reliable bioassay
56 results, as these serve as a starting point for application-based development and further testing, as
57 well as for consideration by regulatory authorities.

58

59 Keywords

60 **bioassay selection; bioactivity; natural products; drug discovery; blue biotechnology; screening;**
61 **bioactivity-guided purification; validation; preclinical trials; biodiscovery**

62

63

64 Abbreviations

65 ABTS/TEAC, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox[®]-Equivalent Antioxidant
66 Capacity; ADMET, absorption, distribution, metabolism, excretion, toxicity; AFST, antifungal
67 susceptibility testing; CADD, computer-aided drug design; CC50, 50 % cytotoxicity concentration;
68 CLSI, Clinical and Laboratory Standards Institute; COST, European Cooperation in Science and
69 Technology; CFU, colony forming unit; CPE, cytopathic effect; CTA, cell transformation assays;
70 CUPRAC, CUPric Reducing Antioxidant Capacity; DPPH, 2,2-Diphenyl-1-picrylhydrazyl; EC50, 50%
71 effective concentration; EFSA, European Food Safety Authority; EMA, European Medicines Agency;
72 ET, electron transfer; EUCAST, European Committee on Antimicrobial Susceptibility Testing; FDA,
73 United States Food and Drug Administration; FFA, focus-forming assay; FMCA, fluorometric
74 microculture cytotoxicity assay; GI50, 50 % growth inhibition; GLP, good laboratory practice; HA,
75 hemagglutinin; HAT, hydrogen atom transfer; HIA, hemagglutination inhibition assay; HTS, high-
76 throughput screening; LLPS, liquid-liquid phase separation; LOD, limit of detection; LOQ, limit of
77 quantitation; MALDI-TOF, matrix-assisted laser desorption ionization–time-of-flight mass
78 spectrometry; MIC, minimum inhibitory concentration; MOI, multiplication of infection; MBC,
79 minimum bactericidal concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
80 bromide; a yellow tetrazole that is reduced to purple formazan in living cells; MS, mass spectrometry;
81 MSPE, magnetic solid phase extraction; NAM, new approach methodology; OECD, Organisation for
82 Economic Co-operation and Development; ORAC, oxygen radical absorbance capacity; PRA, plaque
83 reduction assay; qPCR; quantitative real-time polymerase chain reaction; RBC, red blood cells; SI,
84 selectivity index; SPE, solid phase extraction; VRA, virus yield reduction assay

85

86		
87	Contents	
88	Abstract	2
89	Keywords	2
90	Abbreviations	2
91	Contents	3
92	1. Introduction.....	4
93	2. Bioassay types and their use in bioactive compound discovery	4
94	3. Practical considerations in choosing bioassays to detect target bioactivity	5
95	3.1. Specifics of marine samples	9
96	4. Prevalent bioassays in marine biodiscovery	9
97	4.1. Antimicrobial bioassays.....	10
98	4.1.1. Antibiofilm assays.....	11
99	4.1.2. Special consideration for antifungal bioassays	12
100	4.2. Cytotoxicity bioassays	13
101	4.3. Antiviral Bioassays	15
102	4.4. Bioassays for cosmetics and cosmeceuticals with a focus on antioxidant and anti-ageing	
103	effects 17	
104	5. Quality control and bioassay validation	19
105	5.1. The concept of validation	19
106	5.2. Validation of the analytical method	20
107	5.3. Data integrity and documentation	22
108	5.4. Good Laboratory Practice (GLP)	22
109	6. Bioactivity-guided fractionation and/or purification	22
110	7. Application-oriented development	25
111	7.1. Pharmaceutical drug discovery	26
112	7.2. Cosmetics	29
113	7.3. Food and feed supplements.....	30
114	8. Conclusions.....	31
115	9. Acknowledgments & funding	32
116	10. References.....	32
117	Figure legends	55
118		
119		

120 1. Introduction

121 The most common approach to discovering new bioactive compounds is extensive screening of crude
122 natural extracts using bioassay-guided protocols to determine their activity, followed by isolation and
123 characterization of the active compounds, which are then used in a variety of biotechnological
124 applications, including food, feed, agriculture, cosmetics, and veterinary and human medicine. The
125 discovery of new marine natural products in the last five years has been driven primarily by marine
126 fungi, but also by sponges, tunicates (ascidians), and molluscs/cyanobacteria, which are the source of
127 most of the approved drugs in the marine pharmacology pipeline. In addition, marine viruses, bacteria,
128 archaea, fungi, and phytoplankton or zooplankton, including cyanobacteria, green algae,
129 thraustochytrids, and dinoflagellates, have long been studied as sources of natural bioactive products.
130 To increase the chemical space and diversity of activities detected in bioassays, modifications of culture
131 conditions or co-cultivation are used in the search for natural products from culturable microorganisms
132 (e.g., (Lauritano et al., 2016; Marmann et al., 2014; Oh et al., 2005; Romano et al., 2018). Other sources
133 of marine natural products include actinomycetes, brown, and red algae, cnidarians, bryozoans, and
134 echinoderms (Barreca et al., 2020; Carroll et al., 2021; Jimenez et al., 2020; Rotter et al., 2021a).

135 The authors of this review are members of COST Action CA18238 Ocean4Biotech, a network
136 of more than 150 blue biotechnology scientists and practitioners from 37 countries (Rotter et al.,
137 2021b, 2020). Our goal is to provide a guide for decision making in the selection and use of bioassays
138 to improve the efficiency of bioprospecting and discovery of bioactive marine compounds. A
139 comprehensive overview of bioassays currently used in the marine bioprospecting community is
140 provided, along with their strengths and weaknesses, followed by considerations for bioassay-guided
141 identification and isolation. We also consider the importance of incorporating *in vitro*, *ex vivo*, and 3D
142 human cell- or tissue-based bioassay protocols as important tools in the preclinical process to avoid
143 drug failure in clinical trials, most often due to lack of clinical efficacy and/or unacceptable toxicity. We
144 then present quality control procedures, including validation, that are required for further safety and
145 efficacy testing, which will then pave the way for eventual regulatory approval for commercialization.
146 The procedures and workflows described are general in nature and can be applied to a wide range of
147 potential applications of bioactive compounds, from industrial enzymes to pharmaceuticals for human
148 consumption. Therefore, we use the term bioactive compounds to refer to all structural variants of
149 natural molecules, from small molecules to large polymers, including, for example, proteins and
150 polysaccharides. Finally, we provide an application-oriented overview of the industrial pipelines most
151 commonly supplied with marine-derived natural products, including those focused on the
152 development of pharmaceuticals, dietary supplements, and cosmetics. By providing insight into the
153 assays used to evaluate bioactivity and best practices in bioassays, this review aims to guide the natural
154 products and blue biotechnology community in decision making for natural product discovery and
155 development.

156

157 2. Bioassay types and their use in bioactive compound discovery

158 The biological relevance of natural extracts and pure compounds, whether natural or synthetic, is
159 determined by the bioactivity assays or bioassays used (Weller, 2012). The term “bioactive” is defined
160 as “having or causing an effect on living tissue” (Strömstedt et al., 2014). Different characteristics of
161 bioassays such as throughput, complexity, speed, and cost are relevant to different stages of the
162 biodiscovery process (Fig. 1). In the pre-screening and screening phase, the goal is to detect and

163 potentially quantify bioactivity potential. Therefore, bioassays should be performed in a high-
164 throughput format screening format (HTS) that allows rapid and cost-effective testing of large number
165 of samples or large libraries of extracts, extract fractions. or pure compounds. In the monitoring phase,
166 bioassays are used to guide purification or fractionation processes to isolate and identify single pure
167 bioactive compounds (bioactivity-guided approach), so they must be designed to have a high
168 throughput capacity, be fast and easy to perform, and be cost-effective. Interestingly, innovative *in*
169 *silico* approaches have recently been developed that do not require extract fractionation and are
170 known as compound activity mapping (CAM) and are freely available (www.npanalyst.org) (Gaudêncio
171 et al., 2023; Kurita et al., 2015; Lee et al., 2022; O'Rourke et al., 2020). Finally, in the secondary phase,
172 bioassays are used to identify and characterize the biological mode of action of the bioactive
173 compound, which typically requires a series of bioassays that must be highly specific and accurate and
174 are usually time-consuming and expensive (Claeson and Bohlin, 1997; Strömstedt et al., 2014; Suffness
175 and Pezzuto, 1991).

176 Bioassays can be performed *in silico*, *in vitro*, *ex vivo*, or *in vivo* at any of the levels described, and
177 usually a combination of these methods is used to characterise a new compound or the bioactivity
178 potential of a natural resource. When screening an extract for medicinal activity, *in silico* and *in vitro*
179 assays are typically used to identify the bioactive compound and its mode of action, while *in silico* and
180 *in vivo* assays (e.g., animal studies) provide information on pharmacological activity and toxicity (Mbah
181 et al., 2012; Strömstedt et al., 2014).

182
183

184 3. Practical considerations in choosing bioassays to detect target 185 bioactivity

186 The following paragraphs provide a list of questions and considerations, the answers to which
187 provide information on what to consider when selecting or designing a bioassay (Table 1, Fig. 2).

188 At what stage of the discovery process and for what purpose will the bioassay be performed?
189 Considering the target bioactivity of interest, appropriate bioassays can be selected and used to screen
190 crude or fractionated extracts, to guide subsequent purification, or to explain underlying mechanisms
191 of action, as described in the previous section. First and foremost, the target bioactivity should be
192 selected. An overview of the most commonly used bioassays can be found in Supplementary Table S1.

193 Is there an interest in a specific or general activity? In general, bioassays can be divided into
194 two distinct categories: “single-target bioassays” and “functional multi-target bioassays”. Single-target
195 bioassays are generally designed to detect the effect of the tested compounds on a particular target
196 with a high degree of specificity and based on a distinct mechanism of action (Claeson and Bohlin,
197 1997). Examples include the analysis of specific enzymatic activities, such as the degradation of
198 proteins or breakdown of plastics, or the inhibition of enzymatic activities, such as the inhibition of
199 proteases and the blocking of target receptors. Another variation of single-target bioassays is
200 “chemical-genetic profiling” in yeast. A panel of yeast strains with selective mutations that highlight
201 sensitivity to specific drugs is used to screen known compounds with unknown modes of action or
202 mixtures of compounds such as natural product extracts (Harvey, 2008). The second category,
203 “functional multi-target bioassays”, includes bioassays that use whole animals, organs or cells. These
204 bioassays are non-specific in their outcome and measure phenotype change or a general biological
205 effect, such as an antimicrobial or cytotoxic effect. The response to the bioactive compound tested

206 cannot necessarily be attributed to a specific mode of action. These are often referred to as the
207 “phenotype-based approach” (Claeson and Bohlin, 1997; Swinney, 2013).

208 Which are the most common bioassays for determining target activity? The target bioactivity
209 can be assessed using a variety of bioassays, but the scientific community may prefer certain assays
210 for which troubleshooting, appropriate controls, and interpretation support are available
211 (Supplementary Table S1).

212 Are resources available to perform bioassays (in terms of ease of execution or technical
213 complexity)? Specialized equipment and/or trained personnel are required to perform certain
214 bioassays. In terms of safety, it is also important to consider whether the bioassay uses hazardous
215 chemicals or organisms that must be handled in safety chambers and comply with local regulations
216 (e.g., consider the biosafety level (BSL) of the target organisms or the use of genetically modified
217 organisms (GMOs)).

218 What are the associated costs for personnel, equipment, and materials? Will the bioassay be
219 used as a routine method? A bioassay may be simple (e.g., an enzymatic reaction detected by a colour
220 change) and performed by a technician, whereas some types of bioassays (e.g., bioassays using cell
221 culture) require extensive training. Similarly, bioassays may be more or less labour-intensive and
222 require specialised equipment or expensive consumables.

223 Is high throughput and full automation of the analytical process required? Bioassays often use a
224 96-well plate format. A common plate-related phenomenon is the so-called “edge effect”, in which the
225 response in peripheral wells differs from the response observed in the inner wells of a microplate.
226 There are several approaches to avoid this problem, such as using only the inner wells, randomization
227 in plate design, or replication (White et al., 2019). Recently, some manufacturers offer plates with a
228 built-in moat surrounding the outer wells (or even both inner and outer wells), that is filled with water,
229 and serving as an evaporation buffer during prolonged incubation. Depending on the desired
230 throughput, robotic liquid handling systems can be used to fully automate almost any bioassay
231 workflow, but the initial cost of such systems can be prohibitive for small laboratories.

232 Are standardized forms of bioassay available? Although standardization of bioassays facilitates
233 interpretation and comparison of data between laboratories and allows better monitoring of bioassay
234 performance, standardized bioassay protocols are available for only a limited number of bioassays.
235 Inter-laboratory reproducibility or precision under the same operating conditions becomes more and
236 more valuable in stages of higher levels of technology readiness (TRL).

237 What is required to interpret the results of the bioassay? What are the appropriate controls to
238 distinguish true results from false positives or false negatives? Before beginning to interpret the
239 results, it is assumed that the test performance was appropriate. This can be verified by including an
240 external positive or negative control (or sometimes an internal standard) in the assays, such as
241 organisms with a known phenotype, to ensure that the bioassay performance was optimal. The
242 measurements obtained can be compared to positive and/or negative controls, as well as to blank
243 measurements, to evaluate the effects of medium/buffer/background. Although method validation at
244 the discovery level is not essential, evaluation of precision, i.e., the degree of scatter between a series
245 of replicate measurements obtained from multiple samplings of the same homogeneous sample under
246 the same conditions – expressed as coefficient of variation (CV) - makes the data more robust and
247 reliable.

248 How are the results to be interpreted in a meaningful way? Is the extract/compound bioactive?
249 Benchmarks and thresholds for bioactivity must be considered, as there are common thresholds below

250 which an extract is considered very active or moderately active, while above these thresholds it is
251 considered of little interest for further development. Meaningful evaluation of the results in
252 combination with chemical dereplication strategies (i.e., evaluating the presence of known compounds
253 in the crude extracts) (Gaudêncio and Pereira, 2015) plays a very important role in prioritizing samples
254 for further development and deciding which samples are worthwhile for further development
255 investment.

256 What is the expected content of bioactive compounds in the extract? How complex is the crude
257 extract and what is the level of background substances that would interfere with the measurement of
258 bioactivity? Advanced dereplication methods are used for natural product profiling/fingerprinting of
259 complex extracts (Gaudêncio and Pereira, 2015). An estimate of the expected content of bioactive
260 target compounds helps in the selection of the bioassay to avoid false positives in terms of required
261 sensitivity (high sensitivity for low-content compounds), selectivity (the extent to which the bioassay
262 can differentiate and detect a target analyte without interference from concurrently present irrelevant
263 compounds), and specificity, which is a measure of high selectivity (the ability to unambiguously detect
264 the target analyte in the presence of other substances, including those with similar chemical
265 structures). It also helps in the selection of appropriate controls and thus in the interpretation of data.
266 For some compounds, spiking samples with a reference standard can be a solution for detection and
267 quantitation, but a suitable standard must be available.

268 What is the desired level of quantitative response (qualitative, semi-quantitative, quantitative
269 results)? Does the potency need to be accurately assessed? Measurements can be binary (activity
270 present or absent), or quantitative information can be obtained by comparison with appropriate
271 controls. Although only quantitative bioassays are suitable for unambiguous determination of potency,
272 the need for such accurate information may be more important at later stages of discovery,
273 purification, safety, and efficacy testing. Quantitative assays often use standard compounds (spiking,
274 calibration curves), and it is worthwhile to check the availability of appropriate standards. In the
275 context of interpretation of results, determination of the limit of detection (LOD) and limit of
276 quantification (LOQ) provides better reliability of data. In addition, selection of bioassays with lower
277 limits of detection and quantitation usually results in a higher degree of confidence in the final data.

278 It is useful to know what may affect the precision or repeatability of bioassays. Some metabolites
279 show synergistic effects and bioactivity is lost after fractionation, or metabolites may act
280 antagonistically and activity is detected only after fractionation. In addition, physical parameters of the
281 extract (viscosity, pH, colour, etc.) can lead to false-positive and false-negative results. Potential
282 interferences can arise from the material of the sample containers (usually polypropylene and
283 polystyrene, treated or untreated, or glass), and these should be carefully selected based on the charge
284 and polarity of the molecules to be tested, if known (Strömstedt et al., 2014).

285 What is the solubility and stability of the compound of interest? Is it a small molecule or a
286 complex molecule? The solvent used for extraction must not be toxic or should not be used at a
287 concentration that is toxic to the microorganisms, cells, tissues, organs, or organisms. When aqueous
288 solutions are not used for extraction, extractions are usually performed with dimethyl sulfoxide
289 (DMSO), N,N-dimethylformamide (DMF), methanol, or ethanol, which can be tolerated in microbial or
290 cell-based assays only at low concentrations (e.g., up to 1 % DMSO) and whose presence may affect
291 final results (Dyrda et al., 2019; Hipsher et al., 2021; Rekha et al., 2006). Compounds extracted with
292 organic solvents can be vacuum dried to mitigate this issue. Nevertheless, the effect of extraction
293 solvents can be evaluated by performing the bioassay with the solvent as a control. In addition, poor

294 water solubility can lead to misleading results. Bioassay optimization strategies are recommended to
295 improve bioassay performance for poorly soluble compounds (Di and Kerns, 2006).

296 As mentioned earlier, the effect of extraction medium is evaluated by performing the bioassay
297 with the extraction solution alone. If necessary, this control is performed each time the bioassay is
298 conducted. Characteristics of the extraction medium such as thermostability, volatility, and complexity
299 (sedimentation properties and migration) can also affect the design of the bioassay, while
300 characteristics of the target substance such as thermostability, susceptibility to proteolytic
301 degradation, and complexity that affect the temperature and timing of extraction can also affect the
302 desired bioactivity. For example, enzymes are typically isolated at low temperatures because they can
303 be sensitive to proteolytic degradation or thermal denaturation, which can lead to loss of bioactivity.
304 In addition, natural products should be handled at temperatures below 40 °C to avoid degradation and
305 loss of bioactivity. In general, it is preferable to work with compounds that are stable under various
306 conditions, especially with regard to further development and for practical reasons with regard to the
307 application and marketing of the final products.

308 Do seasonal and geographic differences or legal aspects of sampling affect samples used for
309 bioactivity screening and thus affect biodiscovery? For many types of natural samples, re-sampling is
310 limited due to large seasonal or geographic variations. In addition, issues of safety and sustainability
311 should be considered. Legal issues can also limit transnational access to (marine) biological resources,
312 but this obstacle can be effectively addressed under the Nagoya Protocol and by following well-
313 regulated procedures (Schneider et al., 2022).

314 Is there a need and possibility to validate the bioassay? Validation of bioassays in the discovery
315 phase is useful for evaluating efficacy of candidate bioactivities with high precision and accuracy. This
316 is also important for planning safety and efficacy testing and clinical trials, establishing the basis for
317 discussions with regulatory authorities during planning. At later stages, at the quality control level,
318 bioassays should also reliably assess the quality across different product batches.

319 What are the relevant target organisms? In bioassays involving living organisms, e.g.,
320 microorganisms, cell lines, or animals, it is important to select appropriate target organisms with
321 respect to their relevance and the particular requirements for handling these organisms. An important
322 aspect to consider is the growth conditions, as different growth conditions may affect the outcome of
323 the bioassay.

324 Do we have a clear idea of the intended application? If there is a clear idea of an application/use,
325 the local regulatory authority should be approached early in biodiscovery, as it is beneficial to use
326 those bioassays that are congruent with product development, as this can be very useful to expedite
327 the process.

328

329 **Table 1**

330 What to consider when selecting a bioassay to search for a selected bioactivity

Purpose
Is it aimed at general or specific bioactivity?
How selective should it be?
Are quantitative or qualitative results needed?
How sensitive should it be (what is the requirement for the minimal amount of compound)?
Cost
Time requirement

Labour intensiveness
Cost of material
Requirement of special equipment (different modes of detection)

Effect of the extraction procedure on bioactivity

Selection of source material (amount available, possibility to reacquire)
Availability of source material (seasonal, geographic, legal)
Organic solvent or water-based
Temperature of extraction
Length of extraction
Homogenization steps
Cultivation steps
Stability of bioactive compound
Interference with materials used for extraction (e.g., plastic, solvent components)

Feasibility

Errors caused by the colour or viscosity of extracts
Reproducibility
High-throughput capacity or automation possibility
Ease of results interpretation

Other

Availability of standards
Bioactivity threshold
Capability of dereplication
Regulatory requirements (e.g., use of BSL2 or GMO organisms)

331

332

333 **3.1. Specifics of marine samples**

334 When working with marine extracts or marine microorganisms in bioassays, special considerations
335 should be made and adapted to the presence of salt, poorly hydrophilic, often highly coloured or
336 autofluorescent, and chemically complex materials. Moreover, when working with higher organisms
337 as a source of bioactivity, it should be verified whether the bioactivity originates from the
338 macroorganism or from the associated microbiota (Beutler, 2009; De La Calle, 2017; Macedo et al.,
339 2021). Geographic or seasonal variations in the production of bioactive metabolites, which have been
340 demonstrated for different marine organisms (El-Wahidi et al., 2011; Heavisides et al., 2018; Hellio et
341 al., 2004; Henrikson and Pawlik, 1998), are another important issue.

342

343

344 **4. Prevalent bioassays in marine biodiscovery**

345 Using a literature search of the PubMed database, we analysed research efforts on marine natural
346 product discovery between 2000 and 2022 (Fig. 3). There is a panoply of bioassays that can be used to
347 screen natural resources for their bioactive properties. We have compiled the most common of these
348 in Supplementary Table S1 and provided a critical overview of their advantages and disadvantages.

349 Here, we provide an overview of antimicrobial, antifungal, antiviral, and cytotoxicity bioassays, as well
350 as those that investigate the antioxidant and anti-ageing potential of marine extracts. These include
351 both phenotype-based and single-target bioassays to varying degrees, e.g., antimicrobial assays are
352 mostly phenotype-based, whereas both phenotype-based and single-target bioassays can be used to
353 assess cytotoxicity.

354

355 4.1. Antimicrobial bioassays

356 The strongest research efforts in the field of bioactivity of natural marine sources have been dedicated
357 to the detection of antimicrobial activities using phenotypic assays (Fig. 3). The term antimicrobial
358 activity encompasses both antibacterial and antifungal activities, but is often used in studies that work
359 only with bacteria, whereas other studies claiming antimicrobial activities examine both bacteria and
360 fungi. In addition, there are studies that focus on one group of organisms and investigate either
361 antibacterial or antifungal bioactivity. The increased efforts are mainly due to the worldwide decline
362 in the development of antibiotics, while the increasing emergence of microorganisms resistant to
363 antimicrobials is becoming a global health threat (Dadgostar, 2019). The problem is of particular
364 concern for the Gram-positive and Gram-negative bacterial pathogens that belong to the ESKAPE
365 group (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter*
366 *baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter spp.*), and some fungal pathogens (*Candida*
367 *auris*, *Candida glabrata*, *Aspergillus fumigatus*, *Cryptococcus neoformans*), for which an increasing
368 number of multidrug-resistant strains have been identified worldwide (Arendrup and Patterson, 2017;
369 Liu et al., 2019; Minarini et al., 2020). The ecological diversity of the marine environment and
370 (micro)organisms in this habitat, combined with the large genetic diversity, represents a unique and
371 rich source of compounds that can be exploited by the pharmaceutical industry and potentially provide
372 solutions to the increasing number of drug-resistant infectious diseases (Hughes and Fenical, 2010; Liu
373 et al., 2019).

374 The most commonly used bioassay to investigate the antimicrobial activity of marine natural
375 products is the determination of minimum inhibitory concentration (MIC) in the form of broth
376 microdilution, macrodilution, and agar dilution, followed by the disc diffusion/Kirby–Bauer method
377 (Fig. 4, Supplementary Table S1). These bioassays determine the lowest concentration of an
378 antimicrobial agent that prevents visible or measurable growth of a microorganism. Two organizations
379 develop standardized reference methods for antimicrobial susceptibility testing: the Clinical &
380 Laboratory Standards Institute (CLSI) (<https://clsi.org/>) and the European Committee on Antimicrobial
381 Susceptibility Testing (<https://www.eucast.org/>). Although some guidelines from standardized
382 protocols should also apply to bioassays performed on marine samples, noncompliance with these
383 guidelines is relatively common. Items whose standardization has a critical impact on the repeatability
384 and reliability of results include the selection of microbial species and strains, the size and age of the
385 *inoculum*, the type of culture medium, and the duration of incubation. To ensure the quality of the
386 bioassay performed, a positive control of a standard antibiotic should be tested against authenticated
387 microbial strains, preferably from a type culture collection such as national type cultures collections
388 (e.g., National Collection of Type Cultures (NCTC) in the United Kingdom; German Collection of
389 Microorganisms and Cell Cultures DSMZ; American Type Culture Collection - ATCC). Reagent sterility
390 controls and negative controls (e.g., influence of solvents) should also be included in each bioassay.
391 When working with complex samples such as natural extracts, the presence of other metabolites in
392 the extract can potentially serve as a carbon source for the microorganism used, which can mask the

393 effect. Both technical and biological replicates should be performed to increase measurement
394 accuracy.

395 The main advantages of dilution methods are the ability to obtain quantitative MIC values
396 (minimum concentration that inhibits microbial growth) and MBC values (minimum bactericidal
397 concentration, lowest concentration at which 99.9% of bacteria are killed). Published MIC values for
398 marine extracts vary from $\mu\text{g/mL}$ to even mg/mL and are generally below $100 \mu\text{g/mL}$ for pure
399 compounds (Choudhary et al., 2017). There are common thresholds at which the extract is considered
400 very active ($<10 \mu\text{g/mL}$), moderately active ($10\text{-}250 \mu\text{g/mL}$), and with little or no activity ($> 250 \mu\text{g/mL}$)
401 (Fajarningsih et al., 2018; Nweze et al., 2020; Pech-Puch et al., 2020). The optimal MIC and IC_{50}
402 (concentration at which 50 % of growth inhibition is achieved) for a pure substance should be below 1
403 $\mu\text{g/mL}$, while concentrations above $10 \mu\text{g/mL}$ are considered of little interest for further research
404 (Cushnie et al., 2020). In the diffusion-based method, there is no quantitative result or only a limited
405 one. However, both types of bioassays can be useful to analyse the difference in antimicrobial activity
406 of individual natural products observed in different strains of a given species (e.g., resistant and non-
407 resistant mutants). *In vitro* assays are characterised by simplicity of design and performance. They are
408 traditionally time-consuming but can be automated. However, the results are usually not available
409 within a day and do not provide information on the mechanism of action.

410 Gram-positive bacteria are more sensitive to the effects of many known agents than Gram-
411 negative ones, which increases the likelihood of hits in screening studies (Cos et al., 2006). For this
412 reason, microorganisms from different groups should be included in the screening process. For each
413 microorganism tested, the optimal growth medium and inoculum size should be determined to avoid
414 underestimation or masking of antimicrobial activity (Wiegand et al., 2008). Many published studies
415 have used Lysogeny Broth (LB) media for antibacterial testing, but their use should be avoided due to
416 the imbalanced composition of carbohydrates, low availability of divalent cations, and occasional
417 contamination with bile salts (Nikaido, 2009; Sezonov et al., 2007).

418 The type of extracts (the type of solvent used) should be considered when choosing one of the
419 above methods. For example, lipophilic compounds do not diffuse well into solid culture media,
420 whereas strongly charged molecules may undergo ion exchange processes in agar. Therefore, the agar
421 diffusion method is more suitable for the analysis of single metabolites with known polarity and not
422 for complex extracts.

423 To further investigate the antimicrobial activity of natural molecules, time-kill assays and flow
424 cytometry methods can be used to provide information on the nature of the inhibitory effect and the
425 cellular damage inflicted on the test microorganism (Balouiri et al., 2016). This bioassay is used in a
426 second phase of testing to determine the dynamics of microbial inhibition kinetics (Dinarvand et al.,
427 2020). Most antimicrobial bioassays are performed *in vitro*, but secondary screening for highly potent
428 compounds may also include *in vivo* assays, (e.g., in murine models), to gain better insight into their
429 preclinical potential (Martín et al., 2013). *In vivo* bioassays are generally not performed with extracts
430 because of the difficulty of interpreting effects based on an unknown mixture of compounds. However,
431 in some examples, *in vivo* testing is recommended early in the development timeline because potential
432 systemic side effects may be antagonistic or synergistic (Sabotič et al., 2020).

433

434 4.1.1. Antibiofilm assays

435 In recent years, the control of microbial biofilms has gained significant attention as it is
436 increasingly recognized that biofilms are responsible for microbial persistence. New strategies for

437 combating microorganisms focus on the one hand on preventing biofilm formation by inhibiting
438 adhesion or quorum sensing and on the other hand on eliminating biofilms by dispersion. Antibiofilm
439 agents are therefore considered as an alternative to fight microbial resistance to antibiotics, since
440 microorganisms do not need to develop resistance to adapt, as their population is not decimated, but
441 merely prevented from persisting in the selected environment. To date, there is only one standardized
442 assay for antibiofilm activity, namely the single-tube method (ASTM E2871), which is supported by a
443 standard practice for biofilm growth in a CDC biofilm reactor (ASTM E3161) optimized for biofilms of
444 *Pseudomonas aeruginosa* and *Staphylococcus aureus* (ASTM E2871-21, 2021; ASTM E3161-21, 2022;
445 Lozano et al., 2020). Biofilm formation is usually monitored by crystal violet staining, which is used to
446 stain the biomass of the biofilm. Other commonly used methods include measuring the metabolic
447 activities of biofilm cells with tetrazolium salts, culturing biofilm cells after sonication to determine the
448 number of CFUs (colony forming units) in the biofilm, or microscopy, which can be either scanning
449 electron microscopy or confocal laser scanning microscopy (Bridier et al., 2010; Haney et al., 2021;
450 Kirmusaoğlu, 2019; Klančnik et al., 2017; Peeters et al., 2008). Antibiofilm activity is often expressed
451 as minimum biofilm inhibitory concentration (MBIC) or CFU log reduction. A microplate format can be
452 adapted for high-throughput screening evaluation of antibiofilm efficacy, typically screening individual
453 compounds at concentrations of up to 100 μ M and identifying active hits as those that inhibit biofilm
454 formation by $\geq 80\%$ while simultaneously inhibiting bacterial growth by $\leq 40\%$ (Kwasny and Opperman,
455 2010). Inhibiting biofilm formation without affecting bacterial growth is preferable because there is
456 less pressure on survival and consequently on the development of resistance (Sterniša et al., 2022).

457 Bacterial cell-to-cell communication, which senses the density of bacterial cells and is referred
458 to as quorum sensing, is an important component of the biofilm formation process and bacterial
459 virulence. To identify antibiofilm agents, inhibition of quorum sensing is usually tested using quorum
460 sensing reporter strains. However, this approach has some limitations, including negative effects on
461 reporter strain growth, so appropriate control experiments are essential to obtain reliable results
462 (Defoirdt, 2018; Defoirdt et al., 2013; Taga and Xavier, 2011; Zhao et al., 2020). Alternative methods
463 have been developed that provide a better approximation of real biofilm conditions but require
464 specialized equipment, such as delicate microfluidic systems (Goeres et al., 2005; Millar et al., 2001;
465 Tremblay et al., 2015), the Calgary Biofilm Device (Ceri et al., 1999) or the BioFilm Ring Test (Olivares
466 et al., 2016). Simultaneous detection of antimicrobial and antibiofilm activity against important
467 pathogenic bacteria is also possible by studying their growth kinetics with a microplate reader and
468 using a growth curve analysis (Sterniša et al., 2022). Determination of both antibiofilm (i.e., inhibition
469 of biofilm formation or promotion of biofilm dispersion) and antimicrobial (i.e., inhibition of growth
470 and/or survival) activity is important to understand whether the compounds tested affect biofilm
471 formation directly or indirectly.

472

473 4.1.2. Special consideration for antifungal bioassays

474 The nature of filamentous fungal growth requires the use of adapted bioassays to test the antifungal
475 activities of metabolites and molecules. The prevalence of fungal infections (both invasive and
476 opportunistic fungal infections) is rising due to the increase in the ageing population and
477 immunocompromised patients (Webb et al., 2018). In addition, acquired resistance has emerged in
478 clinically relevant fungi such as *Candida* spp. and *Aspergillus* spp. Therefore, antifungal susceptibility
479 testing (AFST) is of increasing importance in clinical microbiology laboratories, both for selection of
480 appropriate therapy and to provide information on resistance rates at local and global levels in

481 epidemiological studies. The same tests are also used for screening natural products and guiding the
482 discovery of new antifungal agents. Many factors can influence the outcome of *in vitro* AFST tests,
483 including the definition of the endpoint, the inoculum size of the studied fungus, the incubation period,
484 the temperature, and the culture media used for the test (Berkow et al., 2020). For this reason, AFST
485 is not recommended for every fungal pathogen detected in a sample and is performed in clinical
486 microbiology laboratories primarily for yeasts.

487 Broth microdilution bioassays are routinely used for fungi, and there are two standard
488 methods for broth microdilution testing of yeasts in clinical laboratories and two others for molds:
489 those established by the Clinical and Laboratory Standards Institute (CLSI) and those established by the
490 European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Arendrup et al., 2008; Clinical
491 and Laboratory Standards Institute, 2017a, 2017b; Rodriguez-Tudela et al., 2008). The four standards
492 use the same criteria to define the test endpoint and use similar criteria to develop clinical breakpoints
493 and thus interpret antifungal resistance and/or susceptibility. However, they differ in several aspects
494 regarding media composition, test microorganism preparation (including inoculum size),
495 measurement methods, and positive controls. Standardized protocols based on disk diffusion are
496 available for both yeasts (Clinical and Laboratory Standards Institute, 2009) and filamentous fungi
497 (Clinical and Laboratory Standards Institute, 2010). Although the qualitative results of the disk diffusion
498 method are suitable for routine use in the clinical laboratory, the quantitative MIC data are more
499 relevant for the treatment of invasive infections. Agar-based antifungal screening or “poisoned food
500 assays”, in which fungal growth on a standard agar containing antifungal agents is evaluated.
501 Commercial kits are available for antifungal screening of *Candida* and *Aspergillus* spp..

502 Alternative methods for determining antifungal activity using specialized equipment have also
503 been developed. These techniques include flow cytometry, in which changes in fluorescence are
504 interpreted as changes in cell viability and fungal damage (Chaturvedi et al., 2004). With MALDI-TOF,
505 changes in the proteome compared to a drug-free control are interpreted as indicators of antifungal
506 activity (Sanguinetti and Posteraro, 2016). Isothermal microcalorimetry is used to determine changes
507 in metabolic heat flow of cultured fungi in response to an antifungal agent and indirectly assess its
508 activity (Furustrand Tabin et al., 2013).

509

510 4.2. Cytotoxicity bioassays

511 Cytotoxic activity is the second most studied bioactivity for marine natural products in the last twenty
512 years (Fig. 9, Fig. 3, Fig. 5). Cytotoxicity is often studied in terms of possible anticancer activity. There
513 are several types of bioassays to analyse the cytotoxic properties of natural products, which include
514 phenotypic and single-target bioassays. They are based either on the selective penetration of dyes into
515 dead and living cells or on the detection of markers leaking from the cytoplasm of dead cells.
516 Cytotoxicity bioassays based on selective dye penetration can be divided according to the nature of
517 their endpoints into colorimetric assays (e.g., tetrazolium salts such as MTT, MTS, XTT, or WST, trypan
518 blue, sulforhodamine B (SRB), neutral red uptake (NRU), crystal violet), fluorometric assays (Alamar
519 Blue (AB), 5-carboxyfluorescein diacetate, acetoxymethyl ester (CFDA-AM), carboxyfluorescein
520 succinimidyl ester (CFSE), propidium iodide (PI), Hoechst-33342, protease viability using
521 glycyphenylalanyl-aminofluorumarin (GF-AFC) as substrate, and luminometric assays (ATP-based and
522 real-time viability) as reviewed elsewhere (Aslantürk, 2018; Riss et al., 2019). The most commonly used
523 bioassays based on markers leaking from dead cells measure the activity of lactate dehydrogenase
524 (LDH), adenylate kinase (AK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or

525 aminopeptidase. Another option is to preload cells with a measurable marker such as calcein-AM or
526 radioactive ^{51}Cr , which is typically used for mixed cell assays in immunology (Aslantürk, 2018; Riss et
527 al., 2019). Assays are usually performed either in microplate format or flow cytometrically.

528 Testing different cell types is essential, especially in the context of cancer research, as each
529 cell type may respond differently to treatment (Niepel et al., 2017). The screening of 60 human tumour
530 cell lines for anticancer drugs (NCI60) by the US National Cancer Institute (NCI) was developed in the
531 late 1980s as a tool for *in vitro* drug discovery and then expanded into a service screening to support
532 cancer research. In 2018, the NCI established a Program for Natural Product Development (NPNPD) to
533 develop a publicly accessible HTS-amenable library of more than 1,000,000 fractions from 125,000
534 marine, microbial, and plant extracts gathered from around the world to advance HTS efforts and
535 accelerate NP drug development. By 2019, 384-well plates containing over 326,000 fractions were
536 made available for free screening against any disease target (Gaudêncio et al., 2023; Thornburg et al.,
537 2018). Regarding the evaluation criteria for cytotoxic activity, it was suggested that crude extracts
538 showing 50 % growth inhibition (GI_{50}) at concentrations below 100 $\mu\text{g}/\text{ml}$ should be considered
539 cytotoxic, while those holding promise for further investigation should have a GI_{50} below 30 $\mu\text{g}/\text{ml}$
540 (Suffness and Pezzuto, 1991). Although cytotoxicity screening aims to identify compounds with growth
541 inhibitory or toxic effects on specific tumour types (disease-oriented approach), the patterns of
542 relative drug sensitivity and resistance generated with standard anticancer drugs can also help to
543 determine the mechanisms of action of the compounds tested. The information-rich nature of the
544 screening data thus provides additional insight into cytotoxic effects (Shoemaker, 2006). The pattern
545 recognition algorithm COMPARE assigns a biological response pattern to the 60-cell line dose-response
546 data for a compound and evaluates whether the response is unique or resembles a known or
547 prototypical compound to assign a putative mechanism of action to a tested compound. As more data
548 are collected on the characterization of different cellular molecular targets of the compounds tested,
549 the compounds most likely to interact with a particular molecular target can be selected (Park et al.,
550 2010; Zaharevitz et al., 2002). The accuracy of cytotoxic bioassays is strongly influenced by cell type,
551 seeding density, and medium composition. Therefore, it is important to include appropriate controls
552 such as background control (no cells), negative control (untreated cells), and positive control (all cells
553 dead) and to test different cell types (Aslantürk, 2018; Carlsen et al., 2020; Cox et al., 2021; Riss and
554 Moravec, 2004).

555 An important aspect to consider when selecting an appropriate bioassay is understanding the
556 mechanism of cell death and the resulting kinetics. In this context, apoptosis-specific (e.g., Annexin-V
557 binding or addition of a caspase inhibitor) or necrosis-specific assays (e.g., detection of the released
558 High mobility group box 1 (HMGB1) protein or addition of specific inhibitors) can be used (Raucci et
559 al., 2007; Riss and Moravec, 2004; Shouman et al., 1998). Preferably, cytotoxicity assays should be
560 performed to cover multiple endpoints and determine multiple parameters from the same cell sample
561 that can reveal the actual cause of cell death (Aslantürk, 2018; Santacroce et al., 2015). Another aspect
562 to consider is whether the effect is cytotoxic or cytostatic (Anttila et al., 2019; Mervin et al., 2016).
563 Understanding the mode of action and molecular mechanisms targeted by cytotoxic compounds is
564 important for rational decision making about their use in specific cancer types, and for assessing the
565 risk of potential cross-reactivity with other treatments, and side effects.

566

4.3. Antiviral Bioassays

Viral infections are a major cause of disease in the world because of their complexity, diversity, and rapid spread, which is often accelerated by urbanization, increased migration, and globalization (Drexler, 2011). The 21st century is characterized by major viral epidemics and pandemics, such as influenza A (H1N1) pdm/09, Ebola, Zika, severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) and SARS-CoV-2 (Ong et al., 2020). In light of these emerging viruses, as well as endemic viruses and the emergence of viral resistance, attention has focused on natural products as sources of new antiviral drugs, including those from the marine environment (Bhadury et al., 2006; da Silva et al., 2006; Dias et al., 2018; Linnakoski et al., 2018; Tziveleka et al., 2003).

The very first step before an antiviral assay is to determine the potential toxicity of the compounds or extracts to host cells (Fig. 6). This is essential to rule out the possibility that the antiviral properties observed *in vitro* are not due to cytotoxicity. For cytotoxicity screening, any of the methods described in the previous section can be used. Although the MTT assay has been widely used in the past, the ATP-based assay has proven to be the gold standard for measuring cell viability to date. It is more sensitive than conventional biochemical methods because it detects cell death by a general rather than a specific biological mechanism (Herzog et al., 2007; Ponti et al., 2006). However, assays based on cell metabolism are not suitable for metabolically inactive cells, for which the fluorometric microculture cytotoxicity assay (FMCA) is becoming increasingly popular. The FMCA assay is based on the hydrolysis of the fluorescein diacetate (FDA) probe by the cytosolic esterases of intact cells (Burman et al., 2011; Lindhagen et al., 2008; Strömstedt et al., 2014), and cell survival is reported as an index of survival after treatment. If the results of the cytotoxicity assays indicate no effect on cell line fitness, the compounds can then be tested with primary antiviral assays (Supplementary Table S1, Fig. 6)(Gomes et al., 2016).

In cytotoxicity evaluation, the value of the 50% cytotoxicity concentration (CC_{50}), defined as the concentration of a compound that produces a 50% cytotoxic effect (Hu and Hsiung, 1989), is determined and used together with the value of the 50% effective concentration (EC_{50} , i.e., the concentration of a compound that produces a 50% inhibition of viral replication) to evaluate the efficacy of an antiviral candidate. This relative efficacy of a compound in inhibiting viral replication with respect to inducing cell death is defined as the therapeutic or selectivity index (SI). Theoretically, a high SI ratio corresponds to a safer and more effective compound that is cytotoxic only at very high concentrations and exhibits antiviral activity at very low concentrations (Naesens et al., 2006; Reymen et al., 1995). The antiviral activity is considered effective/useful when the CC_{50} value is 20 times higher than the EC_{50} value (Cao et al., 2015). Since the CC_{50} and EC_{50} values for a given compound depend on the assays used, the SI value varies from laboratory to laboratory. Nevertheless, the SI value is a widely accepted parameter of a compound that expresses its *in vitro* efficacy in inhibiting viral replication (Naesens et al., 2006; Reymen et al., 1995).

Several different assays can be used to determine antiviral activity (Supplementary Table S1)(De Clercq et al., 1980; Sauer et al., 1984; Sidwell, 1986; WHO Scientific Group, 1987). At this point, it is necessary to determine the cell system(s) best suited for virus replication on which to test new antiviral agents. Depending on the cell type used, the replication capacity of the virus and its actual effect on cells varies considerably (i.e., some viruses may cause a cytopathic effect (CPE), while others may form plaques or induce specific functions such as hemagglutination (e.g., orthomixyovirus and paramixovirus) or hemadsorption.

610 A cytopathic effect (CPE) test is based on the observation of morphological changes that occur
611 in host cells as a result of viral infection and replication. The CPE-based assay was the first assay
612 developed to evaluate whether a compound is antivirally effective, and it can also be scaled up for
613 high-throughput screening (Maddox et al., 2008; Severson et al., 2007). Because viral replication leads
614 to cell death, cell viability assays can be considered a substitute for CPE assessment because they are
615 more accurate, automatable, and objective compared to visual assessment by an operator. Since CPE
616 is an indirect measure of viral load, the result regarding the protective effect of drugs against a virus
617 may also vary and be lower than other tests that measure viral load directly (PRA, VRA, see below)
618 (Gorshkov et al., 2021). Although the CPE assay was one of the first antiviral assays developed,
619 commercial kits (e.g., Viral ToxGlo Assay) that measure cellular ATP as an indicator of host cell survival
620 have allowed standardization of the procedure in many laboratories, and ATP depletion can be
621 correlated with viral load.

622 A widely used quantitative biological titration method is the plaque reduction assay (PRA). This
623 method is based on counting plaques formed by lysis of infected cells in a monolayer. The plaques are
624 visible to the naked eye or under a light microscope after staining with neutral red or crystal violet.
625 The plaque assay is the preferred method of viral titration because it is economical and technically
626 simple, but it can be tedious because visible viral plaques can take from 24 hours to several weeks to
627 form (El Sayed, 2000). Conflicting results may be obtained due to various limitations (see
628 Supplementary Table S1). Therefore, in addition to PRA, the virus yield reduction assay (VRA) is
629 recommended to determine the EC_{50} value by assessing viral progeny production in a growth
630 experiment. The assay conditions must be optimized, especially the multiplication of infection (MOI,
631 i.e., the ratio of virus to cell number), because this single parameter can significantly affect the
632 evaluation of antiviral activity and (a high MOI reduces the sensitivity of the virus to an antiviral agent
633 (Collins and Bauer, 1977; Sauer et al., 1984). Therefore, it is advisable to perform VRA at both low MOI
634 (multicycle viral replication) and high MOI (single-cycle replication), to compare the resulting EC_{50}
635 values, and to evaluate the range of action of the antiviral molecule as accurately as possible (Yang et
636 al., 1989).

637 For viruses that do not cause cytopathic effects, the focus-forming assay (FFA), an indirect
638 method for virus measurement, can be used. This is a variant of the plaque assay that relies on
639 immunohistochemical techniques, as it uses chemically or fluorescently labelled antibodies specific for
640 a viral antigen to detect infected cells (Flint S.J et al., 2009). For example, quantification of infectious
641 viral particles for α - (hCoV229-E) and β - (hCoV-OC43) coronaviruses relies on an enzymatic antigen
642 detection method that uses horseradish peroxidase (HRP) to label antigen-antibody complexes
643 (Lambert et al., 2008). Alternatively, if the viruses express hemagglutinin (HA), an envelope
644 glycoprotein (e.g., influenza virus, respiratory syncytial virus), the hemagglutination inhibition assay
645 (HIA) can be used. The method is based on measuring the ability of virions to adsorb to and agglutinate
646 red blood cells (RBCs) by binding to glycans (e.g., sialic acid) on the surface of red blood cells (usually
647 from rabbits, horses, chickens or guinea pigs). In practice, the hemagglutination assay is used to
648 determine the viral concentration that agglutinates an exact (standard) number of erythrocytes,
649 making it extremely accurate, although it is only applicable to certain viruses (Joklik, 1988).
650 Standardization of the HIA assay has been described (Kaufmann et al., 2017). In particular, before
651 performing the assay, the following should be considered: (i) although HIA assays provide consistent
652 results across multiple plates, the same amount of virus particles must be used in each plate; (ii)
653 according to WHO, the standard amount of HA used in the HIA assay is 4 units per 25 μ L [HA unit is the

654 amount of virus required to agglutinate an equal volume of standardized RBC suspension]; (iii) the
655 RBCs used depend on the type of influenza virus in the assay; and (iv) for different types of 96-well
656 microtiter plates (V- or U-bottom), the incubation time and the occurrence of nonagglutinated cells
657 are different (Kaufmann et al., 2017).

658 After a certain type of antiviral activity is detected, it is necessary to further investigate this
659 activity using several specialized secondary bioassays for screening and/or monitoring purposes. These
660 *in vitro* or *in vivo* assays are time-consuming, more expensive, and more challenging than the primary
661 screening bioassays and require the expertise of biochemists or pharmacologists. Therefore, they can
662 only be performed by a multidisciplinary team. Such secondary assays are necessary/mandatory to
663 select potential candidates to be tested in human clinical trials (Gomes et al., 2016; Öberg and Vrang,
664 1990).

665 Meanwhile, new modern assays such as flow cytometry, tunable resistive pulse sensing (TRPS),
666 and quantitative real-time PCR (qPCR) are also increasingly being developed to determine antiviral
667 activity. In particular, qPCR was widely used during the SARS-CoV-2 pandemic because it allowed
668 testing of antiviral activity of many molecules against SARS-CoV-2 in a short time. However, it is
669 important to emphasize that during viral replication, the ratio of whole virions to nucleic acid copies is
670 rarely 1:1 and that the viral assembly process can produce complete virions, empty capsids, and/or an
671 excess of free viral genomes. Therefore, positive qPCR results may also be due to the presence of
672 residual viral nucleic acid (i.e., noninfectious virus) rather than infectious virus (Tandon and Mocarski,
673 2012). For this reason, many molecules with true antiviral activity might be rejected *a priori* simply
674 because they are unable to reduce viral genome copy number in a solution, even if the viruses present
675 are no longer active or infectious. Therefore, it is better to use qPCR-based methods for routine
676 laboratory testing and to confirm the results obtained with the classical methods described above
677 when necessary.

678

679 4.4. Bioassays for cosmetics and cosmeceuticals with a focus on antioxidant and 680 anti-ageing effects

681 A variety of specialized bioassays have been developed and routinely used to evaluate the
682 overall cosmetic activity of a marine extract (Fig. 7). The majority of these bioassays are single-target
683 bioassays, but phenotypic bioassays are also available. In the primary screening and secondary testing
684 phases for potential cosmetics and cosmeceuticals, bioassays are mostly based on *in vitro* assays for
685 cytotoxicity, antioxidant and anti-inflammatory activities, using either biochemical cell-free assays or
686 immortalized cell lines (e.g., THP-1 and HaCaT cells). Once selected, the extracts or compounds are
687 tested for safety, activity, and mode of action in preclinical assays using primary cells (e.g.,
688 keratinocytes) and/or *ex vivo* skin tissue models (Brancaccio et al., 2022), with the option to perform
689 final testing in clinical trials (Fig. 9). The anti-inflammatory activity of extracts or pure compounds can
690 be assessed by TNF- α or IL-1 β production measured in LPS-stimulated THP-1 activated human
691 macrophage cells (Lauritano et al., 2016). For example, *in vitro* bioassays are used to investigate the
692 antioxidant capacity of extracts by mimicking the damage caused by radicals in the skin and by
693 assessing the efficacy of natural extracts in combating this damage (Thring et al., 2009). Depending on
694 the mechanism by which radicals are scavenged, antioxidant capacity assays are broadly divided into
695 two categories: electron transfer (ET) and hydrogen atom transfer (HAT) based assays (Apak et al.,
696 2007). Compared to HAT-based assays, the ET reaction is relatively slow, and its actual rate depends
697 greatly on laboratory conditions, such as solvent and pH (Apak et al., 2007; Huang et al., 2005). ET

698 assays widely used in cosmetics include the DPPH (2,2-Diphenyl-1-picrylhydrazyl), ABTS/TEAC (2,2'-
699 azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox[®]-Equivalent Antioxidant Capacity), CUPRAC
700 (CUPric Reducing Antioxidant Capacity), and Folin-Ciocalteu methods, each of which uses a different
701 chromogenic reagent with different redox potential (Ratz-Lyko et al., 2012), as shown in
702 Supplementary Table S1. Although the actual reducing capacity of an extract or compound is not
703 directly related to its ability to scavenge radicals, these biochemical assays are useful for initial
704 screening procedures (Amorati and Valgimigli, 2015; Apak et al., 2007). Most HAT-based assays are
705 kinetic and rely on a competitive reaction scheme in which the antioxidants of a natural extract and an
706 oxidizable probe compete for peroxy radicals, the latter being thermally generated in a solution by
707 the decomposition of azo compounds (Apak et al., 2007; Huang et al., 2005). This is the case with the
708 oxygen radical absorbance capacity (ORAC) assay, which is widely used to measure the antioxidant
709 capacity of natural products with anti-ageing and cosmetic potential (Baldisserotto et al., 2012;
710 Dávalos et al., 2004; Dudonné et al., 2011; Ky and Teissedre, 2015; Le Lann et al., 2016). However, it
711 must be emphasized that most HAT and ET assays are sensitive to either hydrophilic or hydrophobic
712 antioxidants and therefore may underestimate the total activity of an extract (Fraga et al., 2014; Ratz-
713 Lyko et al., 2012). Thus, a combination of these biochemical methods may be required to obtain
714 reliable results (Ratz-Lyko et al., 2012).

715 Another set of *in vitro* assays commonly used in the screening of cosmetics and cosmeceuticals
716 investigates the anti-ageing effects of the extracts, which include antioxidant and anti-inflammatory
717 activities (Brancaccio et al., 2022), but may also be related to their specific ability to block enzymes
718 involved in the breakdown of skin firmness (Thring et al., 2009). These include matrix
719 metalloproteinases (e.g., collagenase), serine proteases (e.g., elastase), and endoglycosidases (e.g.,
720 mucopolysaccharide hyaluronidase), which degrade the major components of the extracellular matrix
721 (ECM) of the skin: collagen, elastin, and hyaluronic acid (Li et al., 2019; Rittie and Fisher, 2002).
722 Maintaining high levels of these components is critical for skin elasticity, firmness, and hydration, and
723 thus inhibitors of these hydrolytic enzymes are being sought (Madan and Nanda, 2018). In addition,
724 there is particular interest in the regulation of melanin levels in the skin (i.e., changes in skin
725 pigmentation), the overproduction of which leads to aesthetic problems such as pigmentation spots
726 (Lall and Kishore, 2014; Saghaie et al., 2013) as well as other skin conditions such as discoloration,
727 freckles, and skin cancer (An et al., 2005). Specific assays are available to study the inhibitory properties
728 of extracts on the activity of the enzyme tyrosinase, which catalyses the first rate-limiting steps of the
729 melanin biosynthetic pathway in melanocytes (Parvez et al., 2006). Typically, L-DOPA (an intermediate
730 in melanogenesis) is used as a substrate and its enzymatic oxidation to the red-colored dopachrome is
731 monitored spectrophotometrically to assess inhibition of tyrosinase. Despite the widespread use of
732 (bio)chemical antioxidant assays, they are usually performed under non-physiological conditions
733 without taking into account the cellular uptake of compounds and their mode of action at the
734 subcellular level, which inherently limits their ability to predict the true antioxidant effect in living
735 systems.

736 *In vitro* phenotypic assays usually investigate the regenerative properties of extracts on
737 specific skin cell lines (e.g., fibroblasts) by monitoring their stimulatory effects on the production of
738 ECM components (Adil et al., 2010; Boonpisuttinant et al., 2014; Pastorino et al., 2017; Roh et al., 2013;
739 Yodkeeree et al., 2018), as well as their photoprotective effects in terms of cell viability (Moon et al.,
740 2008). The protective role of extracts against photooxidative skin damage can also be evaluated by *ex*
741 *vivo* approaches. Specifically, a cosmetic formulation is applied to the skin of human volunteers and

742 after a short period of time, strips of the outermost skin layers are removed, exposed to UV radiation,
743 and lipid peroxidation is assessed by measuring the losses of unsaturated fatty acids and the amounts
744 of primary, secondary, or end products of the reaction (Alonso et al., 2009). Cell line-based bioassays
745 are also used to estimate safety parameters by assessing skin irritation by evaluating direct cytotoxicity
746 or other types of damage to the epithelial barrier of the skin by measuring the permeability of
747 fluorescein through epithelial cell monolayers (OECD test no. 460). In addition, mutagenicity and
748 carcinogenicity (OECD test no. 451) are assessed using cell cultures, e.g., the *in vitro* micronucleus test
749 (OECD test no. 487) to detect chromosomal aberrations and the bacterial reverse mutation test (OECD
750 test no. 471) to detect gene mutations. An alternative to animal models for carcinogenicity testing is
751 cell transformation assays (CTA), which are used in combination with other approaches to evaluate
752 carcinogenic potential (Creton et al., 2012; Mascolo et al., 2018; Organisation for Economic Co-
753 operation and Development - OECD, 2022; Scientific Committee on Consumer Safety - SCCS, 2021).

754 The biochemical and cell-based *in vitro* methods described are suitable for the screening and
755 monitoring phases of the drug discovery pipeline (Fig. 9) because of their greater simplicity, speed,
756 throughput, and cost-effectiveness, although they may not adequately reflect the actual biological
757 processes in skin cells. Therefore, *ex vivo* bioassays using skin tissues have been developed for
758 toxicological studies, such as the reconstructed human epidermis (RhE) test methods (OECD test no.
759 439, 431), using four validated commercial human skin models, viz. i.e., EpiSkin™, EpiDerm™,
760 SkinEthic™, and EpiCS®, which use reconstructed human epidermis equivalents to evaluate cell viability
761 and are used to assess skin corrosion or irritation potential. Bioassays for the assessment of ocular
762 damage include organotypic assay methods using tissues from slaughterhouses, such as bovine
763 corneas (OECD test no. 437) or chicken eyes (OECD test no. 438), or *in vitro* assays using corneal
764 epithelial cell lines to assess irritation by measuring direct cytotoxicity on rabbit corneal cell lines
765 (OECD test no. 491) or human cornea-like epithelium (OECD test no. 492) (e.g., EpiOcular™). For
766 assessment of genotoxicity or reproductive toxicity, new alternative approach methodologies to
767 animal testing are being implemented worldwide, including *in vitro* methods using the whole embryo
768 culture test (WEC) to evaluate developmental toxicity in rodent embryos maintained in culture during
769 the early stages of organ formation, the MicroMass Test (MM), which uses embryonic limb
770 mesenchyme or central nervous system cells from chickens, mice, or rats to evaluate effects on cell
771 differentiation into chondrocytes and neurons as an indication of potential teratogenicity, and the
772 embryonic stem cell assay (EST), which is based on permanent cell lines to predict embryotoxicity by
773 evaluating effects on cell differentiation (Organisation for Economic Co-operation and Development -
774 OECD, 2022; Scientific Committee on Consumer Safety - SCCS, 2021; Seiler and Spielmann, 2011).

775
776

777 5. Quality control and bioassay validation

778 5.1. The concept of validation

779 The concept of validation can be defined as a systematic approach to collecting and analyzing a
780 sufficient amount of data under specified conditions and based on documented evidence (validation
781 report) and scientific judgment, to provide reasonable assurance that the process of interest will
782 reliably and consistently reproduce results within predetermined specifications when operated within
783 specified parameters (Haider, 2006).

784 The main objective of the validation process is to produce reliable and consistent data (quality
785 data). In addition, four critical components of data quality are identified, including analytical

786 instrument qualification, analytical method validation, system stability testing, and quality control
787 sampling (United States Pharmacopeial Convention, 2018), with each of these components
788 contributing to overall quality:

- 789 - Analytical instrument qualification (AIQ) is the collection of documented evidence that an
790 instrument is fit for its intended purpose and that its use provides confidence in the validity of
791 the data produced. It includes (i) design qualification (DQ), which is performed by the
792 manufacturer prior to purchase to ensure the technical characteristics required by the user;
793 (ii) installation qualification (IQ), which is performed prior to and at the time of installation;
794 (iii) operational qualification (OQ), which is performed after installation and major repairs; and
795 (iv) performance qualification (PQ), which is performed periodically to ensure continued
796 satisfactory performance during routine operation and includes preventive maintenance,
797 recalibration, and performance testing (Bansal et al., 2004; Kaminski et al., 2010; Valigra, 2010)
- 798 - Analytical method validation is the collection of documented evidence that demonstrates that
799 an analytical method is fit for its intended purpose and provides assurance that its use with
800 qualified analytical instruments will generate accurate data of acceptable quality (Haider,
801 2006).
- 802 - System suitability tests (SSTs) are used to verify that the system meets predefined criteria.
803 They are performed in conjunction with sample analyses to ensure that the system is
804 functioning properly at the time of testing.
- 805 - Quality control (QC) samples help to ensure the quality of analytical results by being included
806 immediately prior to or during sample analysis.

807

808 5.2. Validation of the analytical method

809 The concept of bioassay validation is often associated with compounds that are classified as drugs by
810 regulatory authorities, because the development, production and testing of these products are strictly
811 regulated. Consequently, bioassay validation is an integral part of the quality control system. This may
812 not be the case for cosmetic preparations or dietary supplements, where product characteristics and
813 claims dictate testing or trial requirements, however, in practice many cosmetic preparations claiming
814 bioactivity are also subject to rigorous testing. For biodiscovery and research, it is not usually necessary
815 to meet quality control requirements, but it is good to keep the concepts of validation in mind and
816 apply them wherever possible. This can facilitate the transition from research to industrial
817 development, as well as communication with regulatory agencies, regardless of the type of application.

818 It is important that the operator performing the validation of the analytical procedure has the
819 scientific and technical understanding, process knowledge, and/or risk assessment capability to
820 adequately perform the quality functions of analytical method validation (Chan, 2011). The parameters
821 to be evaluated for validation depend on the type of method, and the measures used to describe the
822 performance of the analytical method are typically: accuracy (trueness), precision (repeatability), limit
823 of detection (LOD), limit of quantitation (LOQ), linearity (calibration curve), range, selectivity,
824 specificity, and robustness. All of these parameters must be determined for validation of a quantitative
825 analytical method, whereas specificity and limit of detection may be sufficient for a qualitative method.
826 There are numerous guidelines (more than 30) published by regulatory organizations; some of them
827 are summarized in Table 2. These guidelines can be used as a frame of reference for the validation
828 process. Unlike instrument qualification, the type of analytical method (e.g., sample matrix, analytical
829 equipment) determines the parameters to be evaluated, so it is important to select an appropriate

830 guidance document as a frame of reference. It is important to note that the terminology used in
 831 different guidelines varies. For example, selectivity, specificity, or diagnostic specificity are defined
 832 differently in different guidelines (Borman and Elder, 2017; Chan, 2011; Kadian et al., 2016).

833

834 **Table 2**

835 The summary of selected validation guidelines and corresponding organizations

Organization	Abbreviation	Sample Guideline(s)	Area of Interest	Remarks and References
European Medicines Agency	EMA	Guideline on bioanalytical method validation (EMA/CHMP/EWP/192217/ 2009)	Bioanalytical assays for drug development studies (with all clinical trials)	Biological matrices such as blood, urine, tissues etc. (European Medicines Agency, 2011)
European Network of Forensic Science Institutes	ENFSI	Guidelines for the single laboratory Validation of Instrumental and Human Based Methods in Forensic Science	Forensic	Biological matrices such as blood, urine, tissues etc. (De Baere et al., 2014)
International Council for Harmonisation	ICH	Validation Of Analytical Procedures: Text And Methodology Q2(R1)	Pharmaceutical QC analyses	Pharmaceutical samples such as; Active Pharmaceutical Ingredient (API), finished drug samples (ICH Expert Working Group, 2005)
		Bioanalytical method validation and study sample analysis (M10)	Bioanalytical assays for drug development studies	Biological matrices such as blood, urine, tissues etc., Draft document (European Medicines Agency, 2019)
United States Food and Drug Administration	USFDA	Bioanalytical Method Validation- Guidance for Industry	Bioanalytical assays for drug development studies (with all clinical trials) and for veterinary drug development as well	Biological matrices such as blood, urine, tissues etc.(USFDA, 2018)
Association of Analytical Communities	AOAC	Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals	Food & Feed Quality	Food and feed stuffs (Harnly et al., 2012)
International Union of Pure & Applied Chemistry	IUPAC	Harmonized Guidelines for Single laboratory Validation of Methods of Analysis	General terminology on analytical method characteristics	Sample matrices are not specified (Thompson et al., 2002)
European Directorate for the Quality of Medicines & HealthCare-The Directorate-General for Health and Food safety	EDQM/DG-SANTE	Analytical Quality Control and Method Validation; Procedures for Pesticide Residues Analysis in Food and Feed (SANTE/12682/2019)	Food & Feed Quality	Specified on the pesticide analysis in food and feed samples (Philström et al., 2019)
EURACHEM	n/a	The Fitness for Purpose of Analytical Methods- A Laboratory Guide to Method Validation and Related Topics	General terminology on analytical method performance characteristics	Sample matrices is not specified (Barwick et al., 2014)
European Commission Joint Research Centre Institute for Health and Consumer Protection	ECJRC-IHCP	Guidelines for performance criteria and validation procedures of analytical methods used in controls of food contact materials (EUR 24105 EN - 1st edition/2009)	Food Quality	Migration analysis (from the food contacting part of the packing materials) (Batinova et al., 2009)

Organization	Abbreviation	Sample Guideline(s)	Area of Interest	Remarks and References
United States Pharmacopeia	USP	General Chapter <1225> Validation of Compendial Procedures	Pharmaceutical QC analyses	Pharmaceutical samples such as Active Pharmaceutical Ingredient (API) and finished drug samples (USP 40, 2017)
United States Environmental Protection Agency	USEPA	Guidance for Methods Development and Methods Validation for the RCRA Program	Environmental analysis	Test Methods for Evaluating Solid Waste (SW-846) Methods (EPA Office of Solid Waste, 1992)

836
837
838
839
840
841
842
843
844

Validation of analytical methods is a progressive, dynamic, and time-consuming process, so it is recommended that a validation schedule (or protocol) be established (EURL, 2022; Shabir, 2003). In addition, there are fundamental differences in validation parameters between different types of assays (e.g., chromatography-based or ligand-binding assays), and this issue is addressed differently by different regulatory agencies, either by providing separate validation guidelines (e.g., ICH, EMA) or by specifying certain aspects in a guideline (e.g., FDA) (Borman and Elder, 2017; EMA Committee for human Medicinal Products, 2011; USFDA, 2018).

845 5.3. Data integrity and documentation

846 The term data integrity refers to the degree of a data-generating system in which the acquisition and
847 storage of data is undivided, coherent, reliable, and accurate. This does not depend on whether the
848 data are in paper or electronic form (Wingate, 2004). The critical issue in ensuring the quality of
849 analytical procedures and data integrity is the documentation of all steps. Good documentation
850 practices (GDocP) is a term used in the pharmaceutical industry to describe the guidelines, standards,
851 and regulations for creating, maintaining, and archiving documents. These apply to all parties involved
852 in a process and to all activities. GDocP-based records have the following characteristics: they are
853 complete, truthful, clear, permanent, accurate, consistent, legible, and concise (Davani, 2017).

855 5.4. Good Laboratory Practice (GLP)

856 It is recommended that the principles of good laboratory practice (GLP) are followed at all times when
857 performing bioassays. GLP is a quality assurance system that addresses the organizational process and
858 conditions under which nonclinical health and environmental safety studies are planned, performed,
859 monitored, recorded, archived, and reported (OECD Series on Principles of Good Laboratory Practice
860 (GLP) and Compliance Monitoring,
861 [https://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpan
862 dcomplianceandmonitoring.htm](https://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcomplianceandmonitoring.htm), accessed 4 May 2022).

863
864

865 6. Bioactivity-guided fractionation and/or purification

866 With the desired bioactivity in mind, a series of fractionation and analytical steps can be applied to
867 natural resources to isolate and/or purify specific compounds that exhibit the bioactivity of interest.
868 The path from a natural extract exhibiting a specific bioactivity to a dereplicated, purified, identified,
869 and characterised compound exhibiting that bioactivity is often quite long and labour intensive.

870 A significant portion of the labour and operating costs in a biochemical and analytical
871 laboratory is devoted to the preparation (extraction) of samples for subsequent analytical separation.

872 During the extraction process, the target compound is pre-concentrated and converted into a form
873 suitable for subsequent instrumental analysis and chromatographic or electrophoretic separations,
874 and the complexity of the matrix is reduced. Depending on the solvents and procedures used for
875 extraction, we expect to isolate either small molecules such as polyketides, alkaloids, and terpenoids
876 or complex polymers such as proteins and polysaccharides, and the purification steps are then
877 designed accordingly (Fig. 8).

878 Extraction is the first important step in the screening process, and the selection of extraction
879 method and solvent(s) is critical for successful downstream processing. For example, bioactive
880 compounds may be present in both a highly polar/aqueous extract and a moderately nonpolar/organic
881 extract. In addition, the physicochemical properties of the starting material determine the steps in the
882 extraction process. For example, microalgae have a rigid cell wall that acts as a natural barrier to
883 prevent solvent molecules from diffusing into the cells and must be broken by mechanical and/or
884 physical techniques such as high-pressure homogenization, shear mixing (high-speed
885 homogenization), ultrasound-assisted extraction (UAE), microwave-assisted extraction (MAE) prior to
886 or simultaneously with chemical extraction (Benbelkhir and Medjekal, 2022; Tian et al., 2022). It is
887 important to consider all available alternatives of the extraction procedure to optimize the extraction
888 time and avoid possible structural or conformational changes of the extracted molecules that can alter
889 their bioactivity. Such changes are more likely to occur in large molecules (e.g., polysaccharides,
890 oligosaccharides). Switching from slow extraction methods (e.g., hydrothermal extraction), which
891 require longer processing time, to faster technologies such as UAE, MAE, or UMAE can help shorten
892 the extraction process and increase the likelihood that the molecule will remain intact (Guo et al.,
893 2022; Qiu et al., 2022). However, chemical reactions can also occur when microwaves and/or
894 ultrasound are used for extraction.

895 Since a natural extract contains a mixture of molecules, the concept of bioactivity-guided
896 purification is based on the sequential application of different types of fractionations that separate
897 molecules from a mixture and the concurrent application of the selected bioassay to identify fractions
898 containing the bioactive compounds until a satisfactory level of purity is achieved. In each purification
899 step, the individual fractions are tested with the bioassay to select the fractions with the highest
900 bioactivity for further purification. Since numerous fractions usually need to be tested, it is optimal to
901 use a rapid and inexpensive bioassay with low volume requirements. A quantitative bioassay is
902 sufficient to guide the purification.

903 Purification is usually performed by either liquid-liquid phase separation (LLPS) or the currently
904 predominant solid phase extraction (SPE). SPE has become a standard analytical procedure for the
905 enrichment of target analytes by partitioning and/or adsorption onto a solid stationary phase. SPE is
906 currently the most widely used method for the extraction, concentration, purification, and
907 fractionation of organic compounds from a variety of samples, as well as for solvent exchange; in
908 addition, SPE is also used efficiently for the desalting of proteins and glycan samples. SPE offers several
909 advantages over liquid-liquid extraction, including higher recoveries, avoidance of emulsion formation,
910 lower organic solvent consumption, simpler operation and automation capability, improved selectivity
911 and reproducibility, and shorter sample preparation time. The standard SPE procedure begins with the
912 application of an analysed solution to a solid phase (sorbent), usually in a cartridge, in which the target
913 analytes are eluted with a suitable solvent and collected (Andrade-Eiroa et al., 2016; Faraji et al., 2019)

914 There are numerous adsorbents for the extraction of different types of molecules. Various SPE
915 mechanisms can be applied to separate target molecules using specific sorbent materials, such as

916 adsorption (e.g., using silica gel, alumina, florisil, or graphitic carbon-based packing), normal separation
917 (e.g., cyanogen-, diol-, or amino-based silica), reversed phase separation (e.g., octadecyl-, octyl-, butyl-
918 , or phenyl-bonded silica), ion exchange (various cation or anion exchangers), size exclusion (e.g.,
919 macropore silica or organic gels), affinity separation (carriers with immobilized affinity ligands), and
920 immunoaffinity separation (carriers with immobilized specific antibodies); often two separation
921 mechanisms can be used simultaneously (e.g., ion exchange and reverse phase separation) (Andrade-
922 Eiroa et al., 2016).

923 Efficient SPE can also be performed with magnetically responsive adsorbents. Magnetic SPE
924 (MSPE) is becoming increasingly popular due to its ease of use, high extraction efficiency, and
925 straightforward automation (Jiang et al., 2019; Pena-Pereira et al., 2021; Šafaříková and Šafařík, 1999;
926 Vasconcelos and Fernandes, 2017). MSPE uses various types of magnetically responsive adsorbents
927 based on ferrimagnetic iron oxides (magnetite, maghemite) or ferrites to which specific affinity ligands
928 are immobilized. A popular variation of MSPE is immunomagnetic separation (IMS), which uses
929 magnetic nano/microbeads with immobilized specific antibodies (monoclonal, polyclonal, or
930 engineered) to capture target analytes or cells via antigen-antibody interactions (De Meyer et al., 2014;
931 He et al., 2018; Safarik et al., 2012; Šafaříková and Šafařík, 1999). Magnetically responsive materials
932 can also be used to separate and purify various biologically active compounds on a larger scale
933 (Franzreb et al., 2006; Safarik and Safarikova, 2014, 2004). Stir-bar sorptive extraction (SBSE) is based
934 on the use of a magnetic stir bar covered with a suitable sorbent (usually polydimethylsiloxane or
935 ethylene glycol-modified silicone material) into which the analytes are extracted. The technique has
936 been successfully used for the analysis of samples of varying complexity and for the detection,
937 concentration or removal of marine toxins in crude extracts (Chen et al., 2019; González-Jartín et al.,
938 2020; Pena-Pereira et al., 2021; X. Wang et al., 2017).

939 Various SPE mechanisms are used to separate compounds from the extracts, which can be
940 performed in a column chromatography format. These are used to fractionate either by size (e.g., size
941 exclusion chromatography), charge (e.g., ion exchange chromatography), hydrophobicity (e.g.,
942 hydrophobic interaction chromatography), polarity (e.g., reversed-phase vs. normal phase
943 chromatography), or other specific binding interactions (e.g., affinity chromatography). These
944 chromatographic stationary phases can be used in a variety of platforms/equipments, such as fast
945 protein liquid chromatography (FPLC), generally used for proteins or nucleic acids, or high-
946 performance liquid chromatography (HPLC) or ultra-performance liquid chromatography (UPLC), used
947 for both proteins and small molecules. In addition to column mode, other SPE formats can be used
948 such as extraction disks and membranes, which are usually composed of glass fibers forming a matrix
949 on which particles of pure or modified silica gel are anchored (Andrade-Eiroa et al., 2016). Supercritical
950 fluid adsorption (SFA) or supercritical fluid chromatography (SFC) are another option, especially for
951 nonpolar volatile compounds. SFA can also be used for polar compounds that are poorly soluble in
952 supercritical CO₂ by using a suitable co-solvent such as ethanol (Dinarvand et al., 2020). Various types
953 of chromatography used for isolation, purification, and characterization of natural products have been
954 reviewed (e.g., (Bucar et al., 2013; Nehete et al., 2013; Saini et al., 2021; Sarker and Nahar, 2012; Yang
955 et al., 2020). Alternatively, variants of preparative polyacrylamide gel electrophoresis (PAGE) (e.g.,
956 native PAGE, isoelectric focusing, 2D PAGE) can be used to separate mixtures of compounds from
957 extracts. Miniaturized analytical techniques can also be used for sample processing. Pipette tip or in-
958 syringe SPE is a miniaturized version of standard SPE in which the absorbent material is packed in
959 plastic micropipette tips or in the needle of syringes; analytes are extracted by repeated aspiration and

960 desorption of the sample. SPME can also be used for *in vivo* analyses, such as fish tissue sampling, due
961 to its low invasiveness. Headspace SPME allows selective extraction of volatile and semi-volatile
962 compounds from samples. Thin film microextraction (TFME) increases the volume of the extraction
963 phase and the surface-to-volume ratio, allowing higher extraction efficiency and rapid analysis (Faraji
964 et al., 2019; Pena-Pereira et al., 2021).

965 An important step in the isolation process is dereplication (Gaudêncio and Pereira, 2015),
966 which is usually performed using tandem mass spectrometry (MS/MS), which determines the presence
967 of known compounds. The bioactive extracts containing unknown compounds are usually selected for
968 further fractionation. Alternatively, known compounds can be tested for new types of bioactivities
969 using other types of bioassays, a process known as repurposing (Dinarvand et al., 2020; Houssen and
970 Jaspars, 2012; Nothias et al., 2018; Pereira et al., 2020; Pushpakom et al., 2019; Veerapandian et al.,
971 2020).

972 Information about the properties of the bioactive compound can be derived from the
973 purification process, and separation into specific fractions provides information about their
974 characteristics. The number of purification steps required to purify compounds varies from case to
975 case and usually ranges from two to eight. Finally, the structures of compounds are elucidated using
976 1D and 2D nuclear magnetic resonance (NMR), high-resolution mass spectrometry (HR-MS), X-ray
977 diffraction (for crystalline compounds), and other techniques to determine the absolute configuration
978 (for non-crystalline compounds) (Gaudêncio et al., 2023). It is important to note that the use of low-
979 resolution tandem mass spectrometers (e.g., triple quadrupole mass spectrometers) may be sufficient
980 for targeted analysis of known compounds, but for untargeted analysis of unknown compounds, the
981 use of a high-resolution mass spectrometer (HR-MS) in tandem mode (e.g., quadrupole time-of-flight,
982 Orbitrap) is essential for accurate measurement of both molecular and fragment ions (Berlinck et al.,
983 2022; Guo et al., 2022).

984
985

986 7. Application-oriented development

987 Given the enormous richness of the marine environment in terms of global biodiversity, almost
988 unlimited resources of bioactive compounds are available for various applications (Atanasov et al.,
989 2021; Newman and Cragg, 2020; Rotter et al., 2021a). Over 38 000 compounds of marine origin are
990 listed in the Dictionary of Marine Natural Products (<https://dmnp.chemnetbase.com>), the MarinLit
991 database (<http://pubs.rsc.org/marinlit/>), and the Comprehensive Marine Natural Products Database
992 CMNPD (<https://www.cmnpd.org/>) (Lyu et al., 2021). Currently, around 1500 new marine compounds
993 are reported annually (Carroll et al., 2021), a substantial increase from the annual average of 1200
994 compounds reported nearly a decade ago (Kiuru et al., 2014). However, marine natural product
995 discovery faces several challenges. Despite support from research funding organisations in the EU and
996 worldwide, access to the marine environment and sampling of aquatic organisms remain very
997 challenging, while several technical issues, including supply of active compounds and sustainable
998 production, can hinder the biodiscovery process (Schneider et al., 2023, 2022). Furthermore, extracts
999 derived from marine organisms are very complex, and the potentially bioactive components are
1000 usually present at low concentrations or are characterised by high structural novelty/complexity,
1001 making their identification and isolation in sufficient quantities for extensive biological testing difficult.

1002 By overcoming the above-mentioned challenges, a limited number of promising bioactive
1003 compounds are eventually isolated in quantities large enough to enable bioactivity studies and to

1004 support the different stages of natural product development. There are no universal sets of bioassays
1005 that should be used for specific research applications, while different types of bioassays are important
1006 for different phases of biodiscovery and product development. Much practical information on
1007 selecting a bioassay has been discussed in Section 3, but it is prudent to keep in mind the potential
1008 uses and regulatory requirements associated with the various intended applications from early
1009 discovery on. To illustrate this point, we consider the development pipeline (Fig. 9) of a general natural
1010 source value chain and focus on marine products intended for specific target markets, namely the
1011 pharmaceutical industry (medicines), the cosmetics industry, and the food industry (dietary
1012 supplements and/or ingredients for food or feed).

1013

1014 7.1. Pharmaceutical drug discovery

1015 The entire process to approval of a new drug can take 12-15 years for the pharmaceutical industry and
1016 costs up to \$2.8 billion (Wouters et al., 2020). In particular, drug discovery based on natural products
1017 has proven to be an extraordinary laborious, costly, and time-consuming process. Nevertheless, this is
1018 the most effective approach to new drug development, and the number of natural-product-inspired
1019 drugs is much higher than synthetic drugs, as over 67% of modern drugs are based on natural products
1020 or their derivatives. Many pharmaceutical companies have turned to combinatorial chemistry for drug
1021 structure discovery and optimization; however, only three new chemical drugs have been approved
1022 based on this methodology (Jimenez et al., 2020; Newman and Cragg, 2020). To date, 14 approved
1023 marine drugs are in clinical use, including 11 anticancer drugs, and 38 marine natural products are in
1024 clinical trials (18 in Phase I, 14 in Phase II, and 6 in Phase III). The vast majority of the latter (i.e., 33 of
1025 38) are being tested as anticancer drugs, whereas two are being investigated for viral diseases, one for
1026 Alzheimer's disease, one for chronic pain and one for relapsed or refractory systemic amyloidosis
1027 (<https://www.marinepharmacology.org/approved>). The drug development process involves five major
1028 steps: (i) discovery and development; (ii) preclinical research; (iii) clinical development; (iv) review by
1029 a health authority (e.g., FDA or EMA); and (v) postmarketing surveillance, including numerous phases
1030 and stages within each of these steps. Bioassays are primarily used during the first two steps of (i)
1031 discovery, including screening and bioactivity-guided purification, and during (ii) preclinical research,
1032 which serves as the decision-making basis for the next step of clinical trials (Fig. 9). For pharmaceutical
1033 and nutraceutical products, both of which promise health benefits and are subject to the same
1034 regulatory requirements, preclinical testing is followed by (iii) the clinical development phase, which
1035 includes a sequence of clinical trial phases. Phase I clinical trials focus on testing safety, dose and side
1036 effects in a small group of healthy volunteers. Phase II then enrolls a medium-sized group of patients
1037 with the target disease or condition and treats them for several months to two years, comparing them
1038 to a placebo control group or an approved standard drug to obtain efficacy and additional safety data.
1039 Phase III studies are larger and of longer duration (1-4 years) and include approximately 300-3000
1040 patients who are treated and compared to a control group. Data collected in phase III provide
1041 information on long-term and rare side effects compared to the last two phases. After the drug has
1042 been approved (iv) by the regulatory authorities, i.e., the European Medicines Agency (EMA) and the
1043 European Food Safety Authority (EFSA) in Europe and the Food and Drug Administration (FDA) in the
1044 U.S.A., (iv) post-marketing surveillance (Phase IV) is conducted to obtain additional information on the
1045 benefits and risks of using a particular drug.

1046 The screening phase relies on *in silico* and *in vitro* biochemical assays to identify bioactive
1047 extracts, fractions, or lead compounds, with high-throughput screening playing a central role.
1048 However, in recent decades, interest from the pharmaceutical industry in conducting HTS
1049 programmes, particularly for natural products, has tended to decline (Harvey et al., 2015). This is

1050 primarily due to a number of bottlenecks associated with the complexity of biological extracts that can
1051 affect the accuracy of targeted molecular screening (e.g., the effects of active compounds can be
1052 masked by other components in the crude extract), associated costly efforts to reduce matrix
1053 complexity, and the limited success of large HTS campaigns previously conducted by companies.
1054 Nonetheless, interest in HTS natural products for drug discovery remains a hot research topic in
1055 academia. Laboratory-scale studies have reported the application of HTS techniques to a repertoire of
1056 natural products to identify potential therapeutic agents for tumour metastasis (Gallardo et al., 2015),
1057 cancer and necroptosis (Li et al., 2016), cell stress and cytotoxicity (Judson et al., 2016), metabolic and
1058 age-related disorders (C. Wang et al., 2017), and, more recently, COVID -19 (Chen et al., 2021; Coelho
1059 et al., 2020; Gaudêncio et al., 2023). Other studies have investigated natural product-like small
1060 molecules for their antimalarial activity (Kato et al., 2016) and their suitability for genome engineering
1061 technologies (e.g., inhibition of CRISPR-Cas9 (Maji et al., 2019)).

1062 In addition to experimental efforts, complementary dry-lab approaches (e.g., virtual screening)
1063 have emerged under increasing pressure to reduce costs and improve the speed and simplicity of the
1064 biodiscovery process (David et al., 2015). These efforts primarily involve the use of structure-assisted
1065 drug design in conjunction with virtual HTS. With respect to natural products, this approach has been
1066 applied in a substantial number of studies to accelerate the discovery of antiviral agents against
1067 coronaviruses (Jin et al., 2020; Naik et al., 2020), while others have focused on identifying molecular
1068 entities with inhibitory activity against typical disease-related enzymes (e.g., cancer, diabetes, and
1069 neurodegenerative disorders) (Jhong et al., 2015; Khan et al., 2019; Mohammad et al., 2019).

1070 Natural products that have been evaluated for pharmacological or biological activity and have
1071 the potential to be therapeutically useful can be considered drug hits. However, in the early stages of
1072 drug development, a hit-to-lead (H2L) process is used that includes mechanism-of-action studies to
1073 identify the pharmacological targets of potent hits and a limited optimization of their chemical
1074 structure to reduce potential side effects, increase affinity and selectivity, improve efficacy, potency,
1075 metabolic stability (half-life) and oral bioavailability. A lead-optimization (LO) process is then
1076 performed to synthesize, evaluate, and modify the bioactive compounds using medicinal chemistry
1077 approaches to form new chemical entities (NCEs) that improve efficacy and reduce side effects. Lead
1078 optimization also involves experimental *in vitro* and *in vivo* testing in a variety of efficacy studies,
1079 pharmacokinetic studies, and toxicological assessments, as well as ADMET (absorption, distribution,
1080 metabolism, excretion, toxicity) assessments through the use of *in silico* models and animal testing to
1081 develop therapeutically effective drugs. For this reason, the preclinical phase is typically more time-
1082 consuming, more expensive, and requires less testing capacity than the preceding screening phases,
1083 and may require more qualified personnel working according to the principles of good laboratory
1084 practice (Andrade et al., 2016; Claeson and Bohlin, 1997; Collins et al., 2020).

1085 Before the bioactive compound (lead structure) enters a new phase of development for a
1086 specific application, its toxicity to humans, animals, and the environment must be determined. The
1087 conclusions drawn from the safety and toxicity tests are highly dependent on the results of the
1088 bioassays used. Bioactivity must be quantified at this stage to determine dose (exposure) and derive
1089 potency. Different types of bioassays may be required for these steps, but often only validated versions
1090 of the quantitative bioassays already used in the discovery phase are used. The pure compounds (lead
1091 compounds) are tested *in vitro* on primary cell lines or *ex vivo* tissue models, or combinations thereof,
1092 specifically designed for the application of interest. The lack of adequate human disease models has
1093 been described as a major limitation in preclinical drug development (Khanna, 2012). Recently,
1094 however, several preclinical human disease models have been developed for several common chronic

1095 inflammatory diseases (e.g., osteoarthritis, cardiovascular disease, chronic lung disease, psoriasis,
1096 atopic dermatitis) and various cancer types, using two-dimensional (2D) cell culture methods, *ex vivo*
1097 and co-culture models and three-dimensional (3D) organoid structures. These disease models serve as
1098 immediate *in vivo* testing platforms to evaluate the efficacy and safety of drug candidates prior to
1099 entering clinical phases (Araújo et al., 2020; Ho et al., 2018; Jessica E Neil et al., 2022; Muenzebrock et
1100 al., 2022; Veldhuizen et al., 2019). Results from disease models form the basis for designing and
1101 planning potential clinical trials or conducting other safety and efficacy testing required by regulatory
1102 authorities for a particular application (e.g., pharmaceutical, nutraceutical or cosmetic). It should be
1103 emphasized that the safety evaluation of pharmaceutical, food, and cosmetic ingredients is more
1104 stringent than that of well-characterised non-food substances, such as industrial chemicals or
1105 pesticides (Śliwka et al., 2016). Moreover, cosmetics and dietary supplements are not required to be
1106 approved for sale by the FDA or EMA. Nevertheless, the cosmetics industry has recently become
1107 interested in incorporating marine bioactive compounds into cosmetic products (e.g., creams and
1108 lotions) that have medicinal or drug-like effects. In this context, the term "cosmeceuticals" has been
1109 coined to describe the combination of cosmetics and pharmaceuticals, but it does not yet have any
1110 legal meaning under current regulations.

1111 The potential toxicity of compounds is determined based on their chemical structure and
1112 mechanism of action to characterize concentration-dependent effects, long-term effects, and effects
1113 of exposure at low concentrations. Animal testing can provide valuable information on toxicity and
1114 pharmacological activity, including pharmacokinetics (ADME) and pharmacodynamics (interaction
1115 with the organism), but interspecies differences in drug toxicity and efficacy can become an important
1116 issue. Despite the recognized limitations and benefits, there are ongoing efforts to reduce the use of
1117 animals for testing. Indeed, *in vivo* testing in animals and humans is subject to strict ethical constraints,
1118 is costly, and therefore is generally performed only in the final stages of development (Ferdowsian and
1119 Beck, 2011). Current regulatory approaches to toxicity testing and evaluation continue to rely primarily
1120 on a checklist of *in vivo* tests that follow standardized test guidelines or protocols. The Interagency
1121 Coordinating Committee on the Validation of Alternative Methods ICCVAM, along with other
1122 organizations, is promoting the development of non-animal alternatives to current *in vivo* acute
1123 systemic toxicity tests (Clippinger et al., 2018; Hamm et al., 2017; Kleinstreuer et al., 2018). There is a
1124 trend toward increased use of new technologies such as high-throughput screening (HTS), tissue chips,
1125 and computational modelling to better predict human, animal, and environmental responses to a wide
1126 range of substances relevant to new product development. The International Cooperation on
1127 Alternative Test Methods (ICATM) partnership was created to establish international cooperation in
1128 validation studies and the development of harmonized recommendations to ensure global acceptance
1129 of alternative methods and strategies
1130 ([https://ntp.niehs.nih.gov/whatwestudy/niceatm/iccvam/international-](https://ntp.niehs.nih.gov/whatwestudy/niceatm/iccvam/international-partnerships/icatm/index.html)
1131 [partnerships/icatm/index.html](https://ntp.niehs.nih.gov/whatwestudy/niceatm/iccvam/international-partnerships/icatm/index.html)).

1132 Significant efforts are being made to develop *in vitro* tests that cover endpoints and target
1133 organs/tissues that are most relevant to humans (Bal-Price et al., 2015). However, in some cases,
1134 animal models may still be needed to address specific developmental toxicity questions (Clippinger et
1135 al., 2018; Leist et al., 2013; Wambaugh et al., 2018). In this context, zebrafish-based bioassays offer an
1136 interesting combination of an *in vivo* model and the possibility of high-throughput screening with low
1137 compound consumption. For example, zebrafish embryos have been established as an *in vivo* model
1138 for the analysis of angiogenesis and vascular development and can be further developed for other
1139 specific high-throughput screening (Crawford et al., 2011). Another alternative to these assays is the

1140 use of the whole-animal *Caenorhabditis elegans* (e.g. (Durai et al., 2013; Palacios-Gorba et al., 2020).
1141 In addition, phenotype-based bioassays are also used to retarget known compounds to unknown and
1142 novel targets (Pushpakom et al., 2019).

1143 In recent years, computer-assisted methods have been used to predict or model the ADMET
1144 properties of lead compounds, enabling drug design and identification of potentially problematic
1145 structures in the early stages of drug discovery to avoid late-stage failures (Ortega et al., 2012).
1146 Computer-aided drug design (CADD) is increasingly being used in drug discovery. Existing tools for
1147 predicting and visualising ADME/toxicity data include: i) predictors of ADME parameters, ii) predictors
1148 of metabolic fate, iii) predictors of metabolic stability, iv) predictors of cytochrome P450 substrates,
1149 and v) software for physiology-based pharmacokinetic (PBPK) modelling (Romano and Tatonetti, 2019;
1150 Wishart, 2009, 2007). These enable pharmacophore modelling (PM), molecular docking (MD), inverse
1151 docking, chemical similarity search (CS), development of quantitative structure-activity relationships
1152 (QSAR) (Pereira et al., 2015, 2014), virtual screening (VS) (Cruz et al., 2018; Dias et al., 2018; Gaudêncio
1153 and Pereira, 2020) and molecular dynamics simulations (MDS), which effectively predict the
1154 therapeutic outcome of lead structures and drug candidates and accelerate the discovery process. The
1155 importance of predictive models for clinical pharmacology is recognized by regulatory agencies, and
1156 this approach is being used for various applications. These models combine different types of data and
1157 parameters to estimate pharmacological activities and are commonly referred to as physiologically
1158 based pharmacokinetic (PBPK) models. By linking the properties of individual lead molecules to
1159 physiological properties, PBPK models also provide a rational approach to predicting drug similarity
1160 (Benjamin et al., 2010; Deepika and Kumar, 2023; Karnati et al., 2023; Mbah et al., 2012; Strömstedt
1161 et al., 2014).

1162 By exploring structural and other data about the target (enzyme/receptor) and ligands, CADD
1163 approaches have identified compounds that can treat disease. Examples of approved drugs that have
1164 been supported by CADD include dorzolamide, saquinavir, ritonavir, indinavir, captopril, and tirofiban
1165 (Dar et al., 2019). Given the success of this approach, the development of "go/no-go" selection criteria
1166 and optimization strategies for drug candidate development should include the use of advanced CADD
1167 for drug metabolism and pharmacokinetics (DMPK) profiling in the development of safe and effective
1168 drugs.

1169

1170 7.2. Cosmetics

1171 Cosmetic products are intended to be applied to the external parts of the human body, including the
1172 teeth and oral mucous membranes, to cleanse, protect, change their appearance, improve their odour
1173 or keep them in good condition. Their use is regulated in the EU by the EU Cosmetics Directive
1174 (Directive 1223/2009) and in the US by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the
1175 Fair Packaging and Labelling Act (FPLA). In the EU, all cosmetic products are registered with the EU
1176 Cosmetic Products Notification Portal (CPNP) and must undergo a safety assessment, have a product
1177 information file, and report serious undesirable effects. Manufacturing must be in accordance with
1178 good manufacturing practice (GMP), must not involve animal testing, and labelling is subject to strict
1179 rules (Regulation EC 1233/2009). In the U.S., registration under the FDA's Voluntary Cosmetic
1180 Registration Program (VCRP) is not required but it is encouraged, the use of animals for testing is not
1181 prohibited, and truthful labelling is also regulated. It is also important to distinguish between
1182 pharmaceuticals and cosmetics, as pharmaceuticals require FDA approval and include products that
1183 claim, for example, hair restoration, pain relief, anti-ageing effects, relief of eczema, dandruff or acne,

1184 sun protection, etc. Therefore, the path of regulation may vary depending on the product's intended
1185 use. Similarly, if a product corrects or alters physiological functions by exerting a pharmacological,
1186 immunological or metabolic effect, it should be classified as a medicinal product in the EU (Regulation
1187 EC 1233/2009, FDA Cosmetics Laws & Regulations [https://www.fda.gov/cosmetics/cosmetics-](https://www.fda.gov/cosmetics/cosmetics-guidance-regulation/cosmetics-laws-regulations)
1188 [guidance-regulation/cosmetics-laws-regulations](https://www.fda.gov/cosmetics/cosmetics-guidance-regulation/cosmetics-laws-regulations), accessed May 6, 2023).

1189 The ingredients of cosmetic products must not be harmful or toxic and must comply with the
1190 lists of prohibited and restricted substances. Only approved colorants, preservatives, and UV filters
1191 may be included in cosmetic products. The International Nomenclature Committee (INC) manages
1192 internationally recognized systematic names for cosmetic ingredients such as plant extracts, oils and
1193 chemicals with the abbreviation INCI (International Nomenclature Cosmetic Ingredient), which are
1194 used in the European Commission's database for information on cosmetic substances and ingredients
1195 CosIng (<https://ec.europa.eu/growth/tools-databases/cosing/index.cfm>, accessed May 6, 2023), but
1196 inclusion in the database does not imply approval for use. INCI names are primarily used for cosmetic
1197 product labelling to avoid confusion, as an ingredient may have different chemical names (e.g.,
1198 common names, CAS or IUPAC names) in different countries.

1199 Typical safety assessment procedures for cosmetic ingredients include the following elements:
1200 (i) hazard identification to identify the intrinsic toxicological properties of the substance using New
1201 Approach Methodology; (ii) exposure assessment calculated based on the declared functions and uses
1202 of a substance as a cosmetic ingredient, the amount present in each cosmetic product category, and
1203 the frequency of its use; (iii) dose-response assessment; and (iv) risk characterization, which usually
1204 focuses on systemic effects. The ban on animal testing and the requirement to use only validated
1205 replacement alternative methods in Europe ensure that the New Approach Methodology (NAM) is
1206 followed, which includes *in vitro*, *ex vivo*, *in chemico*, and *in silico* approaches, read-across, and
1207 combinations thereof, to support regulatory decision-making by providing information for hazard and
1208 risk assessment (Scientific Committee on Consumer Safety - SCCS, 2021).

1209 Marine resources offer an interesting repertoire of bioactive ingredients with cosmetic potential.
1210 Extracts from seaweed, algae, soft corals, or other marine life are rich in proteins, amino acids,
1211 exopolysaccharides, carbohydrates, vitamins (A, B and C), fatty acids, and trace elements that
1212 contribute to hydration, firming, slimming, shine, and protection of human skin, as well as bioactive
1213 compounds with, for example, antioxidant and anti-inflammatory properties that protect the skin from
1214 ageing and photooxidation (Guillerme et al., 2017). Therefore, beauty products with marine
1215 ingredients are becoming increasingly widespread.

1216

1217 7.3. Food and feed supplements

1218 Food supplements are foods whose purpose is to supplement the normal diet and consist of
1219 concentrated sources of nutrients (e.g., vitamins, amino acids, and minerals) or other substances with
1220 nutritional or physiological effects. Their use is regulated by the establishment of substance lists that
1221 are positively evaluated by a food safety authority, such as the European Food Safety Authority (EFSA)
1222 or United States Food and Drug Administration (FDA) for safety of ingestion and bioavailability (i.e.,
1223 the effectiveness with which the substance is released into the body). These agencies also provide
1224 guidance on the type and extent of information that should be submitted to demonstrate
1225 bioavailability and toxicological data. Special regulations apply to foods for infants and young children
1226 and to foods for special medical purposes (Younes et al., 2021)([https://www.fda.gov/food/guidance-](https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements)
1227 [regulation-food-and-dietary-supplements](https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements), accessed May 6, 2023).

1228 Safety testing evaluates safety based on biological, physical, and chemical parameters. Physical
1229 tests check for the presence of foreign objects. Biological safety tests ensure the absence of pathogens
1230 and toxins, and chemical tests detect trace elements or contaminants such as food additives,
1231 flavourings, contaminants such as heavy metals, nitrates, disinfectants, pesticides, dioxins, residues of
1232 veterinary drugs including antibiotics, and components of food contact materials (EU Food safety 2022,
1233 https://ec.europa.eu/food/safety_en, accessed May 6, 2023).

1234 There is a growing interest in functional food ingredients and dietary supplements for which the
1235 marine environment is an important resource. Numerous compounds such as enzymes, proteins,
1236 peptides, polysaccharides, polyunsaturated ω -3 fatty acids (PUFA), phenols, pigments, and other
1237 secondary metabolites have already found use in the food industry (Bozaris, 2014; Šimat et al., 2020).
1238 In addition to routine identification of known toxins or contaminants using analytical chemistry
1239 methods, bioassays for detection of potentially unknown or unexpected toxic components are
1240 important for food and feed safety. Apart from animal testing, bioassays are the only way to identify
1241 novel risks in food or feed ingredients, especially when new and alternative resources are introduced.
1242 This will become especially important with the advent of the circular economy and green waste plans,
1243 which will increase the input of waste streams into the food chain (Gerssen et al., 2019).

1244
1245

1246 8. Conclusions

1247 Many new and repurposed biologically active natural products from microorganisms and
1248 macroorganisms from the marine environment have been detected and characterized using *in vivo*, *in*
1249 *vitro*, and *in silico* bioassays. The choice of bioassays used in biodiscovery is critical to the successful
1250 path from extract to marketed product. Therefore, it is important to realise that each extract contains
1251 many bioactivities and that when pursuing a bioactive compound using a series of bioassays to isolate
1252 and purify the targeted bioactive compound, the other components of the extract should not be
1253 discarded as inactive. Additional valuable bioactivities may be revealed by other bioassays. Conversely,
1254 a bioactive compound targeted for a particular application can be reassessed for other types of
1255 bioactivities as part of the repurposing process. Only when all these aspects are taken into account is
1256 it possible to optimize the potential and make the best use of the various natural resources and, in
1257 particular, the marine environment, which is now being increasingly explored.

1258 A careful inspection of the literature reveals many questions regarding the performance of
1259 bioassays used for screening and identification of bioactivity. Some of these issues relate to possible
1260 artifacts in assay results, variations in activity within different methods, differences in solubility,
1261 synergy of compounds in the tested extract, proper use of controls, storage conditions of extracts, etc.
1262 For many bioassays routinely used in research laboratories, there are no standardized assay
1263 procedures, so it is often very difficult to compare results reported by different laboratories. To
1264 improve the potential for standardization of bioassays, fundamental properties such as robustness,
1265 reproducibility, relevance, sensitivity, cost-effectiveness, automation, accuracy, and selectivity should
1266 be considered in the development and selection of bioassays to be used. A practical aspect is the use
1267 of validated protocols, appropriate controls, and biologically relevant concentrations in bioassays. In
1268 this way, it can be assessed at an early stage of biodiscovery whether the selected bioactivity has
1269 realistic potential, for example, for pharmacological or cosmetic applications, or whether it is merely
1270 an interesting but descriptive discovery.

1271 It is important to note that computational approaches should be widely incorporated into
1272 biodiscovery screenings for two reasons: (i) these approaches are data-driven, so their inclusion in
1273 screening protocols will provide large amounts of data that can be examined for valuable patterns for
1274 further discovery; and (ii) large amounts of data are already available for analysis, so systematic
1275 analysis of data should become routine, including genome sequences, gene expression, chemical
1276 structures analytical data, genotype or proteome data, human microbiome, or electronic health
1277 records. These analyses, performed using computational tools, can save time through dereplication,
1278 prediction of new targets for already known compounds, and information on modes of action.
1279 Understanding the molecular mode of action of bioactive compounds is particularly important because
1280 this knowledge helps in the development of new ways to elicit the same effect when the original
1281 bioactive compound proves toxic or immunogenic, cannot be synthesised, and/or is not available in
1282 sufficient quantity or is lost from natural resources.

1283 Finally, scientific research must be supported by innovation. The search for products for
1284 human and environmental health and well-being, including the development of new bioassays, must
1285 consider the principles of ethics, responsible research and innovation (RRI) (Schneider et al., 2022),
1286 good laboratory practices, and respect for natural ecosystems and habitats.

1287

1288 9. Acknowledgments & funding

1289 This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST
1290 (European Cooperation in Science and Technology) program.

1291 Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4- 2543, J4-
1292 4555, P4-0127, P4-0432).

1293 Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001
1294 (application No 1.1.1.2/VIAA/3/19/465).

1295 Susana Gaudêncio: This work is financed by national funds from FCT - Fundação para a Ciência e a
1296 Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research
1297 Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate
1298 Laboratory Institute for Health and Bioeconomy - i4HB.

1299 Research of Anna Luganini and Giovanna Cristina Varese was financed by the University of Torino
1300 (Ricerca Locale) and the European Commission – NextGenerationEU, Project "Strengthening the MIRRI
1301 Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.

1302 Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture and
1303 Rural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel

1304 Research of Dina Simes was funded by the Portuguese National Funds from FCT—Foundation for
1305 Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020
1306 and AAC nº 41/ALG/2020 - Project nº 072583 – NUTRISAFE.

1307

1308 10. References

1309 Adil, M.D., Kaiser, P., Satti, N.K., Zargar, A.M., Vishwakarma, R.A., Tasduq, S.A., 2010. Effect of
1310 *Embllica officinalis* (fruit) against UVB-induced photo-aging in human skin fibroblasts. *J*
1311 *Ethnopharmacol* 132, 109–114. <https://doi.org/10.1016/j.jep.2010.07.047>

1312 Alonso, C., Barba, C., Rubio, L., Scott, S., Kilimnik, A., Coderch, L., Notario, J., Parra, J.L., 2009. An ex
1313 vivo methodology to assess the lipid peroxidation in stratum corneum. *J Photochem Photobiol B*
1314 97, 71–76. <https://doi.org/10.1016/j.jphotobiol.2009.08.003>

- 1315 Amorati, R., Valgimigli, L., 2015. Advantages and limitations of common testing methods for
1316 antioxidants. *Free Radic Res* 49, 633–649. <https://doi.org/10.3109/10715762.2014.996146>
- 1317 An, B.-J., Kwak, J.-H., Son, J.-H., Park, J.-M., Lee, J.-Y., Park, T.S., Kim, S.-Y., Kim, Y.-S., Jo, C., Byun, M.-
1318 W., 2005. Physiological Activity of Irradiated Green Tea Polyphenol on the Human Skin. *Am J*
1319 *Chin Med (Gard City N Y)* 33, 535–546. <https://doi.org/10.1142/S0192415X05003144>
- 1320 Andrade, E.L., Bento, A.F., Cavalli, J., Oliveira, S.K., Schwanke, R.C., Siqueira, J.M., Freitas, C.S.,
1321 Marcon, R., Calixto, J.B., 2016. Non-clinical studies in the process of new drug development -
1322 Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to
1323 clinical studies. *Brazilian Journal of Medical and Biological Research* 49, e5646.
1324 <https://doi.org/10.1590/1414-431x20165646>
- 1325 Andrade-Eiroa, A., Canle, M., Leroy-Cancellieri, V., Cerdà, V., 2016. Solid-phase extraction of organic
1326 compounds: A critical review (Part I). *TrAC Trends in Analytical Chemistry* 80, 641–654.
1327 <https://doi.org/10.1016/j.trac.2015.08.015>
- 1328 Anttila, J. V., Shubin, M., Cairns, J., Borse, F., Guo, Q., Mononen, T., Vázquez-García, I., Pulkkinen, O.,
1329 Mustonen, V., 2019. Contrasting the impact of cytotoxic and cytostatic drug therapies on
1330 tumour progression. *PLoS Comput Biol* 15, e1007493.
1331 <https://doi.org/10.1371/journal.pcbi.1007493>
- 1332 Apak, R., Güçlü, K., Demirata, B., Özyürek, M., Çelik, S., Bektaşoğlu, B., Berker, K., Özyurt, D., 2007.
1333 Comparative Evaluation of Various Total Antioxidant Capacity Assays Applied to Phenolic
1334 Compounds with the CUPRAC Assay. *Molecules* 12, 1496–1547.
1335 <https://doi.org/10.3390/12071496>
- 1336 Araújo, N., Viegas, C.S.B., Zubía, E., Magalhães, J., Ramos, A., Carvalho, M.M., Cruz, H., Sousa, J.P.,
1337 Blanco, F.J., Vermeer, C., Simes, D.C., 2020. Amentadione from the Alga *Cystoseira usneoides* as
1338 a Novel Osteoarthritis Protective Agent in an Ex Vivo Co-Culture OA Model. *Mar Drugs* 18, 624.
1339 <https://doi.org/10.3390/md18120624>
- 1340 Arendrup, M.C., Meletiadis, J., Mouton, J.W., Lagrou, K., Hamal, P., Guinea, J., Subcommittee on
1341 Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial
1342 Susceptibility Testing, 2008. EUCAST Technical Note on the method for the determination of
1343 broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming
1344 moulds. *Clinical Microbiology and Infection* 14, 982–984. <https://doi.org/10.1111/j.1469-0691.2008.02086.x>
- 1346 Arendrup, M.C., Patterson, T.F., 2017. Multidrug-Resistant *Candida*: Epidemiology, Molecular
1347 Mechanisms, and Treatment. *J Infect Dis* 216, S445–S451. <https://doi.org/10.1093/infdis/jix131>
- 1348 Aslantürk, Ö.S., 2018. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and
1349 Disadvantages, in: Larramendy, M.L., Soloneski, S. (Eds.), *Genotoxicity - A Predictable Risk to*
1350 *Our Actual World*. InTech, London. <https://doi.org/10.5772/intechopen.71923>
- 1351 ASTM E2871-21, 2021. Standard Test Method for Determining Disinfectant Efficacy Against Biofilm
1352 Grown in the CDC Biofilm Reactor Using the Single Tube Method. *Book of Standards*.
- 1353 ASTM E3161-21, 2022. Standard Practice for Preparing a *Pseudomonas aeruginosa* or *Staphylococcus*
1354 *aureus* Biofilm using the CDC Biofilm Reactor. *Book of Standards*.

- 1355 Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., Erdogan Orhan, I., Banach, M., Rollinger, J.M., Barreca, D.,
1356 Weckwerth, W., Bauer, R., Bayer, E.A., Majeed, M., Bishayee, A., Bochkov, V., Bonn, G.K.,
1357 Braidy, N., Bucar, F., Cifuentes, A., DOnofrio, G., Bodkin, M., Diederich, M., Dinkova-Kostova,
1358 A.T., Efferth, T., El Bairi, K., Arkells, N., Fan, T.-P., Fiebich, B.L., Freissmuth, M., Georgiev, M.I.,
1359 Gibbons, S., Godfrey, K.M., Gruber, C.W., Heer, J., Huber, L.A., Ibanez, E., Kijjoo, A., Kiss, A.K., Lu,
1360 A., Macias, F.A., S Miller, M.J., Mocan, A., Müller, R., Nicoletti, F., Perry, G., Pittalà, V., Rastrelli,
1361 L., Ristow, M., Luigi Russo, G., Sanches Silva, A., Schuster, D., Sheridan, H., Skalicka-Woźniak, K.,
1362 Skaltsounis, L., Sobarzo-Sánchez, E., Brecht, D.S., Stuppner, H., Sureda, A., Tzvetkov, N.T., Anna
1363 Vacca, R., Aggarwal, B.B., Battino, M., Giampieri, F., Wink, M., Wolfender, J.-L., Xiao, J., Wai Kan
1364 Yeung, A., Lizard, G., Popp, M.A., Heinrich, M., Berindan-Neagoe, I., Stadler, M., Daglia, M.,
1365 Verpoorte, R., Supuran, C.T., 2021. Natural products in drug discovery: advances and
1366 opportunities. *Nat Rev Drug Discov* 20, 200–2016. <https://doi.org/10.1038/s41573-020-00114-z>
- 1367 Baldisserotto, A., Malisardi, G., Scalambra, E., Andreotti, E., Romagnoli, C., Vicentini, C., Manfredini,
1368 S., Vertuani, S., 2012. Synthesis, Antioxidant and Antimicrobial Activity of a New Phloridzin
1369 Derivative for Dermo-Cosmetic Applications. *Molecules* 17, 13275–13289.
1370 <https://doi.org/10.3390/molecules171113275>
- 1371 Balouiri, M., Sadiki, M., Ibsouda, S.K., 2016. Methods for in vitro evaluating antimicrobial activity: A
1372 review. *J Pharm Anal* 6, 71–79. <https://doi.org/10.1016/J.JPHA.2015.11.005>
- 1373 Bal-Price, A., Crofton, K.M., Leist, M., Allen, S., Arand, M., Buetler, T., Delrue, N., FitzGerald, R.E.,
1374 Hartung, T., Heinonen, T., Hogberg, H., Bennekou, S.H., Lichtensteiger, W., Oggier, D., Paparella,
1375 M., Axelstad, M., Piersma, A., Rached, E., Schilter, B., Schmuck, G., Stoppini, L., Tongiorgi, E.,
1376 Tiramani, M., Monnet-Tschudi, F., Wilks, M.F., Ylikomi, T., Fritsche, E., 2015. International
1377 STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map
1378 for regulatory purposes. *Arch Toxicol* 89, 269–287. <https://doi.org/10.1007/s00204-015-1464-2>
- 1379 Bansal, S.K., Layloff, T., Bush, E.D., Hamilton, M., Hankinson, E.A., Landy, J.S., Lowes, S., Nasr, M.M.,
1380 St. Jean, P.A., Shah, V.P., 2004. Qualification of analytical instruments for use in the
1381 pharmaceutical industry: A scientific approach. *AAPS PharmSciTech* 5, 151–158.
1382 <https://doi.org/10.1208/pt050122>
- 1383 Barreca, M., Spanò, V., Montalbano, A., Cueto, M., Díaz Marrero, A.R., Deniz, I., Erdoğan, A., Lukić
1384 Bilela, L., Moulin, C., Taffin-de-Givenchy, E., Spriano, F., Perale, G., Mehiri, M., Rotter, A., P.
1385 Thomas, O., Barraja, P., Gaudêncio, S.P., Bertoni, F., 2020. Marine Anticancer Agents: An
1386 Overview with a Particular Focus on Their Chemical Classes. *Mar Drugs* 18, 619.
1387 <https://doi.org/10.3390/md18120619>
- 1388 Barwick, V., Bravo, P.P.M., Ellison, S.L.R., Engman, J., Gjengedal, E.L., Oxenboll Lund, U., Magnusson,
1389 B., Müller, H.-T., Patriarca, M., Pohl, B., Robouch, P., Sibbesen, L.P., Theodorsson, E., Vanstapel,
1390 F., Verduyck, I., Yilmaz, A., Ömeroglu, P.Y., Örnemark, U., 2014. *Eurachem Guide: The fitness
1391 for purpose of analytical methods - a laboratory guide to method validation and related topics*,
1392 2nd ed. Eurachem.
- 1393 Benbelkhir, F.Z., Medjekal, S., 2022. Microalgal carotenoids: A promising alternative to synthetic
1394 dyes. *Algal Res* 66, 102823. <https://doi.org/10.1016/j.algal.2022.102823>
- 1395 Benjamin, B., Kanta Barman, T., Chaira, T., K. Paliwal, J., 2010. Integration of Physicochemical and
1396 Pharmacokinetic Parameters in Lead Optimization: A Physiological Pharmacokinetic Model

- 1397 Based Approach. *Curr Drug Discov Technol* 7, 143–153.
 1398 <https://doi.org/10.2174/157016310793180558>
- 1399 Berkow, E.L., Lockhart, S.R., Ostrosky-Zeichner, L., 2020. Antifungal Susceptibility Testing: Current
 1400 Approaches. *Clin Microbiol Rev* 33. <https://doi.org/10.1128/CMR.00069-19>
- 1401 Berlinck, R.G.S., Crnkovic, C.M., Gubiani, J.R., Bernardi, D.I., Ióca, L.P., Quintana-Bulla, J.I., 2022. The
 1402 isolation of water-soluble natural products – challenges, strategies and perspectives. *Nat Prod*
 1403 *Rep* 39, 596–669. <https://doi.org/10.1039/D1NP00037C>
- 1404 Beutler, J.A., 2009. Natural Products as a Foundation for Drug Discovery. *Curr Protoc Pharmacol* 46.
 1405 <https://doi.org/10.1002/0471141755.ph0911s46>
- 1406 Bhadury, P., Mohammad, B.T., Wright, P.C., 2006. The current status of natural products from marine
 1407 fungi and their potential as anti-infective agents. *J Ind Microbiol Biotechnol* 33, 325–337.
 1408 <https://doi.org/10.1007/s10295-005-0070-3>
- 1409 Boonpisuttinant, K., Sodamook, U., Ruksiriwanich, W., Winitchai, S., 2014. In Vitro Anti-
 1410 melanogenesis and Collagen Biosynthesis Stimulating Activities of Star Grass (*Hypoxis aurea*
 1411 Lour.) Extracts. *Asian Journal of Applied Sciences* 2, 2321–0893.
- 1412 Borman, P., Elder, D., 2017. Q2(R1) Validation of Analytical Procedures, Text and Methodology, in:
 1413 Teasdale, A., Elder, David, Nims, R.W. (Eds.), *ICH Quality Guidelines*. John Wiley & Sons, Inc.,
 1414 Hoboken, NJ, USA. <https://doi.org/10.1002/9781118971147>
- 1415 Boziaris, I.S., 2014. Food ingredients from the marine environment. Marine biotechnology meets
 1416 food science and technology. *Front Mar Sci* 1. <https://doi.org/10.3389/fmars.2014.00066>
- 1417 Brancaccio, M., Milito, A., Viegas, C.A., Palumbo, A., Simes, D.C., Castellano, I., 2022. First evidence of
 1418 dermo-protective activity of marine sulfur-containing histidine compounds. *Free Radic Biol Med*
 1419 192, 224–234. <https://doi.org/10.1016/j.freeradbiomed.2022.09.017>
- 1420 Bratinova, S., Raffael, B., Simoneau, C., 2009. Guidelines for performance criteria and validation
 1421 procedures of analytical methods used in controls of food contact materials. *Ispra*.
 1422 <https://doi.org/10.2788/49046>
- 1423 Bridier, A., Dubois-Brissonnet, F., Boubetra, A., Thomas, V., Briandet, R., 2010. The biofilm
 1424 architecture of sixty opportunistic pathogens deciphered using a high throughput CLSM
 1425 method. *J Microbiol Methods* 82, 64–70. <https://doi.org/10.1016/j.mimet.2010.04.006>
- 1426 Bucar, F., Wube, A., Schmid, M., 2013. Natural product isolation-how to get from biological material
 1427 to pure compounds. *Nat Prod Rep* 30, 525–545. <https://doi.org/10.1039/c3np20106f>
- 1428 Burman, R., Strömstedt, A.A., Malmsten, M., Göransson, U., 2011. Cyclotide–membrane interactions:
 1429 Defining factors of membrane binding, depletion and disruption. *Biochimica et Biophysica Acta*
 1430 (BBA) - Biomembranes 1808, 2665–2673. <https://doi.org/10.1016/j.bbamem.2011.07.004>
- 1431 Cao, L., Zhu, S., Wang, Y., Lou, Z., Sun, Y., 2015. A comprehensive procedure for antiviral inhibitor
 1432 discovery using EV71 as an example. *Biophys Rep* 1, 81–89. <https://doi.org/10.1007/s41048-015-0006-z>
- 1434 Carlsen, J., Cömert, C., Bross, P., Palmfeldt, J., 2020. Optimized High-Contrast Brightfield Microscopy
 1435 Application for Noninvasive Proliferation Assays of Human Cell Cultures. *Assay Drug Dev*
 1436 *Technol* 18, 215–225. <https://doi.org/10.1089/adt.2020.981>

- 1437 Carroll, A.R., Copp, B.R., Davis, R.A., Keyzers, R.A., Michèle, M., Prinsep, R., 2021. Marine natural
1438 products ‡. <https://doi.org/10.1039/d0np00089b>
- 1439 Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D., Buret, A., 1999. The Calgary Biofilm Device:
1440 New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms. *J*
1441 *Clin Microbiol* 37, 1771–1776. <https://doi.org/10.1128/JCM.37.6.1771-1776.1999>
- 1442 Chan, C.C., 2011. Principles and Practices of Analytical Method Validation: Validation of Analytical
1443 Methods is Time-consuming but Essential. *The Quality Assurance Journal* 14, 61–64.
1444 <https://doi.org/10.1002/qaj.477>
- 1445 Chaturvedi, V., Ramani, R., Pfaller, M.A., 2004. Collaborative Study of the NCCLS and Flow Cytometry
1446 Methods for Antifungal Susceptibility Testing of *Candida albicans*. *J Clin Microbiol* 42, 2249–
1447 2251. <https://doi.org/10.1128/JCM.42.5.2249-2251.2004>
- 1448 Chen, C.Z., Shinn, P., Itkin, Z., Eastman, R.T., Bostwick, R., Rasmussen, L., Huang, R., Shen, M., Hu, X.,
1449 Wilson, K.M., Brooks, B.M., Guo, H., Zhao, T., Klump-Thomas, C., Simeonov, A., Michael, S.G.,
1450 Lo, D.C., Hall, M.D., Zheng, W., 2021. Drug Repurposing Screen for Compounds Inhibiting the
1451 Cytopathic Effect of SARS-CoV-2. *Front Pharmacol* 11.
1452 <https://doi.org/10.3389/fphar.2020.592737>
- 1453 Chen, H., Huang, C., Zhang, W., Ding, Q., Gao, J., Zhang, L., 2019. Ultrastable nitrogen-doped carbon
1454 nanotube encapsulated cobalt nanoparticles for magnetic solid-phase extraction of okadaic acid
1455 from aquatic samples. *J Chromatogr A* 1608, 460404.
1456 <https://doi.org/10.1016/j.chroma.2019.460404>
- 1457 Choudhary, A., Naughton, L.M., Montánchez, I., Dobson, A.D.W., Rai, D.K., 2017. Current Status and
1458 Future Prospects of Marine Natural Products (MNPs) as Antimicrobials. *Mar Drugs* 15, 272.
1459 <https://doi.org/10.3390/md15090272>
- 1460 Claeson, P., Bohlin, L., 1997. Some aspects of bioassay methods in natural-product research aimed at
1461 drug lead discovery. *Trends Biotechnol* 15, 245–248. [https://doi.org/10.1016/s0167-](https://doi.org/10.1016/s0167-7799(97)01051-2)
1462 [7799\(97\)01051-2](https://doi.org/10.1016/s0167-7799(97)01051-2)
- 1463 Clinical and Laboratory Standards Institute, 2017a. Reference method for broth dilution antifungal
1464 susceptibility testing of filamentous fungi, 3rd ed. . Wayne, PA.
- 1465 Clinical and Laboratory Standards Institute, 2017b. Reference method for broth dilution antifungal
1466 susceptibility testing of yeasts, 4th ed. Approved standard M27. Wayne, PA.
- 1467 Clinical and Laboratory Standards Institute, 2010. Method for antifungal disk diffusion susceptibility
1468 testing of nondermatophyte filamentous fungi, approved guideline. CLSI document M51-A.
1469 Wayne, PA, USA.
- 1470 Clinical and Laboratory Standards Institute, 2009. Method for antifungal disk diffusion susceptibility
1471 testing of yeasts; approved guideline. CLSI document M44-A2. Wayne, PA, USA.
- 1472 Clippinger, A.J., Allen, D., Behrsing, H., Bérubé, K.A., Bolger, M.B., Casey, W., DeLorme, M., Gaça, M.,
1473 Gehen, S.C., Glover, K., Hayden, P., Hinderliter, P., Hotchkiss, J.A., Iskandar, A., Keyser, B.,
1474 Luettich, K., Ma-Hock, L., Maione, A.G., Makena, P., Melbourne, J., Milchak, L., Ng, S.P., Paini,
1475 A., Page, K., Patlewicz, G., Prieto, P., Raabe, H., Reinke, E.N., Roper, C., Rose, J., Sharma, M.,
1476 Spoo, W., Thorne, P.S., Wilson, D.M., Jarabek, A.M., 2018. Pathway-based predictive

- 1477 approaches for non-animal assessment of acute inhalation toxicity. *Toxicology in Vitro* 52, 131–
1478 145. <https://doi.org/10.1016/j.tiv.2018.06.009>
- 1479 Coelho, C., Gallo, G., Campos, C.B., Hardy, L., Würtele, M., 2020. Biochemical screening for SARS-CoV-
1480 2 main protease inhibitors. *PLoS One* 15, e0240079.
1481 <https://doi.org/10.1371/journal.pone.0240079>
- 1482 Collins, J.E., Vanagt, T., Huys, I., Vieira, H., 2020. Marine Bioresource Development – Stakeholder’s
1483 Challenges, Implementable Actions, and Business Models. *Front Mar Sci* 7.
1484 <https://doi.org/10.3389/fmars.2020.00062>
- 1485 Collins, P., Bauer, D.J., 1977. RELATIVE POTENCIES OF ANTI-HERPES COMPOUNDS. *Ann N Y Acad Sci*
1486 284, 49–59. <https://doi.org/10.1111/j.1749-6632.1977.tb21936.x>
- 1487 Cos, P., Vlietinck, A.J., Berghe, D. Vanden, Maes, L., 2006. Anti-infective potential of natural products:
1488 How to develop a stronger in vitro ‘proof-of-concept.’ *J Ethnopharmacol* 106, 290–302.
1489 <https://doi.org/10.1016/J.JEP.2006.04.003>
- 1490 Cox, M.C., Mendes, R., Silva, F., Mendes, T.F., Zelaya-Lazo, A., Halwachs, K., Purkal, J.J., Isidro, I.A.,
1491 Félix, A., Boghaert, E.R., Brito, C., 2021. Application of LDH assay for therapeutic efficacy
1492 evaluation of ex vivo tumor models. *Sci Rep* 11, 18571. <https://doi.org/10.1038/s41598-021-97894-0>
1493
- 1494 Crawford, A.D., Liekens, S., Kamuhabwa, A.R., Maes, J., Munck, S., 2011. Zebrafish Bioassay-Guided
1495 Natural Product Discovery: Isolation of Angiogenesis Inhibitors from East African Medicinal
1496 Plants. *PLoS One* 6, e14694. <https://doi.org/10.1371/journal.pone.0014694>
- 1497 Creton, S., Aardema, M.J., Carmichael, P.L., Harvey, J.S., Martin, F.L., Newbold, R.F., O’Donovan, M.R.,
1498 Pant, K., Poth, A., Sakai, A., Sasaki, K., Scott, A.D., Schechtman, L.M., Shen, R.R., Tanaka, N.,
1499 Yasaei, H., 2012. Cell transformation assays for prediction of carcinogenic potential: state of the
1500 science and future research needs. *Mutagenesis* 27, 93–101.
1501 <https://doi.org/10.1093/mutage/ger053>
- 1502 Cruz, S., Gomes, S., Borralho, P., Rodrigues, C., Gaudêncio, S., Pereira, F., 2018. In Silico HCT116
1503 Human Colon Cancer Cell-Based Models En Route to the Discovery of Lead-Like Anticancer
1504 Drugs. *Biomolecules* 8, 56. <https://doi.org/10.3390/biom8030056>
- 1505 Cushnie, T.P.T., Cushnie, B., Echeverría, J., Fowsantear, W., Thammawat, S., Dodgson, J.L.A., Law, S.,
1506 Clow, S.M., 2020. Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on
1507 Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls. *Pharm Res* 37, 125.
1508 <https://doi.org/10.1007/s11095-020-02849-1>
- 1509 da Silva, A.C., Kratz, J.M., Farias, F.M., Henriques, A.T., dos Santos, J., Leonel, R.M., Lerner, C.,
1510 Mothes, B., Barardi, C.R.M., Simões, C.M.O., 2006. In Vitro Antiviral Activity of Marine Sponges
1511 Collected Off Brazilian Coast. *Biol Pharm Bull* 29, 135–140. <https://doi.org/10.1248/bpb.29.135>
- 1512 Dadgostar, P., 2019. Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist* 12, 3903–
1513 3910. <https://doi.org/10.2147/IDR.S234610>
- 1514 Dar, K.B., Bhat, A.H., Amin, S., Hamid, R., Anees, S., Anjum, S., Reshi, B.A., Zargar, M.A., Masood, A.,
1515 Ganie, S.A., 2019. Modern Computational Strategies for Designing Drugs to Curb Human
1516 Diseases: A Prospect. *Curr Top Med Chem* 18, 2702–2719.
1517 <https://doi.org/10.2174/1568026619666190119150741>

- 1518 Dávalos, A., Gómez-Cordovés, C., Bartolomé, B., 2004. Extending Applicability of the Oxygen Radical
1519 Absorbance Capacity (ORAC–Fluorescein) Assay. *J Agric Food Chem* 52, 48–54.
1520 <https://doi.org/10.1021/jf0305231>
- 1521 Davani, B., 2017. *Pharmaceutical analysis for small molecules*. Wiley, Hoboken, NJ.
- 1522 David, B., Wolfender, J.-L., Dias, D.A., 2015. The pharmaceutical industry and natural products:
1523 historical status and new trends. *Phytochemistry Reviews* 14, 299–315.
1524 <https://doi.org/10.1007/s11101-014-9367-z>
- 1525 De Baere, T., Dmitruk, W., Magnusson, B., Meuwly, D., O'donnell, G., 2014. Guidelines for the single
1526 laboratory Validation of Instrumental and Human Based Methods in Forensic Science.
- 1527 De Clercq, E., Descamps, J., Verhelst, G., Walker, R.T., Jones, A.S., Torrence, P.F., Shugar, D., 1980.
1528 Comparative Efficacy of Antiherpes Drugs against Different Strains of Herpes Simplex Virus.
1529 *Journal of Infectious Diseases* 141, 563–574. <https://doi.org/10.1093/infdis/141.5.563>
- 1530 De La Calle, F., 2017. Marine microbiome as source of natural products. *Microb Biotechnol* 10, 1293–
1531 1296. <https://doi.org/10.1111/1751-7915.12882>
- 1532 De Meyer, T., Muyldermans, S., Depicker, A., 2014. Nanobody-based products as research and
1533 diagnostic tools. *Trends Biotechnol* 32, 263–270. <https://doi.org/10.1016/j.tibtech.2014.03.001>
- 1534 Deepika, D., Kumar, V., 2023. The Role of “Physiologically Based Pharmacokinetic Model (PBPK)” New
1535 Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk
1536 Assessment. *Int J Environ Res Public Health* 20, 3473. <https://doi.org/10.3390/ijerph20043473>
- 1537 Defoirdt, T., 2018. Quorum-Sensing Systems as Targets for Antivirulence Therapy. *Trends Microbiol*
1538 26, 313–328. <https://doi.org/10.1016/J.TIM.2017.10.005>
- 1539 Defoirdt, T., Brackman, G., Coenye, T., 2013. Quorum sensing inhibitors: how strong is the evidence?
1540 *Trends Microbiol* 21, 619–624. <https://doi.org/10.1016/j.tim.2013.09.006>
- 1541 Di, L., Kerns, E.H., 2006. Biological assay challenges from compound solubility: strategies for bioassay
1542 optimization. *Drug Discov Today* 11, 446–451. <https://doi.org/10.1016/J.DRUDIS.2006.03.004>
- 1543 Dias, T., Gaudêncio, S., Pereira, F., 2018. A Computer-Driven Approach to Discover Natural Product
1544 Leads for Methicillin-Resistant *Staphylococcus aureus* Infection Therapy. *Mar Drugs* 17, 16.
1545 <https://doi.org/10.3390/md17010016>
- 1546 Dinarvand, M., Vafaei, F., Spain, M.P., 2020. Pharmacodynamic Functions of Synthetic Derivatives for
1547 Treatment of Methicillin-Resistant *Staphylococcus aureus* (MRSA) and *Mycobacterium*
1548 *tuberculosis*. *Front Microbiol* 11, 551189. <https://doi.org/10.3389/fmicb.2020.551189>
- 1549 Drexler, M., 2011. *What You Need to Know About Infectious Disease*. National Academies Press,
1550 Washington, D.C. <https://doi.org/10.17226/13006>
- 1551 Dudonné, S., Poupard, P., Coutière, P., Woillez, M., Richard, T., Mérillon, J.-M., Vitrac, X., 2011.
1552 Phenolic Composition and Antioxidant Properties of Poplar Bud (*Populus nigra*) Extract:
1553 Individual Antioxidant Contribution of Phenolics and Transcriptional Effect on Skin Aging. *J Agric*
1554 *Food Chem* 59, 4527–4536. <https://doi.org/10.1021/jf104791t>

- 1555 Durai, S., Vigneshwari, L., Balamurugan, K., 2013. *Caenorhabditis elegans*-based in vivo screening of
1556 bioactives from marine sponge-associated bacteria against *Vibrio alginolyticus*. *J Appl Microbiol*
1557 115, 1329–1342. <https://doi.org/10.1111/jam.12335>
- 1558 Dyrda, G., Boniewska-Bernacka, E., Man, D., Barchiewicz, K., Słota, R., 2019. The effect of organic
1559 solvents on selected microorganisms and model liposome membrane. *Mol Biol Rep* 46, 3225–
1560 3232. <https://doi.org/10.1007/s11033-019-04782-y>
- 1561 El Sayed, K.A., 2000. Natural Products as Antiviral Agents. *Studies in Natural Products Chemistry* 24,
1562 473–572. [https://doi.org/10.1016/S1572-5995\(00\)80051-4](https://doi.org/10.1016/S1572-5995(00)80051-4)
- 1563 El-Wahidi, M., El-Amraoui, B., Biard, J.F., Uriz, M.J., Fassouane, A., Bamhaoud, T., 2011. Variation
1564 saisonnière et géographique de l'activité antifongique des extraits de deux éponges marines
1565 récoltées sur le littoral atlantique d'El Jadida, Maroc. *J Mycol Med* 21, 28–32.
1566 <https://doi.org/10.1016/J.MYCMED.2010.11.005>
- 1567 EMA Committee for human Medicinal Products, 2011. European Medicines Agency Guideline on
1568 bioanalytical method validation. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2** . London.
- 1569 EPA Office of Solid Waste, 1992. Guidance for methods development and methods validation for the
1570 RCRA program.
- 1571 EURL, E.U.R.L., 2022. Analytical Quality Control and Method Validation Procedures for Pesticide
1572 Residues Analysis in Food and Feed. SANTE 11312/2021.
- 1573 European Medicines Agency, 2019. ICH guideline M10 on bioanalytical method validation Step 2b.
1574 London.
- 1575 European Medicines Agency, 2011. Committee for Medicinal Products for Human Use (CHMP)
1576 Guideline on bioanalytical method validation. London.
- 1577 Fajarningsih, N.D., Munifah, I., Zilda, D.S., 2018. Evaluation of Antibacterial Assays for Screening of
1578 Marine Invertebrate Extracts. *Squalen Bulletin of Marine and Fisheries Postharvest and*
1579 *Biotechnology* 13, 1. <https://doi.org/10.15578/squalen.v13i1.294>
- 1580 Faraji, M., Yamini, Y., Gholami, M., 2019. Recent Advances and Trends in Applications of Solid-Phase
1581 Extraction Techniques in Food and Environmental Analysis. *Chromatographia* 82, 1207–1249.
1582 <https://doi.org/10.1007/s10337-019-03726-9>
- 1583 Ferdowsian, H.R., Beck, N., 2011. Ethical and Scientific Considerations Regarding Animal Testing and
1584 Research. *PLoS One* 6, e24059. <https://doi.org/10.1371/journal.pone.0024059>
- 1585 Flint, S.J., Enquist, W., Racaniello, V.R., Skalka, A.M., 2009. Virological Methods, in: *Principles of*
1586 *Virology*. ASM Press.
- 1587 Fraga, C.G., Oteiza, P.I., Galleano, M., 2014. In vitro measurements and interpretation of total
1588 antioxidant capacity. *Biochimica et Biophysica Acta (BBA) - General Subjects* 1840, 931–934.
1589 <https://doi.org/10.1016/J.BBAGEN.2013.06.030>
- 1590 Franzreb, M., Siemann-Herzberg, M., Hobley, T.J., Thomas, O.R.T., 2006. Protein purification using
1591 magnetic adsorbent particles. *Appl Microbiol Biotechnol* 70, 505–516.
1592 <https://doi.org/10.1007/s00253-006-0344-3>

- 1593 Furustrand Tabin, U., Meis, J.F., Trampuz, A., 2013. Microcalorimetry Assay for Rapid Detection of
1594 Voriconazole Resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother* 57, 5704–
1595 5706. <https://doi.org/10.1128/AAC.01379-13>
- 1596 Gallardo, V.E., Varshney, G.K., Lee, M., Bupp, S., Xu, L., Shinn, P., Crawford, N.P., Inglese, J., Burgess,
1597 S.M., 2015. Phenotype-driven chemical screening in zebrafish for compounds that inhibit
1598 collective cell migration identifies multiple pathways potentially involved in metastatic invasion.
1599 *Dis Model Mech* 8, 565–576. <https://doi.org/10.1242/dmm.018689>
- 1600 Gaudêncio, S.P., Bayram, E., Lukić Bilela, L., Cueto, M., Díaz-Marrero, A.R., Haznedaroglu, B.Z.,
1601 Jimenez, C., Mandalakis, M., Pereira, F., Reyes, F., Tasdemir, D., 2023. Advanced Methods for
1602 Natural Products Discovery: Bioactivity Screening, Dereplication, Metabolomics Profiling,
1603 Genomic Sequencing, Databases and Informatic Tools, and Structure Elucidation. *Mar Drugs* 21,
1604 308. <https://doi.org/10.3390/md21050308>
- 1605 Gaudêncio, S.P., Pereira, F., 2020. A Computer-Aided Drug Design Approach to Predict Marine Drug-
1606 Like Leads for SARS-CoV-2 Main Protease Inhibition. *Mar Drugs* 18, 633.
1607 <https://doi.org/10.3390/md18120633>
- 1608 Gaudêncio, S.P., Pereira, F., 2015. Dereplication: racing to speed up the natural products discovery
1609 process. *Nat Prod Rep* 32, 779–810. <https://doi.org/10.1039/C4NP00134F>
- 1610 Gerssen, A., Bovee, T.H.F., van Ginkel, L.A., van Iersel, M.L.P.S., Hoogenboom, R.L.A.P., 2019. Food
1611 and feed safety: Cases and approaches to identify the responsible toxins and toxicants. *Food*
1612 *Control* 98, 9–18. <https://doi.org/10.1016/j.foodcont.2018.10.028>
- 1613 Goeres, D.M., Loetterle, L.R., Hamilton, M.A., Murga, R., Kirby, D.W., Donlan, R.M., 2005. Statistical
1614 assessment of a laboratory method for growing biofilms. *Microbiology (N Y)* 151, 757–762.
1615 <https://doi.org/10.1099/mic.0.27709-0>
- 1616 Gomes, A.R., Duarte, A.C., Rocha-Santos, T.A.P., 2016. Analytical Techniques for Discovery of
1617 Bioactive Compounds from Marine Fungi, in: Merillon, J., Ramawat, K. (Eds.), *Fungal*
1618 *Metabolites*. Reference Series in Phytochemistry. Springer International Publishing, Cham, pp.
1619 1–20. https://doi.org/10.1007/978-3-319-19456-1_9-1
- 1620 González-Jartín, J.M., de Castro Alves, L., Alfonso, A., Piñeiro, Y., Vilar, S.Y., Rodríguez, I., Gomez,
1621 M.G., Osorio, Z.V., Sainz, M.J., Vieytes, M.R., Rivas, J., Botana, L.M., 2020. Magnetic
1622 nanostructures for marine and freshwater toxins removal. *Chemosphere* 256, 127019.
1623 <https://doi.org/10.1016/j.chemosphere.2020.127019>
- 1624 Gorshkov, K., Chen, C.Z., Bostwick, R., Rasmussen, L., Tran, B.N., Cheng, Y.-S., Xu, M., Pradhan, M.,
1625 Henderson, M., Zhu, W., Oh, E., Susumu, K., Wolak, M., Shamim, K., Huang, W., Hu, X., Shen, M.,
1626 Klumpp-Thomas, C., Itkin, Z., Shinn, P., Carlos de la Torre, J., Simeonov, A., Michael, S.G., Hall,
1627 M.D., Lo, D.C., Zheng, W., 2021. The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome
1628 Alkalinizing Small Molecules. *ACS Infect Dis* 7, 1389–1408.
1629 <https://doi.org/10.1021/acsinfecdis.0c00349>
- 1630 Guillerme, J.-B., Couteau, C., Coiffard, L., 2017. Applications for Marine Resources in Cosmetics.
1631 *Cosmetics* 4, 1–15. <https://doi.org/10.3390/cosmetics4030035>

- 1632 Guo, Z., Wei, Y., Zhang, Y., Xu, Y., Zheng, L., Zhu, B., Yao, Z., 2022. Carrageenan oligosaccharides: A
1633 comprehensive review of preparation, isolation, purification, structure, biological activities and
1634 applications. *Algal Res* 61, 102593. <https://doi.org/10.1016/j.algal.2021.102593>
- 1635 Haider, S., 2006. *Validation Standard Operating Procedures*. CRC Press, London.
- 1636 Hamm, J., Sullivan, K., Clippinger, A.J., Strickland, J., Bell, S., Bhatarai, B., Blaauboer, B., Casey, W.,
1637 Dorman, D., Forsby, A., Garcia-Reyero, N., Gehen, S., Graepel, R., Hotchkiss, J., Lowit, A.,
1638 Matheson, J., Reaves, E., Scarano, L., Sprankle, C., Tunkel, J., Wilson, D., Xia, M., Zhu, H., Allen,
1639 D., 2017. Alternative approaches for identifying acute systemic toxicity: Moving from research
1640 to regulatory testing. *Toxicology in Vitro* 41, 245–259. <https://doi.org/10.1016/j.tiv.2017.01.004>
- 1641 Haney, E.F., Trimble, M.J., Hancock, R.E.W., 2021. Microtiter plate assays to assess antibiofilm activity
1642 against bacteria. *Nat Protoc* 16, 2615–2632. <https://doi.org/10.1038/s41596-021-00515-3>
- 1643 Harnly, J., Applequist, W., Brown, P., Caspar, S., Harrington, P., Harbaugh-Reynaud, D., Hill, N.,
1644 LaBudde, R., Neal-Kababick, J., Roman, M., Roman, S., Sullivan, D., Titlow, B., Wehling, P., 2012.
1645 AOAC international guidelines for validation of botanical identification methods. *J AOAC Int* 95,
1646 268–272. <https://doi.org/10.5740/jaoacint.11-447>
- 1647 Harvey, A.L., 2008. Natural products in drug discovery. *Drug Discov Today* 13, 894–901.
1648 <https://doi.org/10.1016/J.DRUDIS.2008.07.004>
- 1649 Harvey, A.L., Edrada-Ebel, R., Quinn, R.J., 2015. The re-emergence of natural products for drug
1650 discovery in the genomics era. *Nat Rev Drug Discov* 14, 111–129.
1651 <https://doi.org/10.1038/nrd4510>
- 1652 He, J., Tian, J., Xu, J., Wang, K., Li, J., Gee, S.J., Hammock, B.D., Li, Q.X., Xu, T., 2018. Strong and
1653 oriented conjugation of nanobodies onto magnetosomes for the development of a rapid
1654 immunomagnetic assay for the environmental detection of tetrabromobisphenol-A. *Anal
1655 Bioanal Chem* 410, 6633–6642. <https://doi.org/10.1007/s00216-018-1270-9>
- 1656 Heavisides, E., Rouger, C., Reichel, A.F., Ulrich, C., Wenzel-Storjohann, A., Sebens, S., Tasdemir, D.,
1657 2018. Seasonal Variations in the Metabolome and Bioactivity Profile of *Fucus vesiculosus*
1658 Extracted by an Optimised, Pressurised Liquid Extraction Protocol. *Mar Drugs* 16, 503.
1659 <https://doi.org/10.3390/md16120503>
- 1660 Hellio, C., Marechal, J.-P., Véron, B.B., Bremer, G., Clare, A.S., Le Gal, Y., 2004. Seasonal Variation of
1661 Antifouling Activities of Marine Algae from the Brittany Coast (France). *Marine Biotechnology* 6,
1662 67–82. <https://doi.org/10.1007/s10126-003-0020-x>
- 1663 Henrikson, A.A., Pawlik, J.R., 1998. Seasonal variation in biofouling of gels containing extracts of
1664 marine organisms. *Biofouling* 12, 245–255. <https://doi.org/10.1080/08927019809378357>
- 1665 Herzog, E., Casey, A., Lyng, F., Chambers, G., Byrne, H., Davoren, M., 2007. A new approach to the
1666 toxicity testing of carbon-based nanomaterials—The clonogenic assay. *Toxicol Lett* 174, 49–60.
1667 <https://doi.org/10.1016/j.toxlet.2007.08.009>
- 1668 Hipsher, C., Barker, J., Lanno, R., MacKay, A., 2021. Solvent choice influences final toxicity results in
1669 *Thamnocephalus platyurus* bioassay when exposed to microcystin -LR. *Toxicol* 197, 33–39.
1670 <https://doi.org/10.1016/J.TOXICON.2021.04.010>

- 1671 Ho, B., Pek, N., Soh, B.-S., 2018. Disease Modeling Using 3D Organoids Derived from Human Induced
1672 Pluripotent Stem Cells. *Int J Mol Sci* 19, 936. <https://doi.org/10.3390/ijms19040936>
- 1673 Houssen, W.E., Jaspars, M., 2012. Isolation of Marine Natural Products, in: Sarker S, Nahar L (Eds.),
1674 Natural Products Isolation. *Methods in Molecular Biology (Methods and Protocols)*. Humana
1675 Press, pp. 367–392. https://doi.org/10.1007/978-1-61779-624-1_14
- 1676 Hu, J.M., Hsiung, G.D., 1989. Evaluation of new antiviral agents: I. In vitro perspectives. *Antiviral Res*
1677 11, 217–232. [https://doi.org/10.1016/0166-3542\(89\)90032-6](https://doi.org/10.1016/0166-3542(89)90032-6)
- 1678 Huang, D., Ou, B., Prior, R.L., 2005. The Chemistry behind Antioxidant Capacity Assays. *J Agric Food*
1679 *Chem* 53, 1841–1856. <https://doi.org/10.1021/jf030723c>
- 1680 Hughes, C.C., Fenical, W., 2010. Antibacterials from the Sea. *Chem. Eur. J* 16, 12512–12525.
1681 <https://doi.org/10.1002/chem.201001279>
- 1682 ICH Expert Working Group, 2005. ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF
1683 ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1).
- 1684 Jessica E Neil, M.S., Lenn, J.D., Brown, M.B., Williams, A.C., 2022. A new ex vivo skin model for
1685 mechanistic understanding of putative anti-inflammatory topical therapeutics. *Int J Pharm* 617,
1686 121610. <https://doi.org/10.1016/j.ijpharm.2022.121610>
- 1687 Jhong, C.-H., Riyaphan, J., Lin, S.-H., Chia, Y.-C., Weng, C.-F., 2015. Screening alpha-glucosidase and
1688 alpha-amylase inhibitors from natural compounds by molecular docking *in silico*. *BioFactors* 41,
1689 242–251. <https://doi.org/10.1002/biof.1219>
- 1690 Jiang, H.L., Li, N., Cui, L., Wang, X., Zhao, R.S., 2019. Recent application of magnetic solid phase
1691 extraction for food safety analysis. *TrAC Trends in Analytical Chemistry* 120, 115632.
1692 <https://doi.org/10.1016/J.TRAC.2019.115632>
- 1693 Jimenez, P.C., Wilke, D. V., Branco, P.C., Bauermeister, A., Rezende-Teixeira, P., Gaudêncio, S.P.,
1694 Costa-Lotufo, L. V., 2020. Enriching cancer pharmacology with drugs of marine origin. *Br J*
1695 *Pharmacol* 177, 3–27. <https://doi.org/10.1111/bph.14876>
- 1696 Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J.,
1697 Wang, L., Yang, K., Liu, F., Jiang, R., Yang, Xinglou, You, T., Liu, Xiaoce, Yang, Xiuna, Bai, F., Liu,
1698 H., Liu, Xiang, Guddat, L.W., Xu, W., Xiao, G., Qin, C., Shi, Z., Jiang, H., Rao, Z., Yang, H., 2020.
1699 Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature* 582, 289–293.
1700 <https://doi.org/10.1038/s41586-020-2223-y>
- 1701 Joklik, W., 1988. *Virology*, 3rd ed. Appleton & Lange, Norwalk, Connecticut, San Mateo.
- 1702 Judson, R., Houck, K., Martin, M., Richard, A.M., Knudsen, T.B., Shah, I., Little, S., Wambaugh, J.,
1703 Woodrow Setzer, R., Kothya, P., Phuong, J., Filer, D., Smith, D., Reif, D., Rotroff, D., Kleinstreuer,
1704 N., Sipes, N., Xia, M., Huang, R., Crofton, K., Thomas, R.S., 2016. Editor’s Highlight: Analysis of
1705 the Effects of Cell Stress and Cytotoxicity on *In Vitro* Assay Activity Across a Diverse Chemical
1706 and Assay Space. *Toxicological Sciences* 152, 323–339. <https://doi.org/10.1093/toxsci/kfw092>
- 1707 Kadian, N., Raju, K.S.R., Rashid, M., Malik, M.Y., Taneja, I., Wahajuddin, M., 2016. Comparative
1708 assessment of bioanalytical method validation guidelines for pharmaceutical industry. *J Pharm*
1709 *Biomed Anal* 126, 83–97. <https://doi.org/10.1016/j.jpba.2016.03.052>

1710 Kaminski, L., Degenhardt, M., Ermer, J., Feussner, C., Höwer-Fritzen, H., Link, P., Renger, B.,
1711 Tegtmeier, M., Wätzig, H., 2010. Efficient and economic HPLC performance qualification. *J*
1712 *Pharm Biomed Anal* 51, 557–64. <https://doi.org/10.1016/j.jpba.2009.09.011>

1713 Karnati, P., Murthy, A., Gundeti, M., Ahmed, T., 2023. Modelling Based Approaches to Support
1714 Generic Drug Regulatory Submissions-Practical Considerations and Case Studies. *AAPS J* 25, 63.
1715 <https://doi.org/10.1208/s12248-023-00831-4>

1716 Kato, N., Comer, E., Sakata-Kato, T., Sharma, Arvind, Sharma, M., Maetani, M., Bastien, J., Brancucci,
1717 N.M., Bittker, J.A., Corey, V., Clarke, D., Derbyshire, E.R., Dornan, G.L., Duffy, S., Eckley, S., Itoe,
1718 M.A., Koolen, K.M.J., Lewis, T.A., Lui, P.S., Lukens, A.K., Lund, E., March, S., Meibalan, E., Meier,
1719 B.C., McPhail, J.A., Mitasev, B., Moss, E.L., Sayes, M., Van Gessel, Y., Wawer, M.J., Yoshinaga, T.,
1720 Zeeman, A.-M., Avery, V.M., Bhatia, S.N., Burke, J.E., Catteruccia, F., Clardy, J.C., Clemons, P.A.,
1721 Dechering, K.J., Duvall, J.R., Foley, M.A., Gusovsky, F., Kocken, C.H.M., Marti, M., Morningstar,
1722 M.L., Munoz, B., Neafsey, D.E., Sharma, Amit, Winzeler, E.A., Wirth, D.F., Scherer, C.A.,
1723 Schreiber, S.L., 2016. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors.
1724 *Nature* 538, 344–349. <https://doi.org/10.1038/nature19804>

1725 Kaufmann, L., Syedbasha, M., Vogt, D., Hollenstein, Y., Hartmann, J., Linnik, J.E., Egli, A., 2017. An
1726 Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers.
1727 *Journal of Visualized Experiments*. <https://doi.org/10.3791/55833>

1728 Khan, P., Queen, A., Mohammad, T., Smita, Khan, N.S., Hafeez, Z. Bin, Hassan, Md.I., Ali, S., 2019.
1729 Identification of α -Mangostin as a Potential Inhibitor of Microtubule Affinity Regulating Kinase
1730 4. *J Nat Prod* 82, 2252–2261. <https://doi.org/10.1021/acs.jnatprod.9b00372>

1731 Khanna, I., 2012. Drug discovery in pharmaceutical industry: productivity challenges and trends. *Drug*
1732 *Discov Today* 17, 1088–1102. <https://doi.org/10.1016/j.drudis.2012.05.007>

1733 Kiuru, P., D’Auria, M.V., Muller, C.D., Tammela, P., Vuirela, H., Yli-Kauhaluoma, J., 2014. Exploring
1734 Marine Resources for Bioactive Compounds. *Planta Med* 80, 1234–1246.
1735 <https://doi.org/10.1055/s-0034-1383001>

1736 Kirmusaoğlu, S., 2019. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of
1737 Agents, in: Kirmusaoğlu (Ed.), *Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and*
1738 *Activity Methods*. IntechOpen, London. <https://doi.org/10.5772/intechopen.84411>

1739 Klančnik, A., Megušar, P., Sterniša, M., Jeršek, B., Bucar, F., Smole-Možina, S., Kos, J., Sabotič, J.,
1740 2017. Aqueous extracts of wild mushrooms show antimicrobial and antiadhesion activities
1741 against bacteria and fungi. *Phytother Res* 31, 1971–1976. <https://doi.org/10.1002/ptr.5934>

1742 Kleinstreuer, N.C., Karmaus, A.L., Mansouri, K., Allen, D.G., Fitzpatrick, J.M., Patlewicz, G., 2018.
1743 Predictive models for acute oral systemic toxicity: A workshop to bridge the gap from research
1744 to regulation. *Computational Toxicology* 8, 21–24.
1745 <https://doi.org/10.1016/j.comtox.2018.08.002>

1746 Kurita, K.L., Glassey, E., Lington, R.G., 2015. Integration of high-content screening and untargeted
1747 metabolomics for comprehensive functional annotation of natural product libraries.
1748 *Proceedings of the National Academy of Sciences* 112, 11999–12004.
1749 <https://doi.org/10.1073/pnas.1507743112>

- 1750 Kwasny, S.M., Opperman, T.J., 2010. Static Biofilm Cultures of Gram-Positive Pathogens Grown in a
 1751 Microtiter Format Used for Anti-Biofilm Drug Discovery. *Curr Protoc Pharmacol* 50.
 1752 <https://doi.org/10.1002/0471141755.ph13a08s50>
- 1753 Ky, I., Teissedre, P.-L., 2015. Characterisation of Mediterranean Grape Pomace Seed and Skin
 1754 Extracts: Polyphenolic Content and Antioxidant Activity. *Molecules* 20, 2190–2207.
 1755 <https://doi.org/10.3390/molecules20022190>
- 1756 Lall, N., Kishore, N., 2014. Are plants used for skin care in South Africa fully explored? *J*
 1757 *Ethnopharmacol* 153, 61–84. <https://doi.org/10.1016/j.jep.2014.02.021>
- 1758 Lambert, F., Jacomy, H., Marceau, G., Talbot, P.J., 2008. Titration of human coronaviruses, HCoV-229E
 1759 and HCoV-OC43, by an indirect immunoperoxidase assay. *Methods Mol Biol* 454, 93–102.
 1760 https://doi.org/10.1007/978-1-59745-181-9_8
- 1761 Lauritano, C., Andersen, J.H., Hansen, E., Albrigtsen, M., Escalera, L., Esposito, F., Helland, K.,
 1762 Hanssen, K.Ø., Romano, G., Ianora, A., 2016. Bioactivity Screening of Microalgae for
 1763 Antioxidant, Anti-Inflammatory, Anticancer, Anti-Diabetes, and Antibacterial Activities. *Front*
 1764 *Mar Sci* 3, 68. <https://doi.org/10.3389/fmars.2016.00068>
- 1765 Le Lann, K., Surget, G., Couteau, C., Coiffard, L., Cérantola, S., Gaillard, F., Larnicol, M., Zubia, M.,
 1766 Guérard, F., Poupart, N., Stiger-Pouvreau, V., 2016. Sunscreen, antioxidant, and bactericide
 1767 capacities of phlorotannins from the brown macroalga *Halidrys siliquosa*. *J Appl Phycol* 28,
 1768 3547–3559. <https://doi.org/10.1007/s10811-016-0853-0>
- 1769 Lee, S., van Santen, J.A., Farzaneh, N., Liu, D.Y., Pye, C.R., Baumeister, T.U.H., Wong, W.R., Lington,
 1770 R.G., 2022. NP Analyst: An Open Online Platform for Compound Activity Mapping. *ACS Cent Sci*
 1771 8, 223–234. <https://doi.org/10.1021/acscentsci.1c01108>
- 1772 Leist, M., Hasiwa, M., Daneshian, M., 2013. Summary and Validation of New Animal-Free Toxicity
 1773 Tests. *ALTEX Proceedings* 2, 27–37.
- 1774 Li, D., Li, C., Li, L., Chen, S., Wang, L., Li, Q., Wang, X., Lei, X., Shen, Z., 2016. Natural Product
 1775 Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis. *Cell*
 1776 *Chem Biol* 23, 257–266. <https://doi.org/10.1016/j.chembiol.2015.08.018>
- 1777 Li, M.X., Bai, X., Ma, Y.-P., Zhang, H.-X., Nama, N., Pei, S.-J., Du, Z.-Z., 2019. Cosmetic potentials of
 1778 extracts and compounds from *Zingiber cassumunar* Roxb. rhizome. *Ind Crops Prod* 141, 111764.
 1779 <https://doi.org/10.1016/j.indcrop.2019.111764>
- 1780 Lindhagen, E., Nygren, P., Larsson, R., 2008. The fluorometric microculture cytotoxicity assay. *Nat*
 1781 *Protoc* 3, 1364–1369. <https://doi.org/10.1038/nprot.2008.114>
- 1782 Linnakoski, R., Reshamwala, D., Veteli, P., Cortina-Escribano, M., Vanhanen, H., Marjomäki, V., 2018.
 1783 Antiviral Agents From Fungi: Diversity, Mechanisms and Potential Applications. *Front Microbiol*
 1784 9. <https://doi.org/10.3389/fmicb.2018.02325>
- 1785 Liu, M., El-Hossary, E.M., Oelschlaeger, T.A., Donia, M.S., Quinn, R.J., Abdelmohsen, U.R., 2019.
 1786 Potential of marine natural products against drug-resistant bacterial infections. *Lancet Infect*
 1787 *Dis*. [https://doi.org/10.1016/S1473-3099\(18\)30711-4](https://doi.org/10.1016/S1473-3099(18)30711-4)

- 1788 Lozano, C., López, M., Rojo-Bezares, B., Sáenz, Y., 2020. Antimicrobial Susceptibility Testing in
1789 *Pseudomonas aeruginosa* Biofilms: One Step Closer to a Standardized Method. *Antibiotics* 9,
1790 880. <https://doi.org/10.3390/antibiotics9120880>
- 1791 Lyu, C., Chen, T., Qiang, B., Liu, N., Wang, H., Zhang, L., Liu, Z., 2021. CMNPD: a comprehensive
1792 marine natural products database towards facilitating drug discovery from the ocean. *Nucleic*
1793 *Acids Res* 49, D509–D515. <https://doi.org/10.1093/nar/gkaa763>
- 1794 Macedo, M.W.F.S., Cunha, N.B. da, Carneiro, J.A., Costa, R.A. da, Alencar, S.A. de, Cardoso, M.H.,
1795 Franco, O.L., Dias, S.C., 2021. Marine Organisms as a Rich Source of Biologically Active Peptides.
1796 *Front Mar Sci* 8, 667764. <https://doi.org/10.3389/fmars.2021.667764>
- 1797 Madan, K., Nanda, S., 2018. In-vitro evaluation of antioxidant, anti-elastase, anti-collagenase, anti-
1798 hyaluronidase activities of safranal and determination of its sun protection factor in skin
1799 photoaging. *Bioorg Chem* 77, 159–167. <https://doi.org/10.1016/j.bioorg.2017.12.030>
- 1800 Maddox, C.B., Rasmussen, L., White, E.L., 2008. Adapting Cell-Based Assays to the High-Throughput
1801 Screening Platform: Problems Encountered and Lessons Learned. *JALA: Journal of the*
1802 *Association for Laboratory Automation* 13, 168–173. <https://doi.org/10.1016/j.jala.2008.02.002>
- 1803 Maji, B., Gangopadhyay, S.A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B., Lim, D., Siriwardena, S.U.,
1804 Paul, B., Dančík, V., Vetere, A., Mesleh, M.F., Marraffini, L.A., Liu, D.R., Clemons, P.A., Wagner,
1805 B.K., Choudhary, A., 2019. A High-Throughput Platform to Identify Small-Molecule Inhibitors of
1806 CRISPR-Cas9. *Cell* 177, 1067-1079.e19. <https://doi.org/10.1016/j.cell.2019.04.009>
- 1807 Marmann, A., Aly, A.H., Lin, W., Wang, B., Proksch, P., 2014. Co-Cultivation-A Powerful Emerging Tool
1808 for Enhancing the Chemical Diversity of Microorganisms. *Mar Drugs* 12, 1043–1065.
1809 <https://doi.org/10.3390/md12021043>
- 1810 Martín, J., Da Sousa, T.S., Crespo, G., Palomo, S., González, I., Tormo, J.R., De La Cruz, M., Anderson,
1811 M., Hill, R.T., Vicente, F., Genilloud, O., Reyes, F., 2013. Kocurin, the true structure of
1812 PM181104, an anti-methicillin-resistant *Staphylococcus aureus* (MRSA) thiazolyl peptide from
1813 the marine-derived bacterium *Kocuria palustris*. *Mar Drugs* 11, 387–398.
1814 <https://doi.org/10.3390/md11020387>
- 1815 Mascolo, M.G., Perdichizzi, S., Vaccari, M., Rotondo, F., Zanzi, C., Grilli, S., Paparella, M., Jacobs, M.N.,
1816 Colacci, A., 2018. The transformics assay: first steps for the development of an integrated
1817 approach to investigate the malignant cell transformation in vitro. *Carcinogenesis* 39, 955–967.
1818 <https://doi.org/10.1093/carcin/bgy037>
- 1819 Mbah, J.A., Ngemenya, M.N., Abawah, A.L., Babiaka, S.B., Nubed, L.N., Nyongbela, K.D., Lemuh, N.D.,
1820 Efang, S.M., 2012. Bioassay-guided discovery of antibacterial agents: in vitro screening of
1821 *Peperomia vulcanica*, *Peperomia fernandopoioana* and *Scleria striatinux*. *Ann Clin Microbiol*
1822 *Antimicrob* 11, 10. <https://doi.org/10.1186/1476-0711-11-10>
- 1823 Mervin, L.H., Cao, Q., Barrett, I.P., Firth, M.A., Murray, D., McWilliams, L., Haddrick, M.,
1824 Wigglesworth, M., Engkvist, O., Bender, A., 2016. Understanding Cytotoxicity and Cytostaticity
1825 in a High-Throughput Screening Collection. *ACS Chem Biol* 11, 3007–3023.
1826 <https://doi.org/10.1021/acscchembio.6b00538>

- 1827 Millar, M.R., Linton, C.J., Sherriff, A., 2001. Use of a continuous culture system linked to a modified
1828 robbins device or flow cell to study attachment of bacteria to surfaces, in: *Methods in*
1829 *Enzymology*. pp. 43–62. [https://doi.org/10.1016/S0076-6879\(01\)37005-2](https://doi.org/10.1016/S0076-6879(01)37005-2)
- 1830 Minarini, L.A.D.R., Andrade, L.N. de, De Gregorio, E., Grosso, F., Naas, T., Zarrilli, R., Camargo, I.L.B.C.,
1831 2020. Editorial: Antimicrobial Resistance as a Global Public Health Problem: How Can We
1832 Address It? *Front Public Health* 8, 612844. <https://doi.org/10.3389/fpubh.2020.612844>
- 1833 Mohammad, T., Khan, F.I., Lobb, K.A., Islam, A., Ahmad, F., Hassan, Md.I., 2019. Identification and
1834 evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-
1835 regulating kinase 4 (MARK4). *J Biomol Struct Dyn* 37, 1813–1829.
1836 <https://doi.org/10.1080/07391102.2018.1468282>
- 1837 Moon, H.J., Lee, S.R., Shim, S.N., Jeong, S.H., Stonik, V.A., Rasskazov, V.A., Zvyagintseva, T., Lee, Y.H.,
1838 2008. Fucoïdan Inhibits UVB-Induced MMP-1 Expression in Human Skin Fibroblasts. *Biol Pharm*
1839 *Bull* 31, 284–289. <https://doi.org/10.1248/bpb.31.284>
- 1840 Muenzebrock, K.A., Kersten, V., Alblas, J., Garcia, J.P., Creemers, L.B., 2022. The Added Value of the
1841 “Co” in Co-Culture Systems in Research on Osteoarthritis Pathology and Treatment
1842 Development. *Front Bioeng Biotechnol* 10. <https://doi.org/10.3389/fbioe.2022.843056>
- 1843 Naesens, L., Bonnafous, P., Agut, H., De Clercq, E., 2006. Antiviral activity of diverse classes of broad-
1844 acting agents and natural compounds in HHV-6-infected lymphoblasts. *Journal of Clinical*
1845 *Virology* 37, S69–S75. [https://doi.org/10.1016/S1386-6532\(06\)70015-4](https://doi.org/10.1016/S1386-6532(06)70015-4)
- 1846 Naik, B., Gupta, N., Ojha, R., Singh, S., Prajapati, V.K., Prusty, D., 2020. High throughput virtual
1847 screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy
1848 for COVID-19 treatment. *Int J Biol Macromol* 160, 1–17.
1849 <https://doi.org/10.1016/j.ijbiomac.2020.05.184>
- 1850 Nehete, J.Y., Bhambar, R.S., Narkhede, M.R., Gawali, S.R., 2013. Natural proteins: Sources, isolation,
1851 characterization and applications. *Pharmacogn Rev* 7, 107–116. <https://doi.org/10.4103/0973-7847.120508>
- 1853 Newman, D.J., Cragg, G.M., 2020. Natural Products as Sources of New Drugs over the Nearly Four
1854 Decades from 01/1981 to 09/2019. *J Nat Prod* 83, 770–803.
1855 <https://doi.org/10.1021/acs.jnatprod.9b01285>
- 1856 Niepel, M., Hafner, M., Duan, Q., Wang, Z., Paull, E.O., Chung, M., Lu, X., Stuart, J.M., Golub, T.R.,
1857 Subramanian, A., Ma’ayan, A., Sorger, P.K., 2017. Common and cell-type specific responses to
1858 anti-cancer drugs revealed by high throughput transcript profiling. *Nat Commun* 8, 1186.
1859 <https://doi.org/10.1038/s41467-017-01383-w>
- 1860 Nikaido, H., 2009. The Limitations of LB Medium. *Small Things Considered*.
- 1861 Nothias, L.-F., Nothias-Esposito, M., da Silva, R., Wang, M., Protsyuk, I., Zhang, Z., Sarvepalli, A.,
1862 Leyssen, P., Touboul, D., Costa, J., Paolini, J., Alexandrov, T., Litaudon, M., Dorrestein, P.C.,
1863 2018. Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural
1864 Product Bioassay-Guided Fractionation. *J Nat Prod* 81, 758–767.
1865 <https://doi.org/10.1021/acs.jnatprod.7b00737>
- 1866 Nweze, J.A., Mbaoji, F.N., Huang, G., Li, Y., Yang, L., Zhang, Y., Huang, S., Pan, L., Yang, D., 2020.
1867 Antibiotics Development and the Potentials of Marine-Derived Compounds to Stem the Tide of

- 1868 Multidrug-Resistant Pathogenic Bacteria, Fungi, and Protozoa. *Mar Drugs* 18, 145.
1869 <https://doi.org/10.3390/md18030145>
- 1870 Öberg, B., Vrang, L., 1990. Screening for new agents. *European Journal of Clinical Microbiology &*
1871 *Infectious Diseases* 9, 466–471. <https://doi.org/10.1007/BF01964285>
- 1872 Oh, D.C., Jensen, P.R., Kauffman, C.A., Fenical, W., 2005. Libertellenones A–D: Induction of cytotoxic
1873 diterpenoid biosynthesis by marine microbial competition. *Bioorg Med Chem* 13, 5267–5273.
1874 <https://doi.org/10.1016/J.BMC.2005.05.068>
- 1875 Olivares, E., Badel-Berchoux, S., Provot, C., Jaulhac, B., Prévost, G., Bernardi, T., Jehl, F., 2016. The
1876 BioFilm Ring Test: a Rapid Method for Routine Analysis of *Pseudomonas aeruginosa* Biofilm
1877 Formation Kinetics. *J Clin Microbiol* 54, 657–661. <https://doi.org/10.1128/JCM.02938-15>
- 1878 Ong, C.W.M., Migliori, G.B., Raviglione, M., MacGregor-Skinner, G., Sotgiu, G., Alffenaar, J.-W., Tiberi,
1879 S., Adlhoch, C., Alonzi, T., Archuleta, S., Brusin, S., Cambau, E., Capobianchi, M.R., Castilletti, C.,
1880 Centis, R., Cirillo, D.M., D’Ambrosio, L., Delogu, G., Esposito, S.M.R., Figueroa, J., Friedland, J.S.,
1881 Ho, B.C.H., Ippolito, G., Jankovic, M., Kim, H.Y., Rosales Klintz, S., Ködmön, C., Lalle, E., Leo, Y.S.,
1882 Leung, C.-C., Mårtson, A.-G., Melazzini, M.G., Najafi Fard, S., Penttinen, P., Petrone, L.,
1883 Petruccioli, E., Pontali, E., Saderi, L., Santin, M., Spanevello, A., van Crevel, R., van der Werf,
1884 M.J., Visca, D., Viveiros, M., Zellweger, J.-P., Zumla, A., Goletti, D., 2020. Epidemic and pandemic
1885 viral infections: impact on tuberculosis and the lung. *European Respiratory Journal* 56, 2001727.
1886 <https://doi.org/10.1183/13993003.01727-2020>
- 1887 Organisation for Economic Co-operation and Development - OECD, 2022. OECD Guidelines for the
1888 Testing of Chemicals, Section 4 Health Effects. OECD. [https://doi.org/10.1787/9789264242548-](https://doi.org/10.1787/9789264242548-en)
1889 [en](https://doi.org/10.1787/9789264242548-en)
- 1890 O’Rourke, A., Beyhan, S., Choi, Y., Morales, P., Chan, A.P., Espinoza, J.L., Dupont, C.L., Meyer, K.J.,
1891 Spoering, A., Lewis, K., Nierman, W.C., Nelson, K.E., 2020. Mechanism-of-Action Classification of
1892 Antibiotics by Global Transcriptome Profiling. *Antimicrob Agents Chemother* 64, e01207-19.
1893 <https://doi.org/10.1128/aac.01207-19>
- 1894 Ortega, S.S., Cara, L.C.L., Salvador, M.K., 2012. In silico pharmacology for a multidisciplinary drug
1895 discovery process. *Drug Metabol Drug Interact* 27, 199–207. [https://doi.org/10.1515/dmdi-](https://doi.org/10.1515/dmdi-2012-0021)
1896 [2012-0021](https://doi.org/10.1515/dmdi-2012-0021)
- 1897 Palacios-Gorba, C., Pina, R., Tortajada-Girbés, M., Jiménez-Belenguer, A., Siguemoto, É., Ferrús, M.A.,
1898 Rodrigo, D., Pina-Pérez, M.C., 2020. Caenorhabditis elegans as an in vivo model to assess
1899 fucoïdan bioactivity preventing *Helicobacter pylori* infection. *Food Funct* 11, 4525–4534.
1900 <https://doi.org/10.1039/D0FO00768D>
- 1901 Park, E.S., Rabinovsky, R., Carey, M., Hennessy, B.T., Agarwal, R., Liu, W., Ju, Z., Deng, W., Lu, Y., Woo,
1902 H.G., Kim, S.-B., Cheong, J.-H., Garraway, L.A., Weinstein, J.N., Mills, G.B., Lee, J.-S., Davies,
1903 M.A., 2010. Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness
1904 in the NCI 60 Cancer Cell Line Set. *Mol Cancer Ther* 9, 257–267. [https://doi.org/10.1158/1535-](https://doi.org/10.1158/1535-7163.MCT-09-0743)
1905 [7163.MCT-09-0743](https://doi.org/10.1158/1535-7163.MCT-09-0743)
- 1906 Parvez, S., Kang, M., Chung, H.-S., Cho, C., Hong, M.-C., Shin, M.-K., Bae, H., 2006. Survey and
1907 mechanism of skin depigmenting and lightening agents. *Phytotherapy Research* 20, 921–934.
1908 <https://doi.org/10.1002/ptr.1954>

- 1909 Pastorino, G., Marchetti, C., Borghesi, B., Cornara, L., Ribulla, S., Burlando, B., 2017. Biological
 1910 activities of the legume crops *Melilotus officinalis* and *Lespedeza capitata* for skin care and
 1911 pharmaceutical applications. *Ind Crops Prod* 96, 158–164.
 1912 <https://doi.org/10.1016/j.indcrop.2016.11.047>
- 1913 Pech-Puch, D., Pérez-Povedano, M., Gómez, P., Martínez-Gutián, M., Lasarte-Monterrubio, C., Carlos
 1914 Vázquez-Ucha, J., Lourdes Novoa-Olmedo, M., Guillén-Hernández, S., Villegas-Hernández, H.,
 1915 Bou, G., Rodríguez, J., Beceiro, A., Jiménez, C., 2020. Marine Organisms from the Yucatan
 1916 Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds. *Mar. Drugs* 18,
 1917 369. <https://doi.org/10.3390/md18070369>
- 1918 Peeters, E., Nelis, H.J., Coenye, T., 2008. Comparison of multiple methods for quantification of
 1919 microbial biofilms grown in microtiter plates. *J Microbiol Methods* 72, 157–165.
 1920 <https://doi.org/10.1016/J.MIMET.2007.11.010>
- 1921 Pena-Pereira, F., Bendicho, C., Pavlović, D.M., Martín-Esteban, A., Díaz-Álvarez, M., Pan, Y., Cooper,
 1922 J., Yang, Z., Safarik, I., Pospiskova, K., Segundo, M.A., Psillakis, E., 2021. Miniaturized analytical
 1923 methods for determination of environmental contaminants of emerging concern – A review.
 1924 *Anal Chim Acta* 1158, 238108. <https://doi.org/10.1016/J.ACA.2020.11.040>
- 1925 Pereira, F., Almeida, J.R., Paulino, M., Grilo, I.R., Macedo, H., Cunha, I., Sobral, R.G., Vasconcelos, V.,
 1926 Gaudêncio, S.P., 2020. Antifouling Napyradiomycins from Marine-Derived Actinomycetes
 1927 *Streptomyces aculeolatus*. *Mar Drugs* 18, 63. <https://doi.org/10.3390/md18010063>
- 1928 Pereira, F., Latino, D., Gaudêncio, S., 2015. QSAR-Assisted Virtual Screening of Lead-Like Molecules
 1929 from Marine and Microbial Natural Sources for Antitumor and Antibiotic Drug Discovery.
 1930 *Molecules* 20, 4848–4873. <https://doi.org/10.3390/molecules20034848>
- 1931 Pereira, F., Latino, D., Gaudêncio, S., 2014. A Chemoinformatics Approach to the Discovery of Lead-
 1932 Like Molecules from Marine and Microbial Sources En Route to Antitumor and Antibiotic Drugs.
 1933 *Mar Drugs* 12, 757–778. <https://doi.org/10.3390/md12020757>
- 1934 Philström, T., Fernández-Alba, A.R., Gamón, M., Amate, C.F., Poulsen, M.E., Lippold, R.,
 1935 Anastassiades, M., De Kok, A., O'Regan, F., Pelosi, P., Valverde, A., Masselter, S., Mol, H.,
 1936 Jezussek, M., 2019. Analytical quality control and method validation procedures for pesticide
 1937 residues analysis in food and feed.
- 1938 Ponti, J., Ceriotti, L., Munaro, B., Farina, M., Munari, A., Whelan, M., Colpo, P., Sabbioni, E., Rossi, F.,
 1939 2006. Comparison of Impedance-based Sensors for Cell Adhesion Monitoring and *In Vitro*
 1940 Methods for Detecting Cytotoxicity Induced by Chemicals. *Alternatives to Laboratory Animals*
 1941 34, 515–525. <https://doi.org/10.1177/026119290603400508>
- 1942 Pushpakom, S., Iorio, F., Eyers, P.A., Escott, K.J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer,
 1943 J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., Pirmohamed, M., 2019. Drug repurposing:
 1944 progress, challenges and recommendations. *Nat Rev Drug Discov* 18, 41–58.
 1945 <https://doi.org/10.1038/nrd.2018.168>
- 1946 Qiu, S.-M., Aweya, J.J., Liu, X., Liu, Y., Tang, S., Zhang, W., Cheong, K.-L., 2022. Bioactive
 1947 polysaccharides from red seaweed as potent food supplements: a systematic review of their
 1948 extraction, purification, and biological activities. *Carbohydr Polym* 275, 118696.
 1949 <https://doi.org/10.1016/j.carbpol.2021.118696>

- 1950 Ratz-Lyko, A., Arct, J., Pytkowska, K., 2012. Methods for evaluation of cosmetic antioxidant capacity.
1951 Skin Research and Technology 18, 421–430. <https://doi.org/10.1111/j.1600-0846.2011.00588.x>
- 1952 Raucchi, A., Palumbo, R., Bianchi, M.E., 2007. HMGB1: a signal of necrosis. *Autoimmunity* 40, 285–9.
1953 <https://doi.org/10.1080/08916930701356978>
- 1954 Rekha, P., Chandra Mouli, B., Vijaya Kumari, S., Indumathi, C., Mithyantha MS, 2006. Studies on the
1955 identification of suitable solvents for microbial bioassay. *Curr Sci* 90, 1663–1667.
- 1956 Reymen, D., Naesens, L., Balzarini, J., Holý, A., Dvořáková, H., De Clercq, E., 1995. Antiviral activity of
1957 selected acyclic nucleoside analogues against human herpesvirus 6. *Antiviral Res* 28, 343–357.
1958 [https://doi.org/10.1016/0166-3542\(95\)00058-5](https://doi.org/10.1016/0166-3542(95)00058-5)
- 1959 Riss, T., Niles, A., Moravec, R., Karassina, N., Vidugiriene, J., 2019. Cytotoxicity Assays: In Vitro
1960 Methods to Measure Dead Cells, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.),
1961 Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells. Eli Lilly & Company and the
1962 National Center for Advancing Translational Sciences, Bethesda, MD.
- 1963 Riss, T.L., Moravec, R.A., 2004. Use of Multiple Assay Endpoints to Investigate the Effects of
1964 Incubation Time, Dose of Toxin, and Plating Density in Cell-Based Cytotoxicity Assays. *Assay
1965 Drug Dev Technol* 2, 51–62. <https://doi.org/10.1089/154065804322966315>
- 1966 Rittie, L., Fisher, G.J., 2002. UV-light-induced signal cascades and skin aging. *Ageing Res Rev* 1, 705–
1967 720. [https://doi.org/10.1016/S1568-1637\(02\)00024-7](https://doi.org/10.1016/S1568-1637(02)00024-7)
- 1968 Rodriguez-Tudela, J.L., Arendrup, M.C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M.,
1969 Dannaoui, E., Denning, D.W., Donnelly, J.P., Dromer, F., Fegeler, W., Lass-Flörl, C., Moore, C.,
1970 Richardson, M., Sandven, P., Velegraki, A., Verweij, P., 2008. EUCAST Definitive Document EDef
1971 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative
1972 yeasts. *Clinical Microbiology and Infection* 14, 398–405. <https://doi.org/10.1111/j.1469-0691.2007.01935.x>
- 1974 Roh, S.-S., Park, S.-B., Park, S.-M., Choi, B.W., Lee, M.-H., Hwang, Y.-L., Kim, C.H., Jeong, H.-A., Kim,
1975 C.D., Lee, J.-H., 2013. A Novel Compound Rasatiol Isolated from *Raphanus sativus* Has a
1976 Potential to Enhance Extracellular Matrix Synthesis in Dermal Fibroblasts. *Ann Dermatol* 25,
1977 315. <https://doi.org/10.5021/ad.2013.25.3.315>
- 1978 Romano, J.D., Tatonetti, N.P., 2019. Informatics and Computational Methods in Natural Product Drug
1979 Discovery: A Review and Perspectives. *Front Genet* 10, 368.
1980 <https://doi.org/10.3389/fgene.2019.00368>
- 1981 Romano, S., Jackson, S.A., Patry, S., Dobson, A.D.W., 2018. Extending the “One Strain Many
1982 Compounds” (OSMAC) Principle to Marine Microorganisms. *Mar Drugs* 16, 244.
1983 <https://doi.org/10.3390/md16070244>
- 1984 Rotter, A., Bacu, A., Barbier, M., Bertoni, F., Bones, A.M., Cancela, M.L., Carlsson, J., Carvalho, M.F.,
1985 Cegłowska, M., Dalay, M.C., Dailianis, T., Deniz, I., Drakulovic, D., Dubnika, A., Einarsson, H.,
1986 Erdoğan, A., Eroldoğan, O.T., Ezra, D., Fazi, S., FitzGerald, R.J., Gargan, L.M., Gaudêncio, S.P.,
1987 Ivošević DeNardis, N., Joksimovic, D., Kataržytė, M., Kotta, J., Mandalakis, M., Matijošytė, I.,
1988 Mazur-Marzec, H., Massa-Gallucci, A., Mehiri, M., Nielsen, S.L., Novoveská, L., Overlingé, D.,
1989 Portman, M.E., Pyrc, K., Rebours, C., Reinsch, T., Reyes, F., Rinkevich, B., Robbens, J., Rudovica,
1990 V., Sabotič, J., Safarik, I., Talve, S., Tasdemir, D., Schneider, X.T., Thomas, O.P., Toruńska-Sitarz,

- 1991 A., Varese, G.C., Vasquez, M.I., 2020. A New Network for the Advancement of Marine
 1992 Biotechnology in Europe and Beyond. *Front Mar Sci* 7.
 1993 <https://doi.org/10.3389/fmars.2020.00278>
- 1994 Rotter, A., Barbier, M., Bertoni, F., Bones, A.M., Cancela, M.L., Carlsson, J., Carvalho, M.F., Cegłowska,
 1995 M., Chirivella-Martorell, J., Conk Dalay, M., Cueto, M., Dailianis, T., Deniz, I., Díaz-Marrero, A.R.,
 1996 Drakulovic, D., Dubnika, A., Edwards, C., Einarsson, H., Erdoğan, A., Eroldoğan, O.T., Ezra, D.,
 1997 Fazi, S., FitzGerald, R.J., Gargan, L.M., Gaudêncio, S.P., Gligora Udovič, M., Ivošević DeNardis, N.,
 1998 Jónsdóttir, R., Kataržytė, M., Klun, K., Kotta, J., Ktari, L., Ljubešić, Z., Lukić Bilela, L., Mandalakis,
 1999 M., Massa-Gallucci, A., Matijošytė, I., Mazur-Marzec, H., Mehiri, M., Nielsen, S.L., Novoveská, L.,
 2000 Overlingė, D., Perale, G., Ramasamy, P., Rebours, C., Reinsch, T., Reyes, F., Rinkevich, B.,
 2001 Robbens, J., Röttinger, E., Rudovica, V., Sabotič, J., Safarik, I., Talve, S., Tasdemir, D., Theodotou
 2002 Schneider, X., Thomas, O.P., Toruńska-Sitarz, A., Varese, G.C., Vasquez, M.I., 2021a. The
 2003 Essentials of Marine Biotechnology. *Front Mar Sci*. <https://doi.org/10.3389/fmars.2021.629629>
- 2004 Rotter, A., Gaudêncio, S.P., Klun, K., Macher, J.-N., Thomas, O.P., Deniz, I., Edwards, C., Grigalionyte-
 2005 Bembič, E., Ljubešić, Z., Robbens, J., Varese, G.C., Vasquez, M.I., 2021b. A New Tool for Faster
 2006 Construction of Marine Biotechnology Collaborative Networks. *Front Mar Sci* 8.
 2007 <https://doi.org/10.3389/fmars.2021.685164>
- 2008 Sabotič, J., Brzin, J., Erjavec, J., Dreo, T., Tušek Žnidarič, M., Ravnikar, M., Kos, J., 2020. L-Amino Acid
 2009 Oxidases From Mushrooms Show Antibacterial Activity Against the Phytopathogen *Ralstonia*
 2010 *solanacearum*. *Front Microbiol* 11, 977. <https://doi.org/10.3389/fmicb.2020.00977>
- 2011 Safarik, I., Horska, K., Pospiskova, K., Safarikova, M., 2012. Magnetic techniques for the detection and
 2012 determination of xenobiotics and cells in water. *Anal Bioanal Chem* 404, 1257–1273.
 2013 <https://doi.org/10.1007/s00216-012-6056-x>
- 2014 Safarik, I., Safarikova, M., 2014. One-step magnetic modification of non-magnetic solid materials.
 2015 *International Journal of Materials Research* 105, 104–107. <https://doi.org/10.3139/146.111009>
- 2016 Safarik, I., Safarikova, M., 2004. Magnetic techniques for the isolation and purification of proteins
 2017 and peptides. *Biomagn Res Technol* 2, 7. <https://doi.org/10.1186/1477-044X-2-7>
- 2018 Šafaříková, M., Šafařík, I., 1999. Magnetic solid-phase extraction. *J Magn Magn Mater* 194, 108–112.
 2019 [https://doi.org/10.1016/S0304-8853\(98\)00566-6](https://doi.org/10.1016/S0304-8853(98)00566-6)
- 2020 Saghaie, L., Pourfarzam, M., Fassihi, A., Sartippour, B., 2013. Synthesis and tyrosinase inhibitory
 2021 properties of some novel derivatives of kojic acid. *Res Pharm Sci* 8, 233–42.
- 2022 Saini, R.K., Prasad, P., Shang, X., Keum, Y.-S., Parinandi, L., 2021. Molecular Sciences Advances in Lipid
 2023 Extraction Methods-A Review. *Int. J. Mol. Sci* 22, 13643.
 2024 <https://doi.org/10.3390/ijms222413643>
- 2025 Sanguinetti, M., Posteraro, B., 2016. Mass spectrometry applications in microbiology beyond microbe
 2026 identification: progress and potential. *Expert Rev Proteomics* 13, 965–977.
 2027 <https://doi.org/10.1080/14789450.2016.1231578>
- 2028 Santacroce, M.P., Pastore, A.S., Tinelli, A., Colamonaco, M., Crescenzo, G., 2015. Implications for
 2029 chronic toxicity of benzo[a]pyrene in sea bream cultured hepatocytes: Cytotoxicity,
 2030 inflammation, and cancerogenesis. *Environ Toxicol* 30, 1045–1062.
 2031 <https://doi.org/10.1002/tox.21978>

- 2032 Sarker, S.D., Nahar, L., 2012. Natural Products Isolation. *Methods in Molecular Biology* 864.
2033 https://doi.org/10.1007/978-1-61779-624-1_1
- 2034 Sauer, G., Amtmann, E., Melber, K., Knapp, A., Müller, K., Hummel, K., Scherm, A., 1984. DNA and
2035 RNA virus species are inhibited by xanthates, a class of antiviral compounds with unique
2036 properties. *Proceedings of the National Academy of Sciences* 81, 3263–3267.
2037 <https://doi.org/10.1073/pnas.81.11.3263>
- 2038 Schneider, X.T., Stroil, B.K., Tourapi, C., Rebours, C., Gaudêncio, S.P., Novoveska, L., Vasquez, M.I.,
2039 2022. Responsible Research and Innovation Framework, the Nagoya Protocol and Other
2040 European Blue Biotechnology Strategies and Regulations: Gaps Analysis and Recommendations
2041 for Increased Knowledge in the Marine Biotechnology Community. *Mar Drugs* 20, 290.
2042 <https://doi.org/10.3390/md20050290>
- 2043 Schneider, X.T., Stroil, B.K., Tourapi, C., Rebours, C., Novoveska, L., Vasquez, M.I., Gaudêncio, S.P.,
2044 2023. Improving awareness, understanding, and enforcement of responsibilities and regulations
2045 in Blue Biotechnology. *Trends Biotechnol.* <https://doi.org/10.1016/j.tibtech.2023.05.011>
- 2046 Scientific Committee on Consumer Safety - SCCS, 2021. SCCS Notes of Guidance for the Testing of
2047 Cosmetic Ingredients and their Safety Evaluation 11th revision. SCCS/1628/21.
- 2048 Seiler, A.E.M., Spielmann, H., 2011. The validated embryonic stem cell test to predict embryotoxicity
2049 in vitro. *Nat Protoc* 6, 961–978. <https://doi.org/10.1038/nprot.2011.348>
- 2050 Severson, W.E., Shindo, N., Sosa, M., Fletcher, I.T., White, E.L., Ananthan, S., Jonsson, C.B., 2007.
2051 Development and Validation of a High-Throughput Screen for Inhibitors of SARS CoV and Its
2052 Application in Screening of a 100,000-Compound Library. *SLAS Discovery* 12, 33–40.
2053 <https://doi.org/10.1177/1087057106296688>
- 2054 Sezonov, G., Joseleau-Petit, D., D’Ari, R., 2007. Escherichia coli physiology in Luria-Bertani broth. *J*
2055 *Bacteriol* 189, 8746–8749. <https://doi.org/10.1128/JB.01368-07>
- 2056 Shabir, G.A., 2003. Validation of high-performance liquid chromatography methods for
2057 pharmaceutical analysis. *J Chromatogr A* 987, 57–66. [https://doi.org/10.1016/S0021-9673\(02\)01536-4](https://doi.org/10.1016/S0021-9673(02)01536-4)
- 2059 Shoemaker, R.H., 2006. The NCI60 human tumour cell line anticancer drug screen. *Nat Rev Cancer* 6,
2060 813–823. <https://doi.org/10.1038/nrc1951>
- 2061 Shounan, Y., Feng, X., O’Connell, P.J., 1998. Apoptosis detection by annexin V binding: a novel
2062 method for the quantitation of cell-mediated cytotoxicity. *J Immunol Methods* 217, 61–70.
2063 [https://doi.org/10.1016/s0022-1759\(98\)00090-8](https://doi.org/10.1016/s0022-1759(98)00090-8)
- 2064 Sidwell, R., 1986. Determination of antiviral activity. *Drugs Pharm Sci* 27, 433–480.
- 2065 Šimat, V., Elabed, N., Kulawik, P., Ceylan, Z., Jamroz, E., Yazgan, H., Čagalj, M., Regenstein, J.M.,
2066 Özogul, F., 2020. Recent Advances in Marine-Based Nutraceuticals and Their Health Benefits.
2067 *Mar Drugs* 18, 627. <https://doi.org/10.3390/md18120627>
- 2068 Śliwka, L., Wiktorska, K., Suchocki, P., Milczarek, M., Mielczarek, S., Lubelska, K., Cierpień, T., Łyżwa,
2069 P., Kiełbasiński, P., Jaromin, A., Flis, A., Chilmonczyk, Z., 2016. The Comparison of MTT and CVS
2070 Assays for the Assessment of Anticancer Agent Interactions. *PLoS One* 11, e0155772.
2071 <https://doi.org/10.1371/journal.pone.0155772>

- 2072 Sterniša, M., Sabotič, J., Klančnik, A., 2022. A novel approach using growth curve analysis to
 2073 distinguish between antimicrobial and anti-biofilm activities against Salmonella. *Int J Food*
 2074 *Microbiol* 364, 109520. <https://doi.org/10.1016/j.ijfoodmicro.2021.109520>
- 2075 Strömstedt, A.A., Felth, J., Bohlin, L., 2014. Bioassays in natural product research - Strategies and
 2076 methods in the search for anti-inflammatory and antimicrobial activity. *Phytochemical Analysis*
 2077 25, 13–28. <https://doi.org/10.1002/PCA.2468>
- 2078 Suffness, M., Pezzuto, J.M., 1991. Assays related to cancer drug discovery, in: Hostettmann, K., Dey,
 2079 P.M., Harborne, J.B. (Eds.), *Methods in Plant Biochemistry*. Academic Press, London, pp. 71–
 2080 153.
- 2081 Swinney, D., 2013. Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. *Clin*
 2082 *Pharmacol Ther* 93, 299–301. <https://doi.org/10.1038/clpt.2012.236>
- 2083 Taga, M.E., Xavier, K.B., 2011. Methods for Analysis of Bacterial Autoinducer-2 Production. *Curr*
 2084 *Protoc Microbiol* 23. <https://doi.org/10.1002/9780471729259.mc01c01s23>
- 2085 Tandon, R., Mocarski, E.S., 2012. Viral and host control of cytomegalovirus maturation. *Trends*
 2086 *Microbiol* 20, 392–401. <https://doi.org/10.1016/j.tim.2012.04.008>
- 2087 Thompson, M., Ellison, S.L.R., Wood, R., 2002. Harmonized guidelines for single laboratory validation
 2088 of methods of analysis (IUPAC Technical Report). *Pure Appl. Chem* 74, 4–5.
- 2089 Thornburg, C.C., Britt, J.R., Evans, J.R., Akee, R.K., Whitt, J.A., Trinh, S.K., Harris, M.J., Thompson, J.R.,
 2090 Ewing, T.L., Shipley, S.M., Grothaus, P.G., Newman, D.J., Schneider, J.P., Grkovic, T., O’Keefe,
 2091 B.R., 2018. NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural
 2092 Product Fractions for High-Throughput Screening. *ACS Chem Biol* 13, 2484–2497.
 2093 <https://doi.org/10.1021/acscchembio.8b00389>
- 2094 Thring, T.S., Hili, P., Naughton, D.P., 2009. Anti-collagenase, anti-elastase and anti-oxidant activities
 2095 of extracts from 21 plants. *BMC Complement Altern Med* 9, 27. [https://doi.org/10.1186/1472-](https://doi.org/10.1186/1472-6882-9-27)
 2096 [6882-9-27](https://doi.org/10.1186/1472-6882-9-27)
- 2097 Tian, Z., Liu, F., Li, D., Fernie, A.R., Chen, W., 2022. Strategies for structure elucidation of small
 2098 molecules based on LC–MS/MS data from complex biological samples. *Comput Struct*
 2099 *Biotechnol J* 20, 5085–5097. <https://doi.org/10.1016/j.csbj.2022.09.004>
- 2100 Tremblay, Y.D.N., Vogeleeer, P., Jacques, M., Harel, J., 2015. High-Throughput Microfluidic Method To
 2101 Study Biofilm Formation and Host-Pathogen Interactions in Pathogenic *Escherichia coli*. *Appl*
 2102 *Environ Microbiol* 81, 2827–2840. <https://doi.org/10.1128/AEM.04208-14>
- 2103 Tziveleka, L.-A., Vagias, C., Roussis, V., 2003. Natural Products with Anti-HIV Activity from Marine
 2104 Organisms. *Curr Top Med Chem* 3, 1512–1535. <https://doi.org/10.2174/1568026033451790>
- 2105 United States Pharmacopeial Convention, 2018. General Chapter <1058> “Analytical Instrument
 2106 Qualification.” Rockville, Maryland, USA.
- 2107 USFDA, 2018. Bioanalytical Method Validation Guidance for Industry.
- 2108 USP 40, 2017. <1225> Validation of Compendial Procedures.

- 2109 Valigra, L., 2010. Qualifying Analytical Instruments: General Chapter <1058> Clarifies
 2110 Terminology, Classifies Instruments. *The Quality Assurance Journal* 13, 67–71.
 2111 <https://doi.org/10.1002/qaj.475>
- 2112 Vasconcelos, I., Fernandes, C., 2017. Magnetic solid phase extraction for determination of drugs in
 2113 biological matrices. *TrAC Trends in Analytical Chemistry* 89, 41–52.
 2114 <https://doi.org/10.1016/J.TRAC.2016.11.011>
- 2115 Veerapandian, R., Paudyal, A., Chang, A., Vedyappan, G., 2020. Separation of Bioactive Small
 2116 Molecules, Peptides from Natural Sources and Proteins from Microbes by Preparative
 2117 Isoelectric Focusing (IEF) Method. *Journal of Visualized Experiments*.
 2118 <https://doi.org/10.3791/61101>
- 2119 Veldhuizen, J., Migrino, R.Q., Nikkhah, M., 2019. Three-dimensional microengineered models of
 2120 human cardiac diseases. *J Biol Eng* 13, 29. <https://doi.org/10.1186/s13036-019-0155-6>
- 2121 Wambaugh, J.F., Hughes, M.F., Ring, C.L., MacMillan, D.K., Ford, J., Fennell, T.R., Black, S.R., Snyder,
 2122 R.W., Sipes, N.S., Wetmore, B.A., Westerhout, J., Setzer, R.W., Pearce, R.G., Simmons, J.E.,
 2123 Thomas, R.S., 2018. Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics. *Toxicological*
 2124 *Sciences* 163, 152–169. <https://doi.org/10.1093/toxsci/kfy020>
- 2125 Wang, C., Niederstrasser, H., Douglas, P.M., Lin, R., Jaramillo, J., Li, Y., Oswald, N.W., Zhou, A.,
 2126 McMillan, E.A., Mendiratta, S., Wang, Z., Zhao, T., Lin, Z., Luo, M., Huang, G., Brekken, R.A.,
 2127 Posner, B.A., MacMillan, J.B., Gao, J., White, M.A., 2017. Small-molecule TFEB pathway agonists
 2128 that ameliorate metabolic syndrome in mice and extend *C. elegans* lifespan. *Nat Commun* 8,
 2129 2270. <https://doi.org/10.1038/s41467-017-02332-3>
- 2130 Wang, X., Li, G., Row, K.H., 2017. Magnetic graphene oxide modified by imidazole-based ionic liquids
 2131 for the magnetic-based solid-phase extraction of polysaccharides from brown alga. *J Sep Sci* 40,
 2132 3301–3310. <https://doi.org/10.1002/jssc.201700393>
- 2133 Webb, B.J., Ferraro, J.P., Rea, S., Kaufusi, S., Goodman, B.E., Spalding, J., 2018. Epidemiology and
 2134 Clinical Features of Invasive Fungal Infection in a US Health Care Network. *Open Forum Infect*
 2135 *Dis* 5. <https://doi.org/10.1093/ofid/ofy187>
- 2136 Weller, M.G., 2012. A Unifying Review of Bioassay-Guided Fractionation, Effect-Directed Analysis and
 2137 Related Techniques. *Sensors* 12, 9181–9209. <https://doi.org/10.3390/s120709181>
- 2138 White, J.R., Abodeely, M., Ahmed, S., Debaue, G., Johnson, E., Meyer, D.M., Mozier, N.M., Naumer,
 2139 M., Pepe, A., Qahwash, I., Rocnik, E., Smith, J.G., Stokes, E.S.E., Talbot, J.J., Wong, P.Y., 2019.
 2140 Best practices in bioassay development to support registration of biopharmaceuticals.
 2141 *Biotechniques* 67, 126–137. <https://doi.org/10.2144/btn-2019-0031>
- 2142 WHO Scientific Group, 1987. Progress in the development and use of antiviral drugs and interferon.
 2143 Geneva.
- 2144 Wiegand, I., Hilpert, K., Hancock, R.E.W., 2008. Agar and broth dilution methods to determine the
 2145 minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat Protoc* 3, 163–175.
 2146 <https://doi.org/10.1038/nprot.2007.521>
- 2147 Wingate, G., 2004. Computer systems validation : quality assurance, risk management, and
 2148 regulatory compliance for pharmaceutical and healthcare companies. Interpharm/CRC, USA.

2149 Wishart, D.S., 2009. Computational strategies for metabolite identification in metabolomics.
2150 *Bioanalysis* 1, 1579–1596. <https://doi.org/10.4155/bio.09.138>

2151 Wishart, D.S., 2007. Improving Early Drug Discovery through ADME Modelling. *Drugs in R & D* 8, 349–
2152 362. <https://doi.org/10.2165/00126839-200708060-00003>

2153 Wouters, O.J., McKee, M., Luyten, J., 2020. Estimated Research and Development Investment
2154 Needed to Bring a New Medicine to Market, 2009-2018. *JAMA* 323, 844.
2155 <https://doi.org/10.1001/jama.2020.1166>

2156 Yang, Y., Khan, B.M., Zhang, X., Zhao, Y., Cheong, K.-L., Liu, Y., 2020. Advances in Separation and
2157 Purification of Bioactive Polysaccharides through High-speed Counter-Current Chromatography
2158 The prospects of bioactive polysaccharides research. *J Chromatogr Sci* 58, 992–1000.
2159 <https://doi.org/10.1093/chromsci/bmaa063>

2160 Yang, Z.H., Lucia, H.L., Tolman, R.L., Colonno, R.J., Hsiung, G.D., 1989. Effect of 2'-nor-cyclic GMP
2161 against guinea pig cytomegalovirus infection. *Antimicrob Agents Chemother* 33, 1563–1568.
2162 <https://doi.org/10.1128/AAC.33.9.1563>

2163 Yodkeeree, S., Thippraphan, P., Punfa, W., Srisomboon, J., Limtrakul(Dejkriengkraikul), P., 2018. Skin
2164 Anti-aging Assays of Proanthocyanidin Rich Red Rice Extract, Oryzanol and Other Phenolic
2165 Compounds. *Nat Prod Commun* 13, 1934578X1801300.
2166 <https://doi.org/10.1177/1934578X1801300812>

2167 Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M.J., Galtier, P.,
2168 Gundert-Remy, U., Kuhnle, G.G., Lambré, C., Leblanc, J., Lillegaard, I.T., Moldeus, P., Mortensen,
2169 A., Oskarsson, A., Stankovic, I., Waalkens-Berendsen, I., Woutersen, R.A., Wright, M., Di
2170 Domenico, A., Fairweather-Tait, S., McArdle, H.J., Smeraldi, C., Gott, D., 2021. Guidance on
2171 safety evaluation of sources of nutrients and bioavailability of nutrient from the sources
2172 (Revision 1)1. *EFSA Journal* 19. <https://doi.org/10.2903/j.efsa.2021.6552>

2173 Zaharevitz, D.W., Holbeck, S.L., Bowerman, C., Svetlik, P.A., 2002. COMPARE: a web accessible tool
2174 for investigating mechanisms of cell growth inhibition. *J Mol Graph Model* 20, 297–303.
2175 [https://doi.org/10.1016/S1093-3263\(01\)00126-7](https://doi.org/10.1016/S1093-3263(01)00126-7)

2176 Zhao, X., Yu, Z., Ding, T., 2020. Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria.
2177 *Microorganisms* 8, 425. <https://doi.org/10.3390/microorganisms8030425>

2178
2179
2180

2181 Figure legends

2182

2183 **Fig. 1.** Characteristics of bioassays used at different stages of biodiscovery.

2184

2185 **Fig. 2.** Characteristics of a good bioassay.

2186

2187 **Fig. 3.** Distribution of research efforts to assess bioactivity of marine natural products from 2000 to
2188 2022 based on the PubMed database. For each bioactivity, the number of publications without reviews
2189 is indicated. The last two years are highlighted, with the number of publications (without reviews) next
2190 to the columns.

2191

2192 **Fig. 4.** Distribution of research methods and target microorganisms for antimicrobial bioactivity of
2193 marine natural products from 2000 to 2022 based on PubMed database. The number of publications
2194 (excluding reviews) is shown for each method or microorganism used. A, research effort by bioassay
2195 method; B, research effort by microbial species. The last two years are highlighted, with the number
2196 of publications (excluding reviews) next to the columns. MIC, minimum inhibitory concentration assay
2197 determines the lowest concentration of a substance that inhibits the visible growth of a
2198 microorganism.

2199

2200 **Fig. 5.** Distribution of research methods used between 2000 and 2022 to assess cytotoxic activity of
2201 marine natural products (based on PubMed database). The total number of publications (excluding
2202 reviews) is shown for each method used, with the last two years highlighted in light blue and the
2203 number next to each column. NRU, neutral red uptake cytotoxicity assay; alamar blue is a metabolic
2204 dye used to quantify proliferation; calcein assay measures cell viability by following conversion of
2205 calcein-AM to fluorescent calcein in living cells; LDH measures the activity of lactate dehydrogenase
2206 released from damaged cells; SRB, sulforhodamine B is a fluorescent dye used to quantify cellular
2207 proteins; PI, propidium iodide is a fluorescent dye that can pass freely through the cell membranes of
2208 dead cells and is excluded from viable cells; ATP, adenosine triphosphate assay measures cell viability
2209 based on the presence of ATP; Annexin-V is a protein that binds to phosphatidylserine on the plasma
2210 membrane and is used to detect apoptosis; MTT, MTS, XTT are tetrazolium salts that are reduced to
2211 formazan in living cells, where MTS and XTT yield a water-soluble formazan dye that is detected
2212 spectrophotometrically.

2213

2214 **Fig. 6.** Screening for antiviral activity begins with determining the potential toxicity of the compounds
2215 or extracts to cell lines that allow viral replication using bioassays such as tetrazolium salts or ATP-
2216 based assays or fluorometric microculture cytotoxicity assays (FMCA). It is then necessary to determine
2217 which cell system(s) is best suited for virus replication to test for antiviral activity. The ability of the cell
2218 line to support viral replication varies and can be measured by cytopathic effect (CPE), focus-forming
2219 assay (FFA), plaque quantification (PRA, VRA), or hemagglutination inhibition (HI). Once specific
2220 antiviral activity has been established, it needs to be verified in more complex systems and using *in*
2221 *vivo* models.

2222

2223 **Fig. 7.** Distribution of research methods for antioxidant and anti-ageing activities of marine natural
2224 products from 2000 to 2022 based on PubMed database. The number of publications (excluding

2225 reviews) is shown for each method. The last two years are highlighted, with the number of publications
2226 (excluding reviews) next to the columns. CUPRAC, CUPric Reducing Antioxidant Capacity; ORAC,
2227 oxygen radical absorbance capacity; ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic
2228 acid)/Trolox[®]-equivalent Antioxidant Capacity; DPPH, 2,2-diphenyl-1-picrylhydrazyl.


2229


2230 **Fig. 8.** The approach for the discovery of new bioactive compounds from marine extracts, with the
2231 methodology for small (left) and large (right) biomolecules indicated separately. After extraction,
2232 bioassays are performed to determine the potential bioactivities of the extract, and several purification
2233 steps are performed to fractionate the extract for analysis and prioritise the purified compounds
2234 according to their novelty, for which the dereplication step is crucial. Several purification and analysis
2235 runs are required to narrow down the selection of bioactive compounds. Finally, a purification
2236 procedure is applied to obtain larger amounts of bioactive compounds that can be further used for
2237 compound identification and structure elucidation. The general approach for the discovery of new
2238 bioactive compounds is the same for each type of molecule, but the analysis and separation
2239 methodology differs depending on the properties.


2240


2241 **Fig. 9.** Overview of the different stages of drug discovery in the early discovery and preclinical phases
2242 of natural product development. Examples are shown of various bioactivity and safety assays that can
2243 be used specifically at each stage.


2244























Supplementary Table S1: Principles and characteristics of popular bioassays used in pre-screening and screening of bioactivities

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Antimicrobial bioassays				
Disc diffusion = Agar disc diffusion method = Kirby-Bauer test = Disc-diffusion antibiotic susceptibility test	<i>In vitro</i> detection of effects on microbial growth or survival on solid media. A microbial inoculum suspension (e.g., 1-2 10 ⁸ CFU/mL for bacteria) is spread on agar plates and the test extract/compound is applied on impregnated paper discs. After 12-24 h incubation (bacteria) or 24 – 48 h incubation (fungi) in suitable growth conditions for the tested microbial strain inhibition zone diameters are read at the point where no growth is observed. Variations are available for yeasts and molds.	<ul style="list-style-type: none"> - Simple - Standardized protocols available for bacteria and yeast (CLSI, EUCAST) - Versatile (suitable for majority of bacterial pathogens) - Controls for bioassay performance available in form of antibiotics and characterized typing strains with known phenotype and antibiogram - No special equipment, only basic microbiological utilities required - Easily used in routine - Reproducible and accurate if standard protocols are followed - Inexpensive - Easy to interpret - Adequate for primary screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Not appropriate for all bacterial pathogens - Diffusion of the extract/compound can be non-homogeneous and affect accuracy - Not appropriate for large molecules, amphiphilic molecules - Importance of the inoculum size and preparation - Importance of growth medium used - Not quantitative – cannot determine MIC value - Qualitative categorization into susceptible, intermediate or resistant is possible based on standardized MIC breakpoints - Cannot distinguish between bactericidal and bacteriostatic effect - Few interpretative criteria are available - Not adapted for filamentous fungi as breakpoints for standard antibiotics are not defined 	(Alastruey-Izquierdo et al., 2015; Balouiri et al., 2016; Matuschek et al., 2014; Strömstedt et al., 2014)
Antimicrobial gradient method = Epsilon meter testing (commercial version Etest®)	<i>In vitro</i> detection of effects on microbial growth or survival on solid media. Variant of agar diffusion method that combines the principle of dilution and diffusion methods to determine MIC. Exponential gradient of substance applied on a plastic or nitrocellulose strip (marked with concentration scale) and placed on a previously inoculated agar surface. After 12-24 h incubation (bacteria) or 24 – 48 h incubation (fungi) in suitable conditions ellipse-shaped zone of inhibition indicates the MIC that can be read off the strip.	<ul style="list-style-type: none"> - Simple - Used for antibiotics, also antimycobacterials - High sensitivity (can detect trace amount of beta-lactamase (ESBL)) - Quantitative (provides MIC value) - Can be used to test interaction of two antimicrobials - Cost-effective - Useful also for yeast and filamentous fungi 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Not appropriate for all bacterial pathogens - Subjective interpretation - Diffusion of the extract/compound can be non-homogeneous and affect accuracy - Not appropriate for large molecules, amphiphilic molecules - Cannot distinguish between bactericidal and bacteriostatic effect - Not used for MNPs (problematic preparation of gradient strip) 	(Idelevich et al., 2018)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
		<ul style="list-style-type: none"> - No special equipment, only basic microbiological utilities required - Easy to interpret - Commercial kits available that can be used as controls 		
Agar plate assay = Poisoned food method for filamentous fungi	<i>In vitro</i> evaluation of antifungal effect against filamentous fungi. The substance or extract is incorporated homogeneously into the molten agar and mycelia disc are inoculated at the center of plate. After incubation under suitable growth conditions the diameters of growth inhibition are read and compared with the unexposed control.	<ul style="list-style-type: none"> - Simple - Standardized protocols available (CLSI, EUCAST) - Easy to interpret - Relatively sensitive - Low cost - Adequate for primary screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - There are some commercial kits that combine identification-susceptibility testing assay for <i>Candida</i> and <i>Aspergillus</i> spp. - Resources for work with fungi - Not quantitative - Possible interference with growth medium components - Not appropriate for heat labile compounds - Requires large amounts of compounds - Time consuming 	(Chadwick et al., 2013)
Broth (micro)dilution for determination of MIC (Minimum Inhibitory Concentration)	<i>In vitro</i> detection of microbial growth inhibition in liquid culture containing a known concentration of drug. Two-fold dilutions of antimicrobial agent or extract are mixed with the inoculum in liquid medium and after suitable growth time period of incubation (12 – 24 h) MIC value is determined by detecting the lowest concentration that inhibited visible microbial growth. Usually performed in 96-well plates (microdilution). Detection of growth is by naked eye or colorimetric assays using tetrazolium salts, resazurin, or ATP can be used to detect metabolically active cells. Different procedures are adapted for yeasts and molds including longer incubation time (24 – 72 h).	<ul style="list-style-type: none"> - Standard protocols are available (CLSI, EUCAST) - Gold standard in clinical microbiology - High-capacity bioassay - Versatile - Accurate and reproducible - Applicable to both yeasts and molds - Economic if plates are produced in the laboratory - Can be used for any new discovered antimicrobials - Low sample volume required - Cost-effective - Adequate for primary screening - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Solubility of organic extract in broth medium can be challenging - Not suitable for large polycationic, amphiphilic molecules - Plastic interference of 96 well plates for peptide antimicrobial assessment - Importance of the inoculum size and preparation - Importance of growth medium used - Subjective interpretation by CLSI methodology alleviated using EUCAST protocol - Labor-intensive - Technical training requirement high - Risk of error with dilution preparation - Edge effect 	(Arendrup et al., 2008; Balouiri et al., 2016; Ezra et al., 2004; Rodriguez-Tudela et al., 2008; Strömstedt et al., 2014)
MBC (Minimum bactericidal)	Common estimation of bactericidal or fungicidal activity determined after broth dilution by	<ul style="list-style-type: none"> - Simple - Quantitative 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility 	(Balouiri et al., 2016)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
concentration), or MFC (minimum fungicidal concentration), or MLC (minimum lethal concentration)	subculturing samples from wells with incubation time from 24 h to 72 h. It is the lowest concentration of antimicrobial agent needed to kill 99.9 % of the final inoculum after 24 h incubation in standardized conditions.	<ul style="list-style-type: none"> - Cost-effective - Adequate for primary screening 	<ul style="list-style-type: none"> - Labor intensive - Importance of growth medium used - Only culturable cells are detected 	
Time-kill assay = Time-kill curve = Growth curve analysis	<i>In vitro</i> test to measure the kinetics of dynamic interaction between the compound and the microbial strain to reveal a time-dependent or a concentration dependent antimicrobial effect. The log CFU/mL of microbial/antimicrobial solution is determined on time scale depending on the bacteria strain and the media used. Alternatively, growth is followed in a microplate reader measuring optical density at 600 nm. Typically used in secondary testing.	<ul style="list-style-type: none"> - Existing standard guidelines CLSI and ASTM - Growth curve analysis offers many variables that may indicate mode of action: growth rate, growth dynamics - Can be used to study synergy/antagonism between substances 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Special software needed for growth curve analysis - Labor intensive - Specialized equipment needed - Inoculum size, growth phase, growth medium affect outcome - Possible interference with growth vessels, medium components and method of growth detection 	(Balouiri et al., 2016)
Bioautography	<i>In vitro</i> direct detection of antibacterial compounds on TLC (Thin Layer Chromatography) plate based on incubation (12 – 24 h) and visualization of microbial growth using vital stains or metabolic stains or dehydrogenase-activity-detecting reagent to reveal zones of inhibition. A variation is possible using bioluminescent bacteria as reporters. Particularly adequate for monitoring.	<ul style="list-style-type: none"> - Simple - Rapid - Results easily visualized - Inexpensive - Applicable to both bacteria and fungi - Can be utilized for spore-producing fungi - Little amount of extract/compound required 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Volume of agar or broth has to be well defined otherwise resulting in poorly defined inhibition zones or irregular bacterial growth - Not quantitative - Difficult to standardize 	(Balouiri et al., 2016; Choma and Grzelak, 2011; Dewanjee et al., 2015; Klöppel et al., 2008; Patil et al., 2017)
Volatile antibiotics bioassays	All versions of these bioassays use the same principle to detect volatile organic compound (VOC) activity. The source of the volatile (a living organism or chemical) is placed on one side of a chamber without direct contact with the target organism, while the target is grown or located on another side or compartment of the chamber. The effect of the volatile on the growth (inhibition) or survival of the target organism is compared to a control using the same container and conditions without the volatiles.	<ul style="list-style-type: none"> - Easy to perform and interpret - Low cost - Sensitive - Adequate for primary screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Not quantitative - Special equipment or material required (sealed chambers) 	(Ezra, 2004; Liarzi et al., 2016; Tomscheck et al., 2010)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Antibiofilm bioassays				
Crystal violet	Gold standard for biofilm quantification in microtiter plates. Inoculum in liquid medium incubated for 24 – 72 h at selected temperature under static conditions. Washing steps and short incubation times in crystal violet, are followed by the colorimetric detection of the stained biomass.	<ul style="list-style-type: none"> - Adapted protocols available for different bacterial species - Different surfaces can be assayed using coupons - Versatile: both for G+ and G- - Qualitative or quantitative, but characterized control strains need to be incorporated for interpretation - Low cost - Can be used to monitor biofilm growth and biofilm eradication - High-throughput (96-well plates) - Adequate for primary screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Non-specific binding to anionic proteins and other negatively charged molecules, like capsules, lipopolysaccharides, and DNA/nucleic acids, leading to an inability to distinguish between live and dead bacterial populations and/or exopolysaccharides - Large variability between samples leading to possibly complicated interpretation - Medium composition important - Culture conditions important - Strain to strain variability is high, need to know primary biofilm phenotype - Interference of the stain with experimental setup possible 	(Haney et al., 2021; O'Toole, 2011)
CFU (Colony Forming Units)	Biofilm is sonicated to dislodge adhered biomass and serial dilutions of homogenized bacterial suspension is plated onto agar plates, incubated 24 – 48 h to count the colony forming units (CFUs).	<ul style="list-style-type: none"> - Simple - Low cost - Adequate for primary screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Need for specialized equipment - Sonication parameters important (can reduce viability of recovered CFUs), - Sonication parameters are different for different bacterial species - aggregation can affect CFU count - Labor intensive - Only culturable cells are detected 	(Haney et al., 2021)
The BioFilm Ring Test	Mobility measurement of magnetic microbeads mixed with bacterial suspension in a polystyrene microplate. Without biofilm growth beads gather together in a visible central spot under magnetic action, while no spot indicates bead immobilization by biofilm formation.	<ul style="list-style-type: none"> - Simple - Rapid - No dyes or stains - No washing steps - Low sample volume required - High-throughput (96- well plates) 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Need for specialized equipment - Interpretation may be challenging - Qualitative 	(Olivares et al., 2016)
The Calgary Biofilm device	Two-part reaction vessel containing a lid with 96 pegs that sit in channels of the reaction vessel that	<ul style="list-style-type: none"> - Standardized protocols available - High-throughput (96-well plates) - Quantitative 	<ul style="list-style-type: none"> - BSL2 and BSL3 level microorganisms require work in suitable facility - Need for specialized equipment 	(Haney et al., 2021;

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	allows flow of medium across pegs to create consistent shear force.		<ul style="list-style-type: none"> - Use of multiple sterile microplates for treatment and washing steps - Relies on viable cell counting for experimental validation 	Kirmusaoğlu, 2019)
MBEC (Minimum biofilm eradication concentration) Assay®	High-throughput screening of antibiofilm activity. Plastic lid with 96 pegs on which biofilms establish under batch conditions and the lid with pegs is transferred to a new 96 well for testing, biofilm is dislodged by sonication and CFUs are determined.	<ul style="list-style-type: none"> - Standardized method for <i>Pseudomonas aeruginosa</i> (ASTM E2799-17) 	<ul style="list-style-type: none"> - BSL2 level microorganisms require work in suitable facility - Aggregation can affect CFU count - Labor intensive - Only culturable cells are detected 	(ASTM, 2022; Parker et al., 2014)
SIMBA – simultaneous detection of antimicrobial and antibiofilm activity	The SIMultaneous detection of antiMicrobial and anti-Biofilm Activity (SIMBA) method combines the testing of antimicrobial and antibiofilm activity against bacteria with the evaluation of the 20-hour growth curve of the <i>Salmonella</i> Infantis ŽM9 strain determined with absorbance measurements at 600 nm in a 96-well plate.	<ul style="list-style-type: none"> - Simple - Rapid - No dyes or stains - Cost-effective - Information on both antimicrobial and antibiofilm activity in one assay - Low sample volume required - High-throughput (96-well plates) - Possibility of automation 	<ul style="list-style-type: none"> - Optimized for one <i>Salmonella</i> strain - Not suitable for dark colored samples - Need for specialized equipment (spectrophotometer with temperature control and shaking capabilities) 	(Sterniša et al., 2023, 2022)
Cytotoxicity bioassays				
MTT (also MTS, XTT, WST)	<i>In vitro</i> colorimetric assay usually performed in 96-well plates to evaluate cellular metabolic activity - glycolytic production of NADH. Based on tetrazolium salts (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; WST, water-soluble tetrazolium salts) – difference between them is the tetrazolium salt used and the solubility and/or absorption spectrum of the formazan product. Eukaryotic cells are treated for 24 - 48 hours with different concentrations of compounds to determine the concentration of the tested	<ul style="list-style-type: none"> - Commercial kits with standardized protocols available - Cost-effective - Relatively simple - Assay for whole cells - Linearity between absorbance and cell count - Versatile: suitable for both adherent and suspended cell cultures - One-step procedure variants using water soluble tetrazolium salts include XTT, MTS, WST - Possibility of automation - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require appropriate facility - Lengthy two-step procedure - Highly variable results depending on: the number of cells per well, and the high pH of the culture medium - Requires optimization of cell density (untreated cells have absorbance values that fall within the linear portion of the growth curve (conditions not too close to saturation) - Requires optimized incubation time - Not suitable for reducing compounds - Not for metabolically poor cells, i.e. thymocytes and splenocytes 	(Balbaied and Moore, 2020; Jo HY et al., 2015; Mccauley et al., 2013; Riss et al., 2019)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	<p>compounds, which produces 50% of cytotoxicity (CC₅₀).</p> <p>Tetrazolium salt (e.g., MTT) is then added to the cells for 2 hours at 37°C. MTT is reduced by a cellular mitochondrial enzyme (succinate dehydrogenase) to violet formazan precipitates, which are subsequently solubilized by organic solvents before absorbance is read. Alternatively, water-soluble tetrazolium salts can be used, omitting the final solubilization step.</p>		<ul style="list-style-type: none"> - Linearity between absorbance and cell count is lost when cells are confluent and cellular metabolism slows down - The result can be variable because metabolic activity depends not only on the number of cells per well but also on several other factors 	
Sulforhodamine B (SRB) assay	<p>Used for cell density determination, based on the measurement of cellular protein content. Toxicity screening of compounds to adherent cells in a 96-well format. After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD determination at 510 nm using a microplate reader.</p>	<ul style="list-style-type: none"> - Simple - Cost-effective - Results linear over a 20-fold range of cell numbers - Sensitivity comparable to those of fluorometric methods - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - Requires microplate reader (absorbance) 	(Vichai and Kirtikara, 2006)
ATP-based test	<p>Gold standard luminescence test. See MTT for the procedure. Quantification of released intracellular ATP by enzymatic reaction between the enzyme luciferase and its substrate, luciferin, to produce luminescence. There is a linear relationship between the intensity of the light signal and the ATP concentration or cell number. It is one of the most sensitive endpoints for measuring cell viability.</p>	<ul style="list-style-type: none"> - One-step procedure - Faster than MTT and MTS - Reduction of artifacts - Sensitive measure of intracellular ATP rather a specific biological effect - More sensitive than conventional biochemical methods - Sensitive compared to other cytotoxicity tests - Interferences minimal - Commercial kits available - Possibility of being automated 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - More expensive than MTT and MTS and fluorescent methods - The ATP assay sensitivity is usually limited by reproducibility of pipetting - Replicate samples rather than a result of the assay chemistry - Need for specialized equipment (luminescence detection) 	(Aslantürk, 2018; Herzog et al., 2007; Ponti et al., 2006)
Automated fluorometric microculture	<p>Based on the measurement of fluorescence generated from cellular hydrolysis of fluorescein diacetate (FDA) to fluorescein by viable cells with</p>	<ul style="list-style-type: none"> - Highly standardized and reproducible one-step procedure - Possibility of being automated 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - Need for specialized equipment 	(Burman et al., 2011;

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
cytotoxicity assay (FMCA)	intact plasma membranes after a 48 – 72 hour culture period in microtiter plates. See MTT for procedure.		(fluorescence detection)	Lindhagen et al., 2008)
Dye exclusion method	The membrane integrity of cell is determined by its permeability to several dyes (eosin, Trypan blue, erythrosine B, Congo red assays). Trypan blue has been used the most extensively to assess the percentage of viable cells in suspension culture.	<ul style="list-style-type: none"> - Simple - Rapid - Small numbers of cells needed - Can be applied in non dividing cell populations 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - Can be challenging to process a large number of samples simultaneously, particularly when the exact timing of progressive cytotoxic effects is taken into consideration - Careful interpretation needed for living cells with metabolic activity loss (trypan blue) - Its toxic side effect of some dyes on mammalian cells (trypan blue) - Not suitable for adherent monolayer cell cultures - Labor intensive 	(Aslantürk, 2018)
LDH (lactate dehydrogenase) cytotoxicity assay	LDH is a cytosolic enzyme present in many different cell types that is released upon damage to the plasma membrane. The assay quantitatively measures the activity of stable, cytosolic LDH released from damaged cells. It is a colorimetric assay.	<ul style="list-style-type: none"> - Suitable for both adherent and suspended cell cultures - Commercial kits available - Detects low level damage to cell membranes which cannot be detected using other methods 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - LDH assay is limited to serum-free or low-serum culture conditions to avoid high background readings. - Interference with serum components 	(Kocherova et al., 2020)
Clonogenic cell survival assay	Determines the ability of a cell to proliferate indefinitely, retaining its reproductive ability to form a colony or a clone. These cells are considered clonogenic. Cells are seeded at low density and growth of colonies/clones is analysed after a week by staining and counting. The gold standard for measuring cellular reproductivity.	<ul style="list-style-type: none"> - Simple - Cost-effective - Gold standard 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - Suitable only for adherent cells - Not suitable for all adherent cell lines (not all cells are able to form colonies in vitro – cell-to-cell contacts and self-produced growth factors are limited at low cell density) 	(Munshi et al., 2005)
DNA synthesis assay 3H-labeled thymidine (3HT)	The process of DNA synthesis is relatively specific for cell division and can therefore be considered a marker of cell proliferation activity. Nucleoside	<ul style="list-style-type: none"> - This assay is commonly regarded as reliable and accurate. 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines require suitable facility - Potential use of radioisotopes 	(Romar et al., 2016)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	analogue incorporation assays are based on the introduction of chemically or radio-labelled nucleosides that are subsequently incorporated into DNA strands synthesised during S phase. A scintillation beta counter is used to measure radioactivity in DNA recovered from cells to determine the extent of cell division that has occurred in response to a test agent. The nucleoside analogue 5-bromo-2'-deoxyuridine (BrdU) is used to avoid the use of radioisotopes and is detected with monoclonal antibodies. Alternatively, thymidine analogues are available that do not require antibody detection.	<ul style="list-style-type: none"> - Suitable for immunohistochemistry or immunocytochemistry, - In-cell ELISA, flow cytometry - It can be performed in experiments <i>in vitro</i> and <i>ex vivo</i>, but not <i>in vivo</i> - Not suitable for screening, used for mechanistic studies - Commercial kits available - Allows quantitative assessment of proliferation levels - Direct measures of proliferation - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - It is an endpoint assay because of the DNA extraction step, and so no further studies can be performed with the treated cells. - synthetic analogues such as 5-bromo-2'-deoxyuridine (BrdU) or 5-ethynyl-2'-deoxyuridine (EdU), are usually preferred (can be used not only <i>in vitro</i> or <i>ex vivo</i> but also <i>in vivo</i>) - Both assays cannot identify cells that have undergone numerous divisions - Need for specialized equipment 	
Antiviral bioassays				
Flow cytometry cell count assay (FACS)	Cytotoxicity-based antiviral assay based on the detection of intact and damaged cells using a flow cytometer and dyes to stain the cells (e.g., propidium iodide, carboxyfluorescein diacetate).	<ul style="list-style-type: none"> - Three populations discriminated (dead, viable, injured) - Reproducible - Rapid (2-6 h to results) 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Need for specialized equipment: flow cytometry equipment - Need for trained personnel - Not easy to interpret - Specific cell lines known to be susceptible to and allowing viral infection with the virus of interest. 	(Balouiri et al., 2016; Zamora and Aguilar, 2018)
Cytopathic effect assay (CPE)	Suitable for primary <i>in vitro</i> antiviral screening. In this assay, cells permissive for a virus are infected with the same virus at serial dilutions. Cells are observed daily until a cytopathic effect is detected. The virus concentration is expressed as infectious tissue culture dose (TCID ₅₀), which is the multiple of dilutions that result in CPE in 50% of wells.	<ul style="list-style-type: none"> - Commercial kit available allowing standardization and automated procedures - For viruses that do or do not form viral plaques - Cell fixation and staining not required - Cost-effective - Operator independent - Technically simple - Reduced reading time 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Only for viruses that cause morphological changes in infected cells - Lengthy: the time required for the cytopathic effect to become apparent - Indirect measure of viral load - Works only with specific cell lines known to be susceptible and permissible to viral infection with the virus of interest. 	(El Sayed, 2000; Suchman and Blair, 2007)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Plaque reduction assay (PRA)	Primary <i>in vitro</i> antiviral screening for the detection of infectious viral particles A viral inoculum of approximately 50-70 viral plaques/well is adsorbed onto permissive cells in the presence of the test substance. After viral adsorption, the unbound virus is removed and the culture is covered with a semi-solid medium (agar, Avicel, methylcellulose). After an incubation period equal to the duration of the replication cycle of the virus, the cells are fixed and stained to count the viral plaques microscopically. Titers are expressed as the number of plaque-forming units (PFU) per milliliter (PFU/ml).	<ul style="list-style-type: none"> - Appropriate for high-throughput screening - Validation with a positive control, such as a commercial compound with known antiviral activity - Commonly used - No special equipment is required in addition to a cell culture laboratory - Results are easily visualized under a microscope or with the naked eye - Cost-effective - Sensitive - Protocols vary from laboratory to laboratory and depend on the type of cells used - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - Equipment required to work with viruses and specialized virology trained personnel - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Only for viruses that form plaques - Labor intensive - Sometimes lengthy - Results not reproducible: depends on cell density, CPE and plaque size - Counting of plaques can be subjective - Specific cell lines known to be susceptible and permissible for viral infection with the virus of interest - Protocol must be adapted for each host-virus combination 	(El Sayed, 2000)
Virus reduction yield assay (VRA)	Primary <i>in vitro</i> antiviral screening to detect infectious viral particles. Permissive cell cultures are infected with a specific amount of virus, and after virus adsorption (usually 2 hours at 37°C or 33°C for temperature-sensitive viruses), the unbound virus is removed, and different concentrations of the same compound are added. After an incubation period that allows virus replication, the total viral yield is titrated and determined.	<ul style="list-style-type: none"> - Less operator-dependent than the PRA - Cost-effective - Sensitive 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Time/material-intensive - Not-automatable - Not reproducible: results depend on harvesting time - Specific cell lines known to be susceptible and permissible to viral infection of the specific virus in focus 	(Collins and Bauer, 1977; Hu and Hsiung, 1989)
Focus Forming assay (FFA)	Primary <i>in vitro</i> antiviral screening for viruses that do not induce CPE. Procedure identical to PRA. FFA doses are expressed as concentration units per milliliter (FFU/mL).	<ul style="list-style-type: none"> - Faster than PRA or TCID₅₀ - Reading time varies depending on the replication cycle of the virus - Sensitive 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Indirect method - Expensive - Specific reagents and equipment required 	(Flint et al., 2009)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
			<ul style="list-style-type: none"> - Specific cell lines that are known to be susceptible and permissible to infection with the virus of interest - Reading time of foci depends on the size of the area the operator is counting. A larger area will take longer, but may provide a more accurate representation of the sample. 	
Hemagglutination inhibition assay (HIA)	<p>Primary <i>in vitro</i> antiviral screening to detect infectious and noninfectious viral particles for viruses that do not form plaques or cause CPE. For HIA, viral samples are first mixed with dilutions of compounds that take time to bind the virus. Then red blood cells (RBCs) are added to the mixture.</p> <p>Antiviral activity: means that there are no free virus particles and the RBCs fall to the bottom of the well by gravity, creating a distinct red spot in a conical well.</p> <p>No antiviral activity: the erythrocytes clump together, resulting in a lattice-like structure.</p>	<ul style="list-style-type: none"> - Simple - Does not require special equipment - Fast evaluation of virus particles - Standardized protocols available - Validation of a modified HAI: more sensitive, easy to analyse, required only a single source of erythrocytes and allowed utilisation of virus strains which are difficult to handle by the standard HAI (e.g., H3N2, H5N1 and H1N1pdm09) 	<ul style="list-style-type: none"> - BSL2 and BSL3 level cell lines and/or viruses require suitable facility - Less sensitive than other methods - Only for hemagglutinating viruses - The red blood cells used depend on the type of influenza virus in the test - Required source of suitable red blood cells (horse, rabbit, chicken, guinea pig) - Optimization of the type and concentration of red blood cells used is necessary to obtain reliable results. - Requires skilled personnel - Manual evaluation may lead to misinterpretation of results - Non-specific inhibition of hemagglutination possible - Low sensitivity - Semiquantitative data 	(Joklik, 1988; Morokutti et al., 2013)
Quantitative polymerase chain reaction (qPCR)	<p>PCR involves amplifying short stretches of longer genomic molecules in a thermocycler, a device that exposes the reaction to a series of different temperatures for a specified time (1 amplification cycle). With each PCR cycle, the amount of target sequence (amplicon) in the reaction theoretically doubles. In quantitative polymerase chain reaction, the amplification rate is monitored in real time during PCR using nonspecific intercalating</p>	<ul style="list-style-type: none"> - Rapid (1-4h response) - Sensitive - High specificity - Possible to validate - Quantitative or semi-quantitative - Protocol needs to be adapted for each virus, but the general guidelines are the same 	<ul style="list-style-type: none"> - Cell lines and/or viruses of BSL2 and BSL3 levels require a suitable facility - More complex compared to PRA - Need for specialized equipment: flow cytometry equipment - Need for trained personnel - Positive detection does not equate to viable (or infectious) virus, therefore not recommended for initial screening - Expensive 	(Engstrom-Melnik et al., 2015; Kralik and Ricci, 2017)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	fluorescent dyes or fluorescently labeled sequence-specific DNA probes.			
Antioxidant assays				
DPPH (2,2'-diphenyl-1-picrylhydrazyl radical) assay	Based on the reaction of the tested antioxidant with the stable synthetic radical 2,2-diphenyl-1-picrylhydrazyl (DPPH•), accompanied by a color shift of the latter. Aliquots of the extracts are mixed with a methanolic solution containing DPPH radicals, and the mixture is incubated in the dark for 30 min. Absorbance is measured with a spectrophotometer at 517 nm. Usually, quercetin is used as a reference standard, and DPPH results are expressed as quercetin equivalents (QE) in μmol per 100 mL.	<ul style="list-style-type: none"> - Commercial kits available - Simple - Cost-effective - Good repeatability - Quantitative - Adequate for primary screening - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - Applicable only for compounds soluble in organic solvents - Radical strongly affected by light, oxygen, pH and type of solvent - Steric hindrance effects for bulky antioxidants - Narrow linear range - Limited relevance to biological systems - Need for specialized equipment (spectrophotometer, multiplate reader) 	(Apak et al., 2006; Awika et al., 2003; Molyneux P, 2004)
ABTS/TEAC (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)/Trolox equivalent antioxidant capacity	With the help of an oxidizing agent, the colorless ABTS salt is converted into its radical cation with characteristic blue-green color, which is then reduced back to its original colorless ABTS form by reaction with the tested antioxidant. Antioxidant activity is defined as the amount of ABTS•+ quenched after a given time (usually 5 minutes) and is expressed in Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) equivalents as TEAC (Trolox Equivalent Antioxidant Capacity).	<ul style="list-style-type: none"> - Rapid - Simple - Sensitive - Reproducible - More sensitive than DPPH assay, high response to antioxidants - Can be performed in a 96-well microplate. - Diverse, flexible usage in multiple media (pH, solvents) - Applicable to both lipophilic and hydrophilic anti-oxidants - Commercial kits available - Quantitative - Adequate for primary screening 	<ul style="list-style-type: none"> - Limited relevance to biological systems - Difficulties in the formation of the colored radical and limited stability - Steric hindrance effects for bulky antioxidants - Specialized equipment required (spectrophotometer, multiplate reader) 	(Apak et al., 2007; Awika et al., 2003; Erel, 2004; Lee et al., 2015; Re et al., 1999)
Cupric ion (Cu^{2+}) reducing assay (CUPRAC)	<i>In vitro</i> assay for measurement of the absorbance of the colored Cu(I)-neocuproine (Nc) chelate formed as a result of the redox reaction between the chromogenic oxidizing CUPRAC reagent (i.e., Cu(II)-Nc) and the chain-breaking antioxidant under study. Trolox is used as the standard.	<ul style="list-style-type: none"> - Applicable to both lipophilic and hydrophilic antioxidants - Selective detection of antioxidants - Simulates antioxidant action under nearly physiological conditions 	<ul style="list-style-type: none"> - Unable to react with compounds having isolated hydrocarbon double bonds or alternating double and single bonds (e.g., ferulic acid, β-carotene) - An incubation at elevated temperature may be required for slow-reacting compounds (e.g., naringin and naringenin) 	(Apak et al., 2007, 2006; Gulcin, 2020; Özyürek et al., 2011)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
		<ul style="list-style-type: none"> - Ffavorable redox potential - High stability of reagents - No steric hindrance effects - Commercial kits available - Quantitative - Adequate for primary screening - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - Need for specialized equipment (spectrophotometer, multiplate reader) 	
Folin-Ciocalteu	The Folin-Ciocalteu phenolic reagent is used to obtain a rough estimate of the total amount of phenolic compounds present in an extract. Specifically, the phenolic compounds undergo a complex redox reaction with the phosphotungstic and phosphomolybdic acids present in the reaction mixture, yielding a blue color proportional to the amount of phenols. The assay can be performed in a 96-well microplate. The absorbance is read at 760 nm and quantification is based on a calibration curve generated using gallic acid standards (GA).	<ul style="list-style-type: none"> - Adequate for primary screening - Simple - Reproducible - Excellent correlation between measured "antioxidant capacity" and "total phenolic content" - Quantitative - Commercial kits available - Adequate for primary screening 	<ul style="list-style-type: none"> - Non-specific to phenolics (it reacts with many non-phenolic compounds) - not applicable to lipophilic components - Need for specialized equipment (spectrophotometer, multiplate reader) 	(Apak et al., 2007; Bravo et al., 2016; Singleton et al., 1999)
Oxygen radical absorbance capacity (ORAC)	This method is based on the ability of antioxidants to protect fluorescein, a highly fluorescent protein, from oxidative damage caused by peroxy radicals. The experimental procedure of ORAC involves the addition of the extract under study and a free radical, usually AAPH (2,2'-azobis(2-amidinopropane) dihydrochloride), which forms a moiety together with fluorescein, followed by heating in a phosphate buffer. Thermal decomposition produces free radicals that react with antioxidant compounds, resulting in loss of fluorescence due to decrease in radical concentration. The test can be performed in a 96-well microplate.	<ul style="list-style-type: none"> - Easily automated and largely standardized - adaptable for numerous sample matrices - High biological relevance - Quantitative - Commercial kits available - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - It is based on fluorescence detection and it requires more expensive instrumentation - Need for specialized equipment (fluorescence detection, multiplate reader) 	(Awika et al., 2003; Bravo et al., 2016; Ou et al., 2001)
Anti-aging enzyme-based assays				
Anti-elastase	This <i>in vitro</i> assay is performed in Tris-HCl buffer and at room temperature using porcine pancreatic	<ul style="list-style-type: none"> - Rapid - Simple 	<ul style="list-style-type: none"> - High cost and limited lifetime of enzymes used 	(Pastorino et al., 2017;

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
	elastase (PPE; E.C.3.4.21.36) and N-succinyl-Ala-Ala-Ala- <i>p</i> -nitroanilide (Suc-Ala3- <i>p</i> NA) as substrate. Inhibition of PPE by natural extracts is determined spectrophotometrically by monitoring the release of <i>p</i> -nitroaniline from Suc-Ala3- <i>p</i> NA at 410 nm. Can be performed in a 96-well microplate. Epigallocatechin-3-gallate (EGCG) is commonly used as a positive control.	<ul style="list-style-type: none"> - Provide effective approaches to evaluate inhibitory effects of unknown samples against skin-aging enzymes - Quantitative - Commercial kits available - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - Considerable consumption of tested compounds/samples - Do not closely mimic cellular processes and <i>in vivo</i> conditions - Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	Thring et al., 2009)
Anti-collagenase	The ability of the extracts to inhibit collagenase activity is evaluated by a spectrophotometric method based on hydrolysis of the synthetic substrate N-[3-(2-furyl)acryloyl]-Leu-Gly-Pro-Ala (FALGPA) using collagenase from <i>Clostridium histolyticum</i> (ChC – EC.3.4.23.3). Can be performed in a 96-well microplate. EGCG is usually used as positive control.	<ul style="list-style-type: none"> - Rapid - Simple - Provide effective approaches to evaluate inhibitory effects of unknown samples against skin-aging enzymes - Quantitative - Commercial kits available - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - High cost and limited lifetime of enzymes used - Considerable consumption of tested compounds/samples - Do not closely mimic cellular processes and <i>in vivo</i> conditions - Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	(Thring et al., 2009; Van Wart and Steinbrink, 1981)
Anti-hyaluronidase	<i>In vitro</i> assay that determines activity indirectly by measuring the amount of undegraded hyaluronic acid (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37°C.	<ul style="list-style-type: none"> - Rapid - Simple - Provide effective approaches to evaluate inhibitory effects of unknown samples against skin-aging enzymes - Standardized protocol - Commercial kits available - Quantitative 	<ul style="list-style-type: none"> - High cost and limited lifetime of enzymes used - Considerable consumption of tested compounds/samples - Do not closely mimic cellular processes and <i>in vivo</i> conditions - Need for specialized equipment (turbidimeter) 	(Bailey and Levine, 1993; Kim et al., 1995)
Anti-tyrosinase	The ability of the extracts to inhibit the catalytic action of tyrosinase in the oxidation of L- DOPA, a precursor of melanin biosynthesis, is usually determined by an enzymatic procedure using the substrate L- DOPA and fungal tyrosinase followed by incubation in a phosphate buffer. The absorbance of the final solutions is measured at 492 nm using a microplate reader. Kojic acid (500 mM) is usually used as a reference inhibitor.	<ul style="list-style-type: none"> - Rapid - Simple - Provide effective approaches to evaluate inhibitory effects of unknown samples against skin-aging enzymes - Quantitative - Commercial kits available - Appropriate for high-throughput screening 	<ul style="list-style-type: none"> - High cost and limited lifetime of enzymes used - Considerable consumption of tested compounds/samples - Do not closely mimic cellular processes and <i>in vivo</i> conditions - Need for specialized equipment (absorbance detection with spectrophotometer or microplate reader) 	(Momtaz et al., 2008)

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Anti-aging Fibroblast-based assays				
Cytotoxicity/cytoprotection	Cultured human fibroblast cell lines are pretreated with the samples and subjected to UV irradiation. Cell viability is measured by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The amount of formazan is measured by recording the absorbance changes at 570 nm with a spectrophotometer.	<ul style="list-style-type: none"> - Rapid - Precise - Avoids manipulation of radioactive isotopes - Constitutes a vital cellular setting and a real-life model for simulating oxidative damages and assessing the protective role of natural extracts/compounds 	<ul style="list-style-type: none"> - Handling and preservation of human fibroblast cell lines can be cumbersome - Results should be interpreted with caution as the biological effect is evaluated against a specific type of cells (the interaction of the tested substance with other cell types are not taken into account) - Need for specialized equipment (cell culture, absorbance detection) 	(Mosmann, 1983; Ramata-Stunda A et al., 2013; Ratz-Lyko et al., 2012; Riss et al., 2019, 2004)
Regenerative potential	This assay involves exposure of seeded human fibroblast cells to extracts followed by washing with chemical reagents and measurement of procollagen type I or hyaluronic acid content in cell-free supernatants by enzyme-linked immunosorbent assay (ELISA).	<ul style="list-style-type: none"> - Constitutes a vital cellular setting and a real-life model for simulating oxidative damages and assessing the protective role of natural extracts/compounds 	<ul style="list-style-type: none"> - Expensive - Results should be interpreted with caution as the biological effect is evaluated against a specific type of cells (the interaction of the tested substance with other cell types are not taken into account) - Need for specialized equipment 	(Koudan et al., 2022)
Pesticidal bioassays				
Feeding bioassay = poisoned food assay	Compound is incorporated into food (mixing in an artificial diet or producing a genetically modified plant) or spread/sprayed over food. Different parameters can be followed after exposure depending on the pest – e.g., survival, weight gain, size gain, offspring count, food consumption or a specific trait	<ul style="list-style-type: none"> - Simple - Easy interpretation - Qualitative or quantitative – depending on the set up 	<ul style="list-style-type: none"> - Live animals (e.g., arthropods, gastropods) are used so a rearing facility is required - Dependent on test insect availability – laboratory cultures or seasonal collection - Time-consuming - Development of artificial diet or GM food can be challenging 	(Burgess et al., 2020; Phan et al., 2020; Portilla, 2020; Razinger et al., 2014; Sanané et al., 2021; Šmid et al., 2015)
Volatile organic compounds (VOCs) Anti-insect activity test	The bioactivity of metabolites can be based on different mechanisms, two of which that are most often studied are to repel or to kill the insect.	<ul style="list-style-type: none"> - Simple - Easy interpretation - Qualitative or quantitative – depending on the set up 	<ul style="list-style-type: none"> - Live animals (e.g., arthropods, gastropods) are used so a rearing facility is required - Dependent on test insect availability – laboratory cultures or seasonal collection - Time-consuming - Need for specialized equipment 	(Daisy et al., 2002; Sternberg et al., 2014)
Other				

Bioassay designation	Principle and general characteristics	Advantages	Limitations	References
Enzymatic activity or inhibition of enzymatic activity	To determine enzymatic activity, the sample is incubated with the substrate in an appropriate buffer and at an appropriate temperature, and the reaction is followed by measuring absorbance or fluorescence change (depending on the substrate used). For inhibition of enzymatic activity, the sample is added to an enzyme in a suitable buffer, and after pre-incubation period of 10 to 60 min the substrate is added and the reaction is followed with a spectrophotometer or fluorimeter kinetically or at a selected endpoint (incubation time).	<ul style="list-style-type: none"> - For some enzymes SOPs (Standard Operating Procedures) available - Simple - Versatile - Quantitative or qualitative - Mechanism of action can be determined - Commercial kits available for selected enzymes - High-throughput 	<ul style="list-style-type: none"> - High cost and limited lifetime of enzymes used - Can be time-consuming - Optimization of conditions (buffer, pH, temperature, cofactors, incubation time) needed for each enzyme - Prone to false positive and false negative results - Enzyme inhibitors in the extracts may affect activity - Specific for each enzyme-substrate pair 	(Brooks et al., 2012; Mohan et al., 2018; Pohanka, 2019; Sabotič et al., 2009; Sepčić et al., 2019)
In-gel detection of enzymatic activity	Sample is resolved in polyacrylamide gel under nondenaturing conditions and gel is then incubated in a series of solutions until colored or fluorescent bands appear.	<ul style="list-style-type: none"> - Additional info on size of enzyme - Can be simple one-step but also multiple step staining - Qualitative, can be semiquantitative 	<ul style="list-style-type: none"> - Not all enzymes withstand the conditions of in-gel separation - Optimization of each enzymatic reaction required with many variables - Can take variable time for signal development (e.g. from minutes to days) 	(Covian et al., 2012; Rivoal et al., 2002; Sabotič et al., 2007; Sepčić et al., 2019; Sims, 1965; Žun et al., 2017)

References

- Alastruey-Izquierdo, A., Melhem, M.S.C., Bonfietti, L.X., Rodriguez-Tudela, J.L., 2015. SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY. *Rev Inst Med Trop Sao Paulo* 57, 57–64. <https://doi.org/10.1590/S0036-46652015000700011>
- Apak, R., Güçlü, K., Demirata, B., Özyürek, M., Çelik, S., Bektaşoğlu, B., Berker, K., Özyurt, D., 2007. Comparative Evaluation of Various Total Antioxidant Capacity Assays Applied to Phenolic Compounds with the CUPRAC Assay. *Molecules* 12, 1496–1547. <https://doi.org/10.3390/12071496>
- Apak, R., Güçlü, K., Özyürek, M., Esin Karademir, S., Erçağ, E., 2006. The cupric ion reducing antioxidant capacity and polyphenolic content of some herbal teas. *Int J Food Sci Nutr* 57, 292–304. <https://doi.org/10.1080/09637480600798132>

- Arendrup, M.C., Meletiadis, J., Mouton, J.W., Lagrou, K., Hamal, P., Guinea, J., Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing, 2008. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. *Clinical Microbiology and Infection* 14, 982–984. <https://doi.org/10.1111/j.1469-0691.2008.02086.x>
- Aslantürk, Ö.S., 2018. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages, in: Larramendy, M.L., Soloneski, S. (Eds.), *Genotoxicity - A Predictable Risk to Our Actual World*. InTech, London. <https://doi.org/10.5772/intechopen.71923>
- ASTM, 2022. Standard Test Method for Testing Disinfectant Efficacy against *Pseudomonas aeruginosa* Biofilm using the MBEC Assay. ASTM E2799-17. <https://doi.org/10.1520/E2799-17>
- Awika, J.M., Rooney, L.W., Wu, X., Prior, R.L., Cisneros-Zevallos, L., 2003. Screening Methods To Measure Antioxidant Activity of Sorghum (*Sorghum bicolor*) and Sorghum Products. *J Agric Food Chem* 51, 6657–6662. <https://doi.org/10.1021/jf034790i>
- Bailey, L.C., Levine, N.A., 1993. Optimization of the USP assay for hyaluronidase. *J Pharm Biomed Anal* 11, 285–292. [https://doi.org/10.1016/0731-7085\(93\)80019-W](https://doi.org/10.1016/0731-7085(93)80019-W)
- Balbaied, T., Moore, E., 2020. Resazurin-Based Assay for Quantifying Living Cells during Alkaline Phosphatase (ALP) Release. *Applied Sciences* 10, 3840. <https://doi.org/10.3390/app10113840>
- Balouiri, M., Sadiki, M., Ibsouda, S.K., 2016. Methods for in vitro evaluating antimicrobial activity: A review. *J Pharm Anal* 6, 71–79. <https://doi.org/10.1016/J.JPHA.2015.11.005>
- Bravo, K., Alzate, F., Osorio, E., 2016. Fruits of selected wild and cultivated Andean plants as sources of potential compounds with antioxidant and anti-aging activity. *Ind Crops Prod* 85, 341–352. <https://doi.org/10.1016/j.indcrop.2015.12.074>
- Brooks, H.B., Geeganage, S., Kahl, S.D., Montrose, C., Sittampalam, S., Smith, M.C., Weidner, J.R., 2012. Basics of Enzymatic Assays for HTS, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.), *Assay Guidance Manual* [Internet]. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD).
- Burgess, E.R., King, B.H., Geden, C.J., 2020. Oral and Topical Insecticide Response Bioassays and Associated Statistical Analyses Used Commonly in Veterinary and Medical Entomology. *Journal of Insect Science* 20. <https://doi.org/10.1093/jisesa/ieaa041>
- Burman, R., Strömstedt, A.A., Malmsten, M., Göransson, U., 2011. Cyclotide–membrane interactions: Defining factors of membrane binding, depletion and disruption. *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1808, 2665–2673. <https://doi.org/10.1016/j.bbamem.2011.07.004>
- Chadwick, S.G., Schuyler, J.A., Vermitsky, J.-P., Adelson, M.E., Mordechai, E., Gyax, S.E., 2013. X-Plate Technology: a new method for detecting fluconazole resistance in *Candida* species. *J Med Microbiol* 62, 720–726. <https://doi.org/10.1099/jmm.0.054445-0>
- Choma, I.M., Grzelak, E.M., 2011. Bioautography detection in thin-layer chromatography. *J Chromatogr A* 1218, 2684–2691. <https://doi.org/10.1016/j.chroma.2010.12.069>

- Collins, P., Bauer, D.J., 1977. RELATIVE POTENCIES OF ANTI-HERPES COMPOUNDS. *Ann N Y Acad Sci* 284, 49–59. <https://doi.org/10.1111/j.1749-6632.1977.tb21936.x>
- Covian, R., Chess, D., Balaban, R.S., 2012. Continuous monitoring of enzymatic activity within native electrophoresis gels: Application to mitochondrial oxidative phosphorylation complexes. *Anal Biochem* 431, 30–39. <https://doi.org/10.1016/j.ab.2012.08.023>
- Daisy, B.H., Strobel, G.A., Castillo, U., Ezra, D., Sears, J., Weaver, D.K., Runyon, J.B., 2002. Naphthalene, an insect repellent, is produced by *Muscodor vitigenus*, a novel endophytic fungus. *Microbiology (N Y)* 148, 3737–3741. <https://doi.org/10.1099/00221287-148-11-3737>
- Dewanjee, S., Gangopadhyay, M., Bhattacharya, N., Khanra, R., Dua, T.K., 2015. Bioautography and its scope in the field of natural product chemistry. *J Pharm Anal* 5, 75–84. <https://doi.org/10.1016/j.jpha.2014.06.002>
- El Sayed, K.A., 2000. Natural Products as Antiviral Agents. *Studies in Natural Products Chemistry* 24, 473–572. [https://doi.org/10.1016/S1572-5995\(00\)80051-4](https://doi.org/10.1016/S1572-5995(00)80051-4)
- Engstrom-Melnyk, J., Rodriguez, P.L., Peraud, O., Hein, R.C., 2015. Clinical Applications of Quantitative Real-Time PCR in Virology, in: *Methods in Microbiology*. pp. 161–197. <https://doi.org/10.1016/bs.mim.2015.04.005>
- Erel, O., 2004. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. *Clin Biochem* 37, 277–285. <https://doi.org/10.1016/j.clinbiochem.2003.11.015>
- Ezra, D., 2004. New endophytic isolates of *Muscodor albus*, a volatile-antibiotic-producing fungus. *Microbiology (N Y)* 150, 4023–4031. <https://doi.org/10.1099/mic.0.27334-0>
- Ezra, D., Castillo, U.F., Strobel, G.A., Hess, W.M., Porter, H., Jensen, J.B., Condrón, M.A.M., Teplow, D.B., Sears, J., Maranta, M., Hunter, M., Weber, B., Yaver, D., 2004. Coronamycins, peptide antibiotics produced by a verticillate *Streptomyces* sp. (MSU-2110) endophytic on *Monstera* sp. *Microbiology (N Y)* 150, 785–793. <https://doi.org/10.1099/mic.0.26645-0>
- Flint, S.J., Enquist, W., Racaniello, V.R., Skalka, A.M., 2009. *Virological Methods*, in: *Principles of Virology*. ASM Press.
- Gulcin, İ., 2020. Antioxidants and antioxidant methods: an updated overview. *Arch Toxicol* 94, 651–715. <https://doi.org/10.1007/s00204-020-02689-3>
- Haney, E.F., Trimble, M.J., Hancock, R.E.W., 2021. Microtiter plate assays to assess antibiofilm activity against bacteria. *Nat Protoc* 16, 2615–2632. <https://doi.org/10.1038/s41596-021-00515-3>
- Herzog, E., Casey, A., Lyng, F., Chambers, G., Byrne, H., Davoren, M., 2007. A new approach to the toxicity testing of carbon-based nanomaterials—The clonogenic assay. *Toxicol Lett* 174, 49–60. <https://doi.org/10.1016/j.toxlet.2007.08.009>
- Hu, J.M., Hsiung, G.D., 1989. Evaluation of new antiviral agents: I. In vitro perspectives. *Antiviral Res* 11, 217–232. [https://doi.org/10.1016/0166-3542\(89\)90032-6](https://doi.org/10.1016/0166-3542(89)90032-6)

- Idelevich, E.A., Groß, U., Becker, K., Bader, O., 2018. Comparative evaluation of different gradient diffusion tests for detection of azole resistance in *Aspergillus fumigatus*. *Diagn Microbiol Infect Dis* 91, 52–54. <https://doi.org/10.1016/j.diagmicrobio.2018.01.003>
- Jo HY, Kim Y, Park HW, Moon HE, Bae S, Kim J, Kim DG, Paek SH., 2015. The Unreliability of MTT Assay in the Cytotoxic Test of Primary Cultured Glioblastoma Cells. *Exp Neurobiol.* 24, 235–245. <https://doi.org/10.5607/en.2015.24.3.235>
- Joklik, W., 1988. *Virology*, 3rd ed. Appleton & Lange, Norwalk, Connecticut, San Mateo.
- Kim, Y.-S., Noh, Y.-K., Lee, G.-I., Kim, Y.-K., Lee, K.-S., Min, K.-R., 1995. Inhibitory Effects of Herbal Medicines on Hyaluronidase Activity. *Korean Journal of Pharmacognosy* 26, 265–272.
- Kirmusaoğlu, S., 2019. The Methods for Detection of Biofilm and Screening Antibiofilm Activity of Agents, in: Kirmusaoğlu (Ed.), *Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods*. IntechOpen, London. <https://doi.org/10.5772/intechopen.84411>
- Klöppel, A., Grasse, W., Brümmer, F., Morlock, G., 2008. HPTLC coupled with bioluminescence and mass spectrometry for bioactivity-based analysis of secondary metabolites in marine sponges. *Journal of Planar Chromatography – Modern TLC* 21, 431–436. <https://doi.org/10.1556/JPC.21.2008.6.7>
- Kocherova, I., Kempisty, B., Hutchings, G., Moncrieff, L., Dompe, C., Janowicz, K., Petite, J., Shibli, J.A., Mozdziak, P., 2020. Cell-based approaches in drug development-a concise review. *Medical Journal of Cell Biology*. <https://doi.org/10.2478/acb-2020-0005>
- Koudan, E. V., Zorina, A.I., Levin, A.A., Pereira, F.D.A.S., Petrov, S. V., Karshieva, S.Sh., Kasyanov, V.A., Manturova, N.E., Ustyugov, A.Yu., Potekaev, N.N., Parfenov, V.A., Karalkin, P.A., Khesuani, Y.D., Bulanova, E.A., Kopnin, P.B., Isaev, A.A., Mironov, V.A., Zorin, V.L., 2022. Correlation of the regenerative potential of dermal fibroblasts in 2D culture with the biological properties of fibroblast-derived tissue spheroids. *Cell Tissue Res* 390, 453–464. <https://doi.org/10.1007/s00441-022-03690-1>
- Kralik, P., Ricchi, M., 2017. A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything. *Front Microbiol* 8. <https://doi.org/10.3389/fmicb.2017.00108>
- Lee, K.J., Oh, Y.C., Cho, W.K., Ma, J.Y., 2015. Antioxidant and Anti-Inflammatory Activity Determination of One Hundred Kinds of Pure Chemical Compounds Using Offline and Online Screening HPLC Assay. *Evidence-Based Complementary and Alternative Medicine* 2015, 1–13. <https://doi.org/10.1155/2015/165457>
- Liarzi, O., Bar, E., Lewinsohn, E., Ezra, D., 2016. Use of the Endophytic Fungus *Daldinia cf. concentrica* and Its Volatiles as Bio-Control Agents. *PLoS One* 11, e0168242. <https://doi.org/10.1371/journal.pone.0168242>
- Lindhagen, E., Nygren, P., Larsson, R., 2008. The fluorometric microculture cytotoxicity assay. *Nat Protoc* 3, 1364–1369. <https://doi.org/10.1038/nprot.2008.114>
- Matuschek, E., Brown, D.F.J., Kahlmeter, G., 2014. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. *Clinical Microbiology and Infection* 20, O255–O266. <https://doi.org/10.1111/1469-0691.12373>

- Mccauley, J., Zivanovic, A., Skropeta, D., 2013. Bioassays for Anticancer Activities, in: *Methods in Molecular Biology*. pp. 191–205. https://doi.org/10.1007/978-1-62703-577-4_14
- Mohan, M., Kozhithodi, S., Nayariseri, A., Elyas, K.K., 2018. Screening, Purification and Characterization of Protease Inhibitor from *Capsicum frutescens*. *Bioinformation* 14, 285–293. <https://doi.org/10.6026/97320630014285>
- Molyneux P, 2004. The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. *Songklanakarin Journal of Science and Technology (SJST)* 26, 211–219.
- Momtaz, S., Mapunya, B.M., Houghton, P.J., Edgerly, C., Hussein, A., Naidoo, S., Lall, N., 2008. Tyrosinase inhibition by extracts and constituents of *Sideroxylon inerme* L. stem bark, used in South Africa for skin lightening. *J Ethnopharmacol* 119, 507–512. <https://doi.org/10.1016/j.jep.2008.06.006>
- Morokutti, A., Redlberger-Fritz, M., Nakowitsch, S., Krenn, B.M., Wressnigg, N., Jungbauer, A., Romanova, J., Muster, T., Popow-Kraupp, T., Ferko, B., 2013. Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response. *Journal of Clinical Virology* 56, 323–330. <https://doi.org/10.1016/j.jcv.2012.12.002>
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J Immunol Methods* 65, 55–63. [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4)
- Munshi, A., Hobbs, M., Meyn, R.E., 2005. Clonogenic Cell Survival Assay, in: *Methods in Molecular Medicine*. pp. 21–28.
- Olivares, E., Badel-Berchoux, S., Provot, C., Jaulhac, B., Prévost, G., Bernardi, T., Jehl, F., 2016. The BioFilm Ring Test: a Rapid Method for Routine Analysis of *Pseudomonas aeruginosa* Biofilm Formation Kinetics. *J Clin Microbiol* 54, 657–661. <https://doi.org/10.1128/JCM.02938-15>
- O'Toole, G.A., 2011. Microtiter Dish Biofilm Formation Assay. *Journal of Visualized Experiments*. <https://doi.org/10.3791/2437>
- Ou, B., Hampsch-Woodill, M., Prior, R.L., 2001. Development and Validation of an Improved Oxygen Radical Absorbance Capacity Assay Using Fluorescein as the Fluorescent Probe. *J Agric Food Chem* 49, 4619–4626. <https://doi.org/10.1021/jf010586o>
- Özyürek, M., Güçlü, K., Tütem, E., Başkan, K.S., Erçağ, E., Esin Çelik, S., Baki, S., Yıldız, L., Karaman, Ş., Apak, R., 2011. A comprehensive review of CUPRAC methodology. *Analytical Methods* 3, 2439. <https://doi.org/10.1039/c1ay05320e>
- Parker, A.E., Walker, D.K., Goeres, D.M., Allan, N., Olson, M.E., Omar, A., 2014. Ruggedness and reproducibility of the MBEC biofilm disinfectant efficacy test. *J Microbiol Methods* 102, 55–64. <https://doi.org/10.1016/j.mimet.2014.04.013>
- Pastorino, G., Marchetti, C., Borghesi, B., Cornara, L., Ribulla, S., Burlando, B., 2017. Biological activities of the legume crops *Melilotus officinalis* and *Lespedeza capitata* for skin care and pharmaceutical applications. *Ind Crops Prod* 96, 158–164. <https://doi.org/10.1016/j.indcrop.2016.11.047>

- Patil, A.S., Paikrao, H.M., Kale, A.S., Manik, S.R., 2017. A TLC-Direct Bioautography Method for Detection of Antiuro lithiatic Metabolites. *J Chromatogr Sci* 55, 578–585. <https://doi.org/10.1093/chromsci/bmx002>
- Phan, N.T., Joshi, N.K., Rajotte, E.G., López-Urbe, M.M., Zhu, F., Biddinger, D.J., 2020. A new ingestion bioassay protocol for assessing pesticide toxicity to the adult Japanese orchard bee (*Osmia cornifrons*). *Sci Rep* 10, 9517. <https://doi.org/10.1038/s41598-020-66118-2>
- Pohanka, M., 2019. Biosensors and Bioassays Based on Lipases, Principles and Applications, a Review. *Molecules* 24, 616. <https://doi.org/10.3390/molecules24030616>
- Ponti, J., Ceriotti, L., Munaro, B., Farina, M., Munari, A., Whelan, M., Colpo, P., Sabbioni, E., Rossi, F., 2006. Comparison of Impedance-based Sensors for Cell Adhesion Monitoring and *In Vitro* Methods for Detecting Cytotoxicity Induced by Chemicals. *Alternatives to Laboratory Animals* 34, 515–525. <https://doi.org/10.1177/026119290603400508>
- Portilla, M., 2020. A Laboratory Diet-Overlay Bioassay to Monitor Resistance in *Lygus lineolaris* (Hemiptera: Miridae) to Insecticides Commonly Used in the Mississippi Delta. *Journal of Insect Science* 20. <https://doi.org/10.1093/jisesa/ieaa067>
- Ramata-Stunda A, Boroduskis M, Vorobjeva V, Ancans J, 2013. Cell and Tissue Culture-Based *In Vitro* Test Systems For Evaluation of Natural Skin Care Product Ingredients. *Environmental and Experimental Biology* 11, 159–177.
- Ratz-Lyko, A., Arct, J., Pytkowska, K., 2012. Methods for evaluation of cosmetic antioxidant capacity. *Skin Research and Technology* 18, 421–430. <https://doi.org/10.1111/j.1600-0846.2011.00588.x>
- Razinger, J., Lutz, M., Schroers, H.-J., Urek, G., Grunder, J., 2014. Evaluation of Insect Associated and Plant Growth Promoting Fungi in the Control of Cabbage Root Flies. *J Econ Entomol* 107, 1348–1354. <https://doi.org/10.1603/EC14004>
- Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., 1999. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic Biol Med* 26, 1231–1237. [https://doi.org/10.1016/S0891-5849\(98\)00315-3](https://doi.org/10.1016/S0891-5849(98)00315-3)
- Riss, T., Niles, A., Moravec, R., Karassina, N., Vidugiriene, J., 2019. Cytotoxicity Assays: *In Vitro* Methods to Measure Dead Cells, in: Markossian S, Grossman A, Brimacombe K, et al. (Eds.), *Cytotoxicity Assays: In Vitro Methods to Measure Dead Cells*. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD.
- Riss, T.L., Moravec, R.A., Niles, A.L., Duellman, S., Benink, H.A., Worzella, T.J., Minor, L., 2004. *Cell Viability Assays*.
- Rivoal, J., Smith, C.R., Moraes, T.F., Turpin, D.H., Plaxton, W.C., 2002. A Method for Activity Staining after Native Polyacrylamide Gel Electrophoresis Using a Coupled Enzyme Assay and Fluorescence Detection: Application to the Analysis of Several Glycolytic Enzymes. *Anal Biochem* 300, 94–99. <https://doi.org/10.1006/abio.2001.5445>

- Rodriguez-Tudela, J.L., Arendrup, M.C., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D.W., Donnelly, J.P., Dromer, F., Fegeler, W., Lass-Flörl, C., Moore, C., Richardson, M., Sandven, P., Velegraki, A., Verweij, P., 2008. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. *Clinical Microbiology and Infection* 14, 398–405. <https://doi.org/10.1111/j.1469-0691.2007.01935.x>
- Romar, G.A., Kupper, T.S., Divito, S.J., 2016. Research Techniques Made Simple: Techniques to Assess Cell Proliferation. *Journal of Investigative Dermatology* 136, e1–e7. <https://doi.org/10.1016/J.JID.2015.11.020>
- Sabotič, J., Popovič, T., Brzin, J., 2009. Aspartic proteases from basidiomycete *Clitocybe nebularis*. *Croatica Chemica Acta* 82.
- Sabotič, J., Trček, T., Popovič, T., Brzin, J., 2007. Basidiomycetes harbour a hidden treasure of proteolytic diversity. *J Biotechnol* 128, 297–307. <https://doi.org/10.1016/j.jbiotec.2006.10.006>
- Sanané, I., Legrand, J., Dillmann, C., Marion-Poll, F., 2021. High-Throughput Feeding Bioassay for Lepidoptera Larvae. *J Chem Ecol* 47, 642–652. <https://doi.org/10.1007/s10886-021-01290-x>
- Sepčić, K., Sabotič, J., A. Ohm, R., Drobne, D., Jemec Kokalj, A., 2019. First evidence of cholinesterase-like activity in Basidiomycota. *PLoS One* 14, e0216077. <https://doi.org/10.1371/journal.pone.0216077>
- Sims, M., 1965. Methods for Detection of Enzymatic Activity after Electrophoresis on Polyacrylamide Gel in *Drosophila* Species. *Nature* 207, 757–758. <https://doi.org/10.1038/207757b0>
- Singleton, V.L., Orthofer, R., Lamuela-Raventós, R.M., 1999. Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent, in: *Methods in Enzymology*. Elsevier, pp. 152–178. [https://doi.org/10.1016/S0076-6879\(99\)99017-1](https://doi.org/10.1016/S0076-6879(99)99017-1)
- Šmid, I., Rotter, A., Gruden, K., Brzin, J., Buh Gašparič, M., Kos, J., Žel, J., Sabotič, J., 2015. Clitocybin, a fungal cysteine protease inhibitor, exerts its insecticidal effect on Colorado potato beetle larvae by inhibiting their digestive cysteine proteases. *Pestic Biochem Physiol* 122, 59–66. <https://doi.org/10.1016/j.pestbp.2014.12.022>
- Sternberg, E.D., Waite, J.L., Thomas, M.B., 2014. Evaluating the efficacy of biological and conventional insecticides with the new ‘MCD bottle’ bioassay. *Malar J* 13, 499. <https://doi.org/10.1186/1475-2875-13-499>
- Sterniša, M., Sabotič, J., Janež, N., Curk, T., Klančnik, A., 2023. SIMBA method - simultaneous detection of antimicrobial and anti-biofilm activity of new compounds using *Salmonella* *Infantis*. *Bio Protoc*.
- Sterniša, M., Sabotič, J., Klančnik, A., 2022. A novel approach using growth curve analysis to distinguish between antimicrobial and anti-biofilm activities against *Salmonella*. *Int J Food Microbiol* 364, 109520. <https://doi.org/10.1016/j.ijfoodmicro.2021.109520>

- Strömstedt, A.A., Felth, J., Bohlin, L., 2014. Bioassays in natural product research - Strategies and methods in the search for anti-inflammatory and antimicrobial activity. *Phytochemical Analysis* 25, 13–28. <https://doi.org/10.1002/PCA.2468>
- Suchman, E., Blair, C., 2007. *Cytopathic Effects of Viruses Protocols*. ASM Protocols.
- Thring, T.S., Hili, P., Naughton, D.P., 2009. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. *BMC Complement Altern Med* 9, 27. <https://doi.org/10.1186/1472-6882-9-27>
- Tomscheck, A.R., Strobel, G.A., Booth, E., Geary, B., Spakowicz, D., Knighton, B., Floerchinger, C., Sears, J., Liarzi, O., Ezra, D., 2010. Hypoxylon sp., an Endophyte of *Persea indica*, Producing 1,8-Cineole and Other Bioactive Volatiles with Fuel Potential. *Microb Ecol* 60, 903–914. <https://doi.org/10.1007/s00248-010-9759-6>
- Van Wart, H.E., Steinbrink, D.R., 1981. A continuous spectrophotometric assay for *Clostridium histolyticum* collagenase. *Anal Biochem* 113, 356–365. [https://doi.org/10.1016/0003-2697\(81\)90089-0](https://doi.org/10.1016/0003-2697(81)90089-0)
- Vichai, V., Kirtikara, K., 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protoc* 1, 1112–1116. <https://doi.org/10.1038/nprot.2006.179>
- Zamora, J.L.R., Aguilar, H.C., 2018. Flow virometry as a tool to study viruses. *Methods* 134–135, 87–97. <https://doi.org/10.1016/j.ymeth.2017.12.011>
- Žun, G., Kos, J., Sabotič, J., 2017. Higher fungi are a rich source of l-amino acid oxidases. *3 Biotech* 7, 230. <https://doi.org/10.1007/s13205-017-0813-7>

Author declaration

[Instructions: Please check all applicable boxes and provide additional information as requested.]

1. Conflict of Interest

Potential conflict of interest exists:

We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below:

No conflict of interest exists.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

2. Funding

Funding was received for this work.

All of the sources of funding for the work described in this publication are acknowledged below:

[List funding sources and their role in study design, data analysis, and result interpretation]

Funding sources had no role in study design, data analysis or result interpretation.

This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) program.

Research of Jerica Sabotič and Nika Janež was supported by Slovenian Research agency (J4- 2543, J4-4555, P4-0127, P4-0432).

Research of Evita Strode was supported by ERDF post-doctoral research grant 1.1.1.2/16/I/001 (application No 1.1.1.2/VIAA/3/19/465).

Susana Gaudêncio: This work is financed by national funds from FCT - Fundação para a

Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB.

Research of Anna Lugini and Giovanna Cristina Varese was financed by the University of Torino (Ricerca Locale) and the European Commission – NextGenerationEU, Project "Strengthening the MIRRI Italian Research Infrastructure for Sustainable Bioscience and Bioeconomy", code n. IR0000005.

Research of David Ezra was supported by The Chief Scientist of the Israeli Ministry of Agriculture and Rural Development (MOARD), grant number 20-02-0122, and Copia Agro Israel

Research of Dina Simes was funded by the Portuguese National Funds from FCT— Foundation for Science and Technology, through projects UIDB/04326/2020, UIDP/04326/2020 and LA/P/0101/2020 and AAC n° 41/ALG/2020 - Project n° 072583 – NUTRISAFE.

No funding was received for this work.

3. Intellectual Property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

4. Research Ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases)

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

5. Authorship

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two>.

All listed authors meet the ICMJE criteria. ^[L]_[SEP] We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

One or more listed authors do(es) not meet the ICMJE criteria.

We believe these individuals should be listed as authors because:

[Please elaborate below] ^[L]_[SEP]

We confirm that the manuscript has been read and approved by all named authors.

We confirm that the order of authors listed in the manuscript has been approved by all named authors.

6. Contact with the Editorial Office

The Corresponding Author declared on the title page of the manuscript is:

[Insert name below]

Jerica Sabotič

This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

[Insert email address you wish to use for communication with the journal here]

Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

[Insert name below]

We understand that this author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.

We the undersigned agree with all of the above.

Author's name (Fist, Last)	Signature	Date
1. <u>Jerica Sabotič</u>	 <small>Digitally signed by JERICA SABOTIČ Date: 2023.07.08 22:47:22 +02'00'</small>	8 July 2023 <u> </u>